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The G protein-coupled receptor (GPCR) C-C chemokine receptor 5 (CCR5) is the major 
co-receptor for HIV-1. CCR5 binds to the viral glycoprotein gp120 allowing HIV 
particles to infect T cells. Currently, maraviroc is the only Food and Drug Administration 
(FDA) approved entry inhibitor for HIV-1 but resistance to maraviroc has been reported 
indicating the need for novel entry inhibitors. Recently, four peptides derived from 
RANTES (Regulated on Activation, Normal T cell Expressed and Secreted), the 
endogenous ligand of CCR5, were shown to induce different CCR5 signaling pathways 
and efficiently block viral entry. The peptide analogues are 5P12, which blocks HIV-1 
entry but does not induce signaling or receptor internalization; 6P4, which is a non-biased 
ligand; PSC, which is a super agonist relative to RANTES; and 5P14, which does not 
activate G-protein mediated signaling yet induces receptor internalization. Yet, we lack 
mechanistic knowledge about how the analogues bind to CCR5. To address this issue, we 
have employed fluorescence cross-correlation spectroscopy (FCCS) to determine 
equilibrium dissociation and inhibition constants for the RANTES analogues binding to 
CCR5. 
We developed a tandem affinity purification protocol to purify full-length, monomeric 
CCR5 from receptor truncations and oligomers. We fluorescently labeled CCR5 using the 
SNAP tag, a functional tag derived from DNA alkyl transferase, with Alexa-488. We 
show similar cell surface expression for CCR5-SNAP and wild-type CCR5 using flow 
cytometry with different epitope recognizing antibodies. We demonstrate that CCR5-
SNAP activates G-proteins and internalizes similarly as wild type CCR5 in response to 
chemokine stimulus. We perform saturation and competition binding with the Alexa-647 
labeled RANTES analogues and show that they bind with picomolar to nanomolar 
affinities. Global fitting on the binding isotherms shows that the RANTES analogues 
bind to 38% of CCR5-SNAP and recognize two different species that are non-
interconvertible. Competition binding with gp120 complexed to soluble CD4 shows that 
the RANTES analogues are efficient at blocking Env binding. We also show that the 
native chemokines are incapable of displacing the RANTES analogues from CCR5-
SNAP. We speculate that CCR5-SNAP is modified differentially with post-translational 
modifications that affect receptor affinity for the analogues. Our studies were performed 
with CCR5-SNAP in detergent solution that is not suitable to investigate the role G-
protein on CCR5-SNAP ligand binding. To address this issue, we developed a novel 
zebrafish derived apolipoprotein AI (ZapN1) for the assembly of nanoscale 
apolipoprotein bound bilayers (NABBs). We optimized expression and purification of 
ZapN1 from E. coli and the assembly of NABBs with different lipids and detergent 
conditions. We performed FCCS ligand binding with CCR5-SNAP in NABBs to show 
that the receptor can recognize a conformationally sensitive antibody. Our studies 
illustrate the advantage of single molecule ligand binding assays to study receptor species 
that are averaged in ensemble measurements
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CHAPTER ONE: INTRODUCTION 
 
1.1 G Protein-Coupled Receptors Activation and Signaling Pathways 
 
G-protein coupled receptors (GPCRs) are heptahelical trans-membrane receptors 
responsible for signal transduction across the plasma membrane.[1] GPCRs regulate 
many important physiological processes, such as vision, smell, cognitive, metabolic, and 
immune responses.[2] GPCRs constitute a large and diverse family of receptors with 
more than 800 members classified into 5 classes: rhodopsin (class A), secretin (class B), 
adhesion (originally class B), glutamate (class C), and frizzled/taste2.[3] The largest 
GPCR class is the rhodopsin family with 701 members of which 241 receptors are non-
olfactory receptors. GPCRs share a common structural framework of 7 transmembrane α-
helices with an extracellular N-terminus, intracellular C-terminus, and various loops 
between transmembrane helices.[4] Ligands bind GPCRs on the extracellular side leading 
to receptor structural rearrangements that allow coupling and activation of G protein on 
the intracellular side.[5] GPCRs bind a plethora of chemically diverse ligands such as 
ions, synthetic molecules, lipids, and proteins despite their conserved structural 
framework.[2] Specific receptor-ligand contacts in the N-terminus and transmembrane 
interhelix domain dictates ligand specificity.[6, 7] Despite their broad ligand recognition, 
GPCRs share a common mechanism of activation and G-protein coupling.[6, 8] 
GPCRs share conserved structural motifs in the transmembrane interhelix domain 
responsible for receptor activation.[9] Two such motifs, the (D/E)RY and NPxxY(x)5,6F 
motifs regulate receptor transition from the inactive to the active state.[6] The (D/E)RY 
2 
motif is conserved in several receptors located between transmembrane III (TMIII) and 
intracellular loop 2 (ICL2). [10] The arginine residue forms a salt bridge with either the 
glutamic or aspartic residue in TMVI constraining the receptor in an ‘inactive’ 
conformation. Ligand binding displaces TMVI from the interhelix domain breaking the 
salt bridge leading to an ‘active’ receptor conformation.[11, 12] Mutations of glutamic or 
aspartic acid lead to constitutionally active receptors. The (D/E)RY motif functions to 
keep the receptor in the inactive state to prevent its activation. GPCRs also encode for 
another conserved motif, NPxxY(x)5,6F, which connects TMVII and cytoplasmic helix 
VIII.[13] The NPxxY(x)5,6F motif forms a helix-turn-helix structure which is stabilized 
by hydrophobic interactions between the tyrosine and phenylalanine residues.[14] 
Alanine mutations in the NPxxY(x)5,6F motif that disrupt the hydrophobic interaction 
allows the receptor to proceed to the ‘active’ state at the expense of reduced G-protein 
activation. The NPxxY(x)5,6F motif is important for receptor activation and G-protein 
coupling. Yet, not at all GPCRs encode for these conserved motifs indicating that they 
are not essential for GPCR activation and G-protein coupling. 
Ligand binding on the EC domain allows heterotrimeric G-protein to bind the active state 
receptor in the IC side. G-proteins are composed of Gα, Gβ, and Gγ subunits of which Gα 
contains the catalytic site for nucleotide exchange.[15] GPCR activation leads to the 
exchange of GDP to GTP in Gα and its dissociation from the Gβγ dimer. Gα is classified 
into 4 different sub-families, Gαi, Gαs, Gαq, and Gα12/13 based on their signaling pathway 
coupling.[16] Gαi and Gαs bind to adenylyl cyclase either inhibiting or stimulating 
production of cyclic adenosine monophosphate (cAMP) respectively. Gαq activates 
phospholipase C which cleaves phosphatidylinositol 4,5-bisphosphate (PIP2) into diacyl 
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glycerol (DAG) and inositol 1,4,5-trisphosphate (IP3).[17] Gα12/13 activates members of 
the RhoGTPase nucleotide exchange factors (RhoGEFs) family such as p115-
RhoGEF.[18] The Gβγ dimer activates voltage-gated calcium and potassium channels, 
and regulates several signaling effectors such as adenylyl cyclase and phospholipase 
C.[19] Following G-protein dissociation from the receptor-ligand complex, GPCRs can 
be phosphorylated by G protein-coupled receptor kinases (GRKs) on serine and threonine 
residues located in the IC loops and receptor C-terminus.[20] GPCR phosphorylation 
induces high affinity binding of the intracellular effector arrestin.[21] Arrestin prevents 
further G-protein activation and targets the receptor for internalization via clathrin-
mediated endocytosis. Arrestin also regulates activation of several kinases such as the Scr 
family of tyrosine kinases, c-Jun N-terminal kinase 3, mitogen-activated protein (MAP) 
kinases, and extracellular signal-regulated kinases (ERK) 1 and 2. Internalized GPCRs 
are then targeted to the lysosome for degradation or recycled to the plasma membrane for 
future activation.[22] 
Ligands can modulate GPCR coupling to either G-protein or arrestin in a phenomenon 
known as “biased agonism” [8]. For example, SNC80, a δ-opioid receptor agonist, 
induces high receptor internalization in the central and peripheral nervous system which 
leads to behavioral desensitization in animals [23]. ARM390 is another δ-opioid agonist 
with similar selectivity and potency as SNC80 but it induces low internalization 
abolishing behavioral desensitization. Biased signaling has been observed for several 
other GPCRs including the beta adrenergic receptors 1 and 2, the ghrelin receptor, 
vasopressin 2 receptor, and serotonin 5HT2B and receptors.[24] The binary model of 
GPCR activation assumes that the receptors exists between an inactive and active 
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states.[8] Ligand binding stabilizes the active state which is responsible for intracellular 
partner binding and regulation. However, the binary model cannot account for biased 
signaling since one receptor conformation cannot be responsible for G-protein, GRK, and 
arrestin coupling. Given this, GPCRs are believed to adopt multiple conformations, 
which can be stabilized differentially by ligands. Structural and biophysical evidence 
shows that GPCRs are dynamic structures that can adopt multiple conformations.[25] For 
example, 19F-NMR studies in the β2-adrenergic receptor revealed the existence of two 
receptor conformational states associated with TMVI and TMVII. Agonist binding 
shifted the equilibrium towards the TMVI conformational state while arrestin biased 
agonists shifted the equilibrium towards the TMVII state. Crystal structure of the β2-
adrenergic receptor bound Gαs showed that TMVI was displaced away from the 
transmembrane interhelix domain by 14 Å.[26] In contrast, the rhodopsin-arrestin 
complex shows additional contacts made with TMVII and cytoplasmic helix 8 and the 
receptor C-terminus makes several ionic contacts with positively charged residues in 
arrestin.[27] Despite the available structural data, we do not understand how ligands 
modulate receptor transitions along the conformational landscape. Given this, further 
studies are required to understand the mechanistic parameters that define biased agonism. 
Such understanding will guide future therapeutic development of novel drugs that 
mitigate unwanted side effects while retaining the desired effect. [28, 29] We propose to 
investigate how a series of biased peptide analogues bind to the chemokine receptor 
CCR5. 
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1.2 CCR5 is a Model GPCR 
CCR5 is a chemokine GPCR that is expressed on monocytes, macrophages, dendritic 
cell, natural killer cells, memory and effector T cells, fibroblasts, and neuronal cells 
where it directs cells to inflammation and infection sites and stimulates T-cells [30, 31]. 
Chemokines are small chemoattractant cytokines that modulate various biological 
processes such as chemotaxis, inflammation, and viral infection.[32] Chemokines are 
sub-divided into 4 families differentiated by their cysteine motifs: CXC chemokines (α-
chemokines), CC (β-chemokines), C chemokines (γ-chemokines), and CX3C chemokines 
(δ-chemokines).[33] CCR5 recognizes primarily the CC chemokines CCL5 (RANTES), 
CCL3 (MIP-α), and CCL4 (MIP-1β).[34] RANTES mediates proliferation and activation 
of natural killer cells and induces chemotaxis in T cell, monocytes, and dendritic cells. 
MIP-α and MIP-1β also induce chemotaxis in monocytes, macrophages, and dendritic 
cells but MIP-α preferentially attracts CD8+ T cells while MIP-1β preferentially attracts 
CD4+ T cells.[35, 36] CCR5 also recognizes envelope glycoprotein gp120 in HIV. 
Gp120 first binds to the membrane receptor CD4 which then exposes variable loop 3 
(V3) in gp120 that then binds to CCR5 [37]. Maraviroc is the only Federal Drug 
Administration (FDA) approved HIV-1 entry inhibitor but there are viral strains that are 
resistant to Maraviroc [38]. RANTES inhibits HIV-1 replication but it has very low 
potency compared to other entry inhibitors such as Maraviroc [39]. To address this issue, 
RANTES analogs that inhibit HIV-1 with picomolar potencies were developed by 
random mutagenesis in the first 9 amino acids (Table 1.1.2)[40, 41]  
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Table 1.2 Characterization of RANTES and some of its peptide analogues. The RANTES 
analogues investigated in this report have several amino acid mutations within the first 9 
amino acids. The RANTES N-terminus sequence is shown for comparison. PSC-
RANTES is the only analogue to be chemically modified where PSC is Nα-(n-nonanoyl)-
des-Ser1-[L-thioproline2, L-α-cyclohexyglycine3]. RANTES has very low anti-HIV 
potency while the RANTES analogues display picomolar inhibition potencies. PSC and 
6P4-RANTES display “super-agonist” activity in comparison to RANTES in that they 
are more effective in G-protein signaling and CCR5 internalization than RANTES 
(numbers are % of PSC-RANTES activity). 5P12-RANTES does not show appreciable 
G-protein signaling or CCR5 internalization by either functional assay. 5P14-RANTES 
shows no G-protein signaling but can induce CCR5 internalization. The RANTES 
analogues show similar affinities based on the displacement of 125I-MIP-1β from CHO 
cells expressing CCR5. 











RANTES S-P-Y-S-S-D-T-T-P ~ 1000000 50 64 7.9 
PSC-RANTES PSC-S-S-D-T-T-P 25 100 100 1.9 
6P4-RANTES Q-G-P-P-G-D-I-V-L-A 21 88 93 0.3 
5P12-RANTES Q-G-P-P-L-M-A-T-Q-S 28 <5 3 1.3 
5P14-RANTES Q-G-P-P-L-M-S-L-Q-V 26 <5 47 1.2 
Remarkably, the RANTES analogues display very different functional properties from 
RANTES on CCR5 cell-based assays. For example, PSC-RANTES (PSC) and 6P4-
RANTES (6P4) display “super-agonist” activity in comparison to RANTES while 5P14-
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RANTES (5P14) and 5P12-RANTES (5P12) show no G-protein activation by calcium 
flux. 5P14 was half-effective at inducing CCR5 internalization when compared to PSC 
while 5P12 did not induce CCR5 internalization (Table 1.1.2). The RANTES analogues 
display similar affinities towards CCR5 expressed in cells based on their displacement of 
125I-MIP-1β.[40] Gaertner (2008). deduced that their similar affinities could not account 
for the analogues different pharmacological properties. However, CCR5 is known to 
partition into different lipid environments and measured affinities from cell based assays 
are an average of all CCR5 states [42, 43]. Therefore, we propose to derive dissociation 
binding constants, 𝐾𝐷, and constants of inhibition, 𝐾𝑖, for the RANTES analogues at the 
single molecule scale to characterize their binding mechanism to CCR5 [44, 45].  
1.3   Ligand Binding Assays 
We propose to perform saturation binding and competition binding with the RANTES 
analogues and native chemokines to derive their 𝐾𝐷 and 𝐾𝑖 values. Equilibrium binding 
assays provide information about ligand affinities, receptor species, and the mechanism 
by which ligands interact with receptors.[46] We hypothesize that the RANTES 
analogues bind to different CCR5 conformations or receptor species, which may be 
responsible for their pharmacological properties. Traditionally, radiolabeled ligands had 
been employed to measure affinities to a receptor expressed in cells or purified in 
membrane preparations.[47]  Radioligand binding assays are advantageous in that they 
can be performed in primary cell cultures and recombinant expression systems. As such, 
radioligand binding assays probe receptor-ligand interactions in a native environment 
without disrupting receptor function. Radioligand binding assays are also advantageous 
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in that they provide information about receptor distribution, density, and dynamics. Yet, 
radioligand binding assays present several disadvantages such as working with 
radioactive reagents, which are hazardous and expensive to synthesize. Radiolabeling can 
also modify ligand properties specially if the labeling site is not specific. An alternative 
to radioligand binding assays is surface plasmon resonance (SPR) or isothermal titration 
calorimetry (ITC) that can measure affinities on purified or reconstituted receptor without 
labeling or ligand or receptor. 
Surface plasmon resonance detects refractive index changes from addition of an analyte 
to a sensor surface with immobilized receptor. Unlike radioligand binding assays, most 
SPR assays require receptor purification, which may affect its ligand binding properties. 
However, SPR offers several advantages over radioligand binding assays. For example, 
SPR relies on measuring refractive index changes, which do not require labels on either 
the ligand or receptor. Furthermore, SPR monitors reactions on real-time allowing 
derivation of rate constants and 𝐾𝐷 values from the same experiments. SPR requires 
lower concentration of reagents in comparison to radioligand binding assays. Yet, SPR 
does have disadvantages in comparison to radioligand binding assays. For example, 
analytes that induce small changes in refractive index may not be observed at all. Also, 
SPR measurements are susceptible to mass transport effects. SPR data analysis requires 
the assumption that the free analyte concentration is uniform in space and time. However, 
the assumption breaks down when analyte diffusion and/or flow does not result in a 
homogeneous analyte distribution in the sensor chip. As such, ligand association rates to 
the receptor are dependent on analyte diffusion into the receptor-dextran matrix. SPR also 
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requires receptor surface immobilization, which can introduce artifacts or alter receptor 
function.  
An alternative to SPR is ITC, which measures changes in heat released or absorbed 
caused by a binding event. Unlike SPR, ITC measures ligand interactions in solution 
overcoming possible immobilization artifacts and the technique is not limited by the 
molecular weight of the analytes. ITC provides information such as 𝐾𝐷, the number of 
binding sites, and thermodynamic parameters such as the change of enthalpy and entropy 
but it does not provide rate constants. ITC is useful to measure ligand-binding 
interactions with affinities in the millimolar to nanomolar range. However, the technique 
is limited to high reagent concentrations are required to detect ligand binding. For 
example, the minimum protein required is 10 µM for a 200 µl cell and a ΔH of 5 
kcal/mol.[48] Ideally, we would like to use a technique that can detect ligand binding 
with nanomolar receptor and ligand concentrations. ITC measurements are also 
susceptible to buffer mismatch between the ligand and receptor, which affect the 
measured ΔH.  
Methods such as X-ray crystallography and NMR provide precise information about the 
structural determinants of ligand binding at atomic resolution. In the last decade, several 
GPCR structures bound to antagonists, agonists, G-protein mimics and G-protein, and 
arrestin have emerged providing key insights into different ligand binding modes and 
receptor activation. GPCRs are notoriously difficult to purify in high quantities and to 
crystallize due to their inherent dynamical nature. In many cases, GPCRs were heavily 
modified with stabilizing mutations and fused to proteins such as T4 lysozyme to create 
larger lattice contacts. Also, structural methods provide a snapshot of a single receptor 
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conformation eliminating the conformational diversity that characterizes these proteins. 
Given this, we advocate for a technique that allow us to probe ligand-binding interactions 
without heavily perturbing receptor structure and function. Also, we would prefer a 
technique that allow us to investigate the dynamic behavior of these receptors in an 
environment that preserves their function.   
Fluorescence based ligand binding assays offer several advantages over traditional 
methods. For example, fluorescence detection can be performed using different 
wavelengths of light, which allows for multi-color detection of several species. For 
example, the ligand and receptor can be monitored independently in binding 
measurements by placing different labels on them. Fluorescent ligand binding assays can 
be performed on cells or in solution allowing for direct comparison of measured 
affinities. Yet, fluorescence detection offers a tremendous advantage that the previously 
discussed methods do not offer. Given the conformational diversity of GPCRs, methods 
such as SPR and radioligand binding would not provide information about such different 
conformations since they average the entire ensemble. Single molecule interrogation 
allows us to observe conformations or transitions along the reaction pathway that are 
typically averaged in ensemble measurements. Given this, we propose to perform single 
molecule ligand binding measurements using a technique known as fluorescence 
correlation spectroscopy.  
11 
1.4   Fluorescence Auto- and Cross-Correlation Spectroscopy 
Fluorescence correlation spectroscopy (FCS) is a statistical method that analyzes 
fluorescence fluctuations from molecules in a femtoliter sized volume of focused laser 
excitation. [49] To derive physical parameters, an autocorrelation analysis is performed 
on the fluorescence intensity profile. FCS can be used to monitor any process that causes 
fluorescence fluctuations such as diffusion, chemical reactions, changes in concentration, 
rotational diffusion, triplet state kinetics, and ligand binding. In 1972, Magde et al. 
derived the mathematical expressions to determine rate constants and diffusion 
coefficients for ethidium bromide binding to DNA. Recent advances in confocal 
microscopy such as correlators and improved laser for diffraction-limited sensitivity have 
allowed FCS to become a more routine method.[49] The auto-correlation function is 




 (Equation 1.1) 
Where 𝐹(𝑡) is the fluorescence intensity in time and  𝐹(𝑡 +  𝜏) is the fluorescence 
intensity at a lag time after 𝑡. To derive parameters that describe the system, an analytical 
expression of the auto-correlation function is fitted to the experimental correlation trace. 
Equation 1.2 gives the general form of the analytical expression for the correlation 
function 
𝐺𝑇𝑜𝑡𝑎𝑙 = 1 + 𝐴 +∏ ∑ 𝐺𝑘,𝑙(𝜏)𝑙𝑘  (Equation 1.2) 
12 
Where 𝐴 is the amplitude of the correlation function and 𝐺𝑘,𝑙(𝜏) is the correlation for a 
single process where the suffixes are correlation terms that represent dependent or 
independent processes. Functional expressions of  𝐺𝑘,𝑙(𝜏) can be used to derived 
concentrations, particle size, and triplet state fraction.[50] For example, 𝐴, the correlation 
amplitude 𝐺(0), is given by 1
𝑁
 where 𝑁 is the number of fluorescent species. As such, 
changes in 𝐺(0) can be used to determine fluctuations in concentration caused by 
chemical reactions. To illustrate how correlation traces change with varying 
concentration, particle size, and triplet state fraction, we have modeled correlation traces 
for such processes using functional forms 𝐺𝑘,𝑙(𝜏) (Methods and Materials) with a set of 
fixed parameters. Figure 1.1.4a shows the modeled correlation traces and how changes in 
concentration, size, and triplet state fraction affect the form of the correlation function.  
Figure 1.1.4a Dependency of correlation trace amplitudes and lag time (τ) on fluorescent 
species concentration (a); molecular size (b); and triplet state fraction (c). Correlation 
amplitude is plotted on the y-axis, 𝐺𝑅(0), as a function of lag time, τ, in a logarithmic x-
axis.  
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As described before,  𝐺(0), is inversely proportional to the total number of particles 
present in the sample. If the concentration of the fluorescent species decrease, then the 
autocorrelation amplitude increases (Figure 1.1.4a). The diffusion time, 𝜏𝐷, of a particle 
is related to the particle’s molecular weight and diffusion coefficient. Increases in the 
diffusion time can be used to detect ligand binding or changes in particle size (Figure 
1.1.4a). Fluorescence fluctuations also arise from triplet state transitions that appear as a 
second decay component in the microsecond timescale (Figure 1.1.4a). FCS is 
advantageous over other single molecule techniques in that concentrations can be derived 
directly for any fluorescent sample. Binding interactions are observed in solution 
eliminating immobilization artifacts common to other single molecule techniques.  
FCS has previously been employed to derive 𝐾𝐷 values for the serotonin receptor 5HT3AS 
antagonist GR-119566X labeled with different fluorophores in solution [51]. Measuring 
binding interactions by FCS is limited to ligand-receptor pairs that are vastly different in 
size. Fluorescence cross-correlation spectroscopy (FCCS) overcomes this limitation by 
cross-correlating the fluorescence fluctuations from two different fluorescent species.[52] 
Figure 1.1.4b shows a schematic of two confocal volumes (blue corresponds to 488 nm 
excitation and red to 633 nm excitation) overlapping with each other under the 
assumption of no chromatic aberrations. In each case, we show particles that are bound to 
each and diffusing together or do not interact and diffuse through the confocal volumes 
independently.  
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Figure 1.1.4b Schematic showing the confocal volumes for 488 nm excitation (blue 
ellipse), 633 nm excitation (red ellipse), and their calculated sizes and orientations (𝑥𝑦𝑧 
coordinates). Green sphere corresponds to a green-labeled species and the red sphere to a 
red labeled species that either interact (left) or do not interact (right).  
We have previously determined the confocal volumes for 488 and 633 nm excitations and 
determined their values to be 0.18 fl and 0.35 fl respectively. Particles that are bound 
diffuse together yielding a cross-correlation amplitude that is dependent only on the 
bound complex concentration. Figure 1.1.4c shows the averaged fluorescence intensity 
profiles for the two binding cases and their associated auto- and cross-correlation traces.  
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Figure 1.1.4c Averaged fluorescence intensity profiles for green and red labeled particles 
that are interacting (a) or not interacting (b). Correlation traces for green and red labeled 
particles that bind or do not bind. Particles that bind (c) yield a cross-correlation 
amplitude (blue line), which is absent if the particles do not interact. 
The averaged fluorescence intensity profiles overlap with each other if the particles 
interact. In the case where the particles do not interact, the averaged fluorescence 
intensity profiles do not overlap with each other. Correlation analysis on the intensity 
profiles yields a third correlation trace, which is dependent solely on the concentration of 
complex. In the case where particles bind, the cross-correlation amplitude is present 
whereas in the non-binding case the cross-correlation amplitude is absent. FCCS has been 
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employed previously to derive 𝐾𝐷 values for the peptide ligand Leu-enkephalin binding 
to the human µ-opioid receptor in membrane nanopatches [53]. FCCS has also been 
employed to derive 𝐾𝐷 and 𝐾𝑖 values for different fluorescent labeled ligands binding to 
solubilized GPCRs in cell lysate supernatant [54]. Given the advantages of FCCS over 
FCS and other ligand binding methods, we propose to employ FCCS on CCR5 to derive 
equilibrium dissociation constants, 𝐾𝐷, and constants of inhibition, 𝐾𝑖, for the RANTES 
analogues. We propose to perform saturation and competition binding on purified CCR5 
in a well-defined micelle-lipid system where we can identify possible CCR5 species that 
are masked in ensemble measurements 15,16. 
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CHAPTER TWO: FUNCTIONAL CHARACTERIZATION, EXPRESSION, 
LABELING, AND PURIFICATION OF CCR5 
2.1  Introduction 
To perform FCCS measurements on CCR5 and the chemokines, we must label the 
receptor and chemokines with two different fluorophores. Also, we need to purify CCR5 
in a suitable buffer-detergent solution to high purity to avoid heterogeneities in the final 
purification product. Given these challenges, we have designed a CCR5 construct fused 
to several functional tags that allow us to label the receptor with any small organic 
fluorophore and purify the full-length receptor from cell lysates. Human CCR5 was 
codon optimized for higher expression in mammalian cells and fused to the SNAP tag for 
fluorescent labeling. The SNAP tag is an O6-guanine nucleotide alkyltransferase 
mutant.[55] The SNAP tag unlike traditional fluorescent proteins allow us to covalently 
attach any benzyl guanine derivatized fluorophore into the protein. The SNAP tag works 
by binding the benzyl guanine moiety and then using a free cysteine performs 
nucleophilic substitution to attach itself to the fluorophore (Figure 2.1.1) 
Figure 2.2.1 SNAP-tag labeling mechanism. 
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Because the SNAP tag recognizes only benzyl guanine derivatives, the SNAP tag offers 
excellent bio-orthogonality in comparison to other labeling methods. For FCCS, we will 
employ Alexa-647 labeled chemokines synthesized by Oliver Hartley’s group. We will 
label CCR5 with Alexa-488 using a C-terminal SNAP-tag. We chose the C-terminal 
position since the N-terminal fusion construct can undergo FRET with the labeled 
chemokine affecting FCCS measurements.  
Since we want to purify our CCR5-SNAP fusion protein from cells, we have designed 
our construct to encode for three additional functional tags for purification and 
expression. For receptor purification, we will employ an N-terminal FLAG and C-
terminal 1D4 tags. The positions of the functional tags allow us to purify full-length 
receptor from the cell lysate. Studies in CXCR4, a related chemokine receptor, have 
shown that N-terminal modifications severely affect receptor trafficking to the plasma 
membrane (unpublished observation). To resolve this issue, we also introduced a signal 
peptide from the serotonin 5HT3A receptor upstream the FLAG tag to induce proper 
receptor trafficking and expression.[56] We also characterized CCR5-SNAP using 
pharmacological assays to demonstrate that the receptor functions like WT CCR5.  
In the following sections, we describe CCR5-SNAP construct design from a previous 
template to introduce the signal peptide and the FLAG tag. We also describe several 
functional assays such as calcium mobilization and cAMP inhibition to demonstrate that 
the receptor functions like WT CCR5. We also describe the labeling and purification 
method developed to obtain full-length, monomeric CCR5-SNAP from HEK2P3T cells. 
We employed SDS-PAGE analysis and FCS to evaluate the affinity purification. We 
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show that CCR5-SNAP can be purified away from receptor truncations and aggregates 
and that the method is robust and reproducible.  
2.2  Materials and Methods 
2.2.1  Sequence Design and  Molecular Cloning of CCR5-SNAP 
1.0 μg of plasmid encoding the 5HT3A serotonin receptor signal peptide and FLAG tag 
(SP-FLAG) sequence was digested with MlyI (New England Biolabs, Ipswich, MA) for 2 
hours at 37 °C. MlyI was heat-inactivated by incubating for 20 minutes at 65 °C. The SP-
FLAG fragment was purified from the linearized plasmid by agarose gel (0.8%) 
electrophoresis in 1x TAE with ethidium bromide (0.5 µg/ml). The desired bands were 
isolated from the gel and purified using QIAGEN’s gel purify kit per the manufacturer’s 
instructions (Germantown, MD). Methylation-free SP-FLAG was generated using 
Invitrogen’s Pfx Platinum polymerase (Grand Island, NY) using the following forward 
primers 5-‘GCTTCCTGCAGGAGATGATACC-3’ and reverse primer 5-
GCTGGACACCTGGTAATCCAT-3. Methylation-free SP-FLAG was purified by 
adding the PCR reaction directly to the spin filter from QIAGEN’s gel purify kit and then 
proceeding with the protocol per the manufacturer’s instructions. FLAG-SP was inserted 
upstream of human CCR5 using Agilent’s Quikchange Lightning mutagenesis kit (Santa 
Clara, CA) with slight modifications. Briefly, 25 ng of CCR5 was added to 250 ng of 
purified, methylation-free SP-FLAG in the presence of dNTPs, Quikchange buffer, and 
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polymerase in 25 µl total volume. The PCR mixture was cycled using the parameters 
shown in Table 2.2.1. 
Table 2.2.1 PCR cycling times and temperatures used to generate SP-FLAG-CCR5. 
The PCR reaction was then used for bacterial transformation per Agilent’s instructions.  
Single colonies were inoculated in 5 ml of LB media with ampicillin (50 μg/ml) and 
incubated for 12 hours at 37 °C. Plasmid DNA was isolated and purified from 3 ml of 
culture using QIAGEN’s miniprep kit per the manufacturer’s instructions. Samples were 
sequenced using the T7 forward primer, BGHR reverse primer, and several CCR5 
internal primers. Sequencing results were analyzed using Snapgene and Omega Clustal.  
To generate FLAG-SP-CCR5-SNAP, FLAG-SP-CCR5 and CCR5-SNAP were digested 
with HindIII and KpnI-HF endonucleases for 16 hours at 37 °C. Enzymes were heat-
inactivated by incubating the samples at 80 °C for 20 minutes. The DNA fragments were 
resolved by agarose gel (1.0 %) electrophoresis in 1x TAE. The desired bands were 
isolated using Millipore’s DNA extraction centrifugal filter units (Billerica, MA). 
Ligation reactions were set-up using T4 DNA ligase (New England Biolabs) per the 
manufacturer’s instructions. Reactions were incubated for 30 minutes at room 
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temperature and then 2 µl of sample was added to 20 µl of TOP10 chemically competent 
cells. Cells were incubated on ice for 30 minutes before heat-shocking them at 42 °C for 
45 seconds. Cells were placed on ice for an additional 2 minutes and then 180 µl of SOC 
media was added to each sample. Cells were recovered for 1 hour at 37 °C with shaking 
in an Eppendorf thermomixer at 1,100 rpm. 200 µl of sample were plated onto individual 
LB-agar plates with ampicillin (50 µg/ml) for 16 hours at 37 °C. Single colonies were 
inoculated in LB media (5 ml) with ampicillin and incubated at 37 °C for 16 hours. DNA 
was isolated from 3 ml of culture using QIAGEN’s miniprep and sequenced using T7 and 
BGHR primers. Successful clone was re-named simply as CCR5-SNAP.  
 
2.2.2  Cell Culture and Transfection 
 
HEK293T cells (passage number 5 to 15, ATCC, Manassas, VA) were maintained in 
DMEM-Q, 1% penicillin-streptomycin, and 10% fetal bovine serum (FBS) from Atlanta 
Biologicals (Flowery Branch, GA). Transient transfections including high-throughput in-
plate transfections were performed using Lipofectamine 2000 according to 
manufacturer’s instructions with some modifications as described previously (Berchiche 
& Sakmar 2016). Total transfected DNA was kept constant in all our experiments at 12 
µg in 10cm dishes; 2 µg in 6 well plates; 100 ng in 96 well plates and 20 ng in 384 well 





2.2.3  Flow Cytometry 
 
HEK293T cells transfected in six-well plates with 0.75 µg CCR5 W.T. or 2.0 µg CCR5-
SNAP or 2 µg of empty vector pcDNA3.1+. Cells were detached in ice cold PBS. Cells 
were then distributed in 96 well round bottom plates, spun down and re-suspended in 
BRET buffer (PBS containing 0.5mM MgCl2 and 0.1% BSA) containing, anti-CCR5 
mAb (Clone 2D7) or anti-CCR5 (Clone T21/8) or anti-Flag PE for 45 minutes at 4°C. 
Cells were then washed three times in ice cold PBS. Cell surface expression was 
quantified by flow cytometry using the Accuri C6 flow cytometer (BD Biosciences). 
 
2.2.4  Adenylyl Cyclase Activity 
 
HEK293T cells were co-transfected in a high-throughput in-plate manner with 12 ng 
Rluc3-EPAC-GFP, a BRET2 cAMP sensor, and 23 ng CCR5 W.T. or 60 ng CCR5-SNAP 
or 88 ng of empty vector pcDNA3.1+. Cells were then plated into 0.01% poly-D-Lysine 
coated 96-well, white microplates with clear bottom at a density of 100,000 cells/well. 
Twenty-four hours post transfection; media was replaced with BRET buffer. 
Coelenterazine 400A was added at a final concentration of 5 µM followed by a 5 minutes 
incubation at room temperature (RT). Cells were then stimulated with ligand in the 
presence or absence of 5 µM of forskolin at room temperature for 5 minutes. 
Luminescence and fluorescence readings were collected using the Synergy NEO2 plate 
reader from Biotek (Winooski, USA) and Gen5 software. BRET2 readings between Rluc3 
and GFP10 were collected by sequential integration of the signals detected in the 365 to 
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435 nm (Rluc3) and 505 to 525 nm (GFP10) windows. BRET2 ratios were calculated as 
described previously [57, 58]. 
2.2.5  Calcium Flux Assay 
For each well of a 384-well plate, 20,000 HEK293T cells were transfected with 10 ng 
CCR5 W.T. or 20 ng CCR5-SNAP. Transfected HEK293T cells were plated into 384-
well plates (Corning) coated with poly-D-lysine hybrobromide (Sigma-Aldrich, St. Louis, 
MO) at 20 uL/well. Twenty-four hours post-transfection, 20 uL/well FLIPR calcium 6 
dye (Molecular Devices, Sunnyvale, CA) was added to the cells and incubated for 1.5 
hours at 37°C with 5% CO2. The dye was dissolved in HBSS-H (Hank’s Balanced Salt 
Solution with 20 mM HEPES, pH 7.4) and supplemented with 0.4% BSA (fatty acid free-
Free, Roche). Prior to measurement, the plate was incubated at 37ºC for an additional 30 
minutes in a pre-warmed FlexStation II 384 Plate Reader (Molecular Devices). Ligands 
at a 5x final concentration were diluted in HBSS-H supplemented with 0.2% BSA. 
Fluorescence readings were collected using the FlexStation plate reader with excitation at 
485 nm, emission at 535 nm and dichroic mirror at 525 nm. The FlexStation took 
measurements over a 100 second time course, with 10 µL of ligand added to the cells 20 
seconds after the start of measurement. Relative fluorescence units (RFU) are reported as 
the peak magnitude signal subtracted by the basal signal in each well. 
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2.2.6 Lipids and Buffer N Preparation 
 
DOPC and DOPS chloroform solutions are added to a previously tared round bottom 
flask separately. Chloroform solutions are gently swirled under an argon stream to 
evaporate the solvent and leave a thin and uniform lipid film. Round bottom flasks are 
placed inside a rotovap to evaporate the remaining chloroform under vacuum. Flasks are 
re-weighted to determine the total weight of the lipids. 10% DDM solution is added to the 
lipids to bring them to 1% (w/v) final concentration. Solutions are then repeatedly freeze-
thawed in liquid nitrogen-warm water to bring the lipids into solution. Lipids are stored at 
-20 °C for long-term storage. To prepare Buffer N, a solution containing 100 mM HEPES 
pH 7.4, 0.5 M (NH4)2SO4, 5 mM CaCl2, and 25 mM MgCl2 is added to a 50 ml vessel. 
Glycerol is then added to a final concentration of 10% (v/v) along with the lipids and 
detergents to the desired concentration. Lipids and detergents have been previously 
normalized to ensure that the total detergent concentration does not exceed the desired 
final concentration. The solution is brought to 50 ml total volume with Millipore grade 
water and then filtered using a 0.45 µm vacuum filter unit. Buffer N is stored at -20 °C 
for long-term storage.  
 
2.2.7  Expression, Labeling, and Purification of CCR5-SNAP 
 
To purify CCR5-SNAP, we employed a tandem affinity purification protocol employing 
the FLAG and 1D4 epitopes to remove receptor truncations (Figure 2.2.8). 10 100mm x 
20mm polystyrene dishes are plated with HEK293T cells at 4.0x106 cells/dish in DMEM 
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+ FBS. 24 hours post-plating, 100 µl of Plus Reagent is mixed with 80 µg of CCR5-
SNAP in 7.5 ml of DMEM. In a separate vessel, 170 µl of lipofectamine reagent is mixed 
with 5 ml of DMEM. After 15 minutes, the transfection solutions are mixed and 
incubated for 15 minutes. Media is removed from HEK293T cells and supplemented with 
2.8 ml of DMEM. 1.2 ml of the transfection solution is added to each plate and the cells 
are incubated for 4 hours before supplementing the media with 4 ml of DMEM + 20% 
FBS. 24 hours post-transfection, media is removed from the cells and cells are harvested 
in 2 ml/dish of PBS and 1 mM phenylmethylsulfonyl fluoride (PMSF). Cells are pelleted 
in a 50 ml vessel at 1,500 rpm using a Beckman GS-6R centrifuge at 4 °C for 5 minutes. 
The harvesting solution is removed and the cell pellet is solubilized in 5 mls of Buffer L 
(20 mM HEPES pH 7.4, 0.1 M (NH4)2SO4, 1 mM CaCl2, 5 mM MgCl2, 10% Glycerol, 
0.1% CHS, 1.0% DDM, 1.0% CHAPS) supplemented with a protease inhibitor cocktail 
for 2 hours at 4 °C. Cell lysates are then centrifuged at 55,000 rpm for 30 minutes, 4 °C, 
using a TLA 100.3 rotor. The supernatant was added to 600 µl of 50% slurry 1D4 mAb 
Sepharose 2B resin and incubated overnight at 4 °C. Resin is pelleted in a GS-6R for 5 
minutes, 2,000 rpm, 4 °C and then transferred to a Ultrafree-MC-HV Durapore PVDF 
0.45 µm centrifugal unit. CCR5-SNAP was labeled in 400 µl of buffer N (20 mM 
HEPES pH 7.4, 0.1 M (NH4)2SO4, 1 mM CaCl2, 5 mM MgCl2, 10% Glycerol, 0.07% 
CHS, 0.33% DDM, 0.33% CHAPS, 0.018% DOPC, 0.008% DOPS) with 50 µM SNAP-
substrate and 1 mM DTT for 30 minutes at R.T. Resin was then washed 3 x 0.5 ml in 
Buffer N for 30 minutes each at 4 °C. CCR5-SNAP was eluted from the 1D4 resin by 
incubating the sample with 1D5 peptide in Buffer N (0.33 mg/ml) twice for 30 minutes 
on ice and eluting by centrifugation. 1D4 purified CCR5-SNAP was added to 100 µl of 
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FLAG M2 resin and incubated overnight at 4 °C. FLAG resin was transferred to a 
separate Durapore spin filter and washed 3 times with 0.5 ml of Buffer N for 30 minutes 
each at 4 °C. CCR5-SNAP was eluted by incubating the resin twice with 100 µl of buffer 
N and FLAG peptide (200 µg/ml) 30 minutes on ice. FLAG purified CCR5-SNAP was 
loaded into a Superdex 200 10/300 GL column previously equilibrated with Buffer N and 
0.1 mg/ml BSA (IgG free). CCR5-SNAP was eluted over 1 column volume into 0.5 ml 
fractions. Western immunoblotting and fluorescence correlation spectroscopy were 
employed to analyze the SEC fractions.  
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Figure 2.2.8. Schematic displaying the tandem affinity protocol developed to purify full 
length, monomeric CCR5-SNAP from mammalian cells. 
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2.2.8  Immunostaining and TIRF microscopy 
HEK293T cells were plated onto 35 mm glass bottom (1.5) Matek plates at 300,000 cells 
per dish. Cells were transfected with CCR5 W.T. at 0.75 µg or CCR5-SNAP at 0.2 µg or 
pCDNA3.1+ at 2.0 µg at a total DNA/dish of 2.0 µg using Lipofectamine 2000 per 
manufacturer’s instructions. 24 hours post-transfection, media was aspirated from the 
plates and cells washed with 1 x 2 ml of PBS supplemented with Ca and Mg (Ca/Mg). 
Cells were then permeabilized with 1 ml of cold methanol for 5 minutes at -20 °C. Cells 
were then washed 3x1 ml of cold PBS (Ca/Mg) before blocking overnight in 0.5% BSA 
in PBS (Ca/Mg) at 4 °C. Blocking solution was removed and 1D4 monoclonal antibody 
at a dilution of 1:2,000 in 0.5% BSA-PBS (Ca/Mg) was added for 1 hour at room 
temperature. Cells were then washed with 3x1 ml of PBS (Ca/Mg). Secondary antibodies 
conjugated to Alexa-488 were added at a final dilution of 1:500 in 0.5% BSA-PBS 
(Ca/Mg) for 1 hour at room temperature. Cells were washed again 3x1 ml of PBS 
(Ca/Mg) and then LiCor mounting media containing DAPI was added to the cells. Cells 
were visualized on a Nikon TiE inverted TIRF-FLIM microscope using an Apo TIRF 
100x oil N2 objective (N.A. 1.49). Images were collected on an Andor NEO sCMOS 
camera using 405 and 488 nm excitation with a total exposure of 150 ms per image. 
Images were acquired at room temperature using the following dimension order, 
XYCZT, which are 2048, 2048, 3, 1, 1 pixels respectively.  Filters used were 525/50 and 
450/40. Images were processed using ImageJ and Adobe Illustrator. 
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2.2.9  SDS-PAGE Analysis and Immunoblotting 
Samples were mixed with DTT at 150 mM final concentration and NuPAGE loading 
buffer. Samples were loaded into a NuPAGE 4-12% Bis-Tris gel in MES-SDS buffer. 
Electrophoresis was conducted at a constant voltage of 115V. The gel was removed from 
the cassette and rinsed in water before equilibrating in Western Transfer buffer (48 mM 
Tris, 39 mM glycine, 1.3 mM SDS, 20% methanol, pH 9.2). 1 piece of Immobilon PVDF 
membrane-Fl was incubated for 1 minute at room temperature in 100% methanol. The 
PVDF membrane and 2 pieces of extra thick blot papers (Bio-rad) were rinsed in Western 
transfer buffer. Western transfer was performed in a semi-dry apparatus for 45 minutes 
with a constant voltage of 18V. After electrophoresis, the membrane was placed in 10 ml 
of Odyssey blocking buffer (PBS) and incubated for 1 hour at room temperature. The 
membrane was then placed in 10 ml of blocking buffer with anti-1D4 mouse monoclonal 
(1:1,000), anti-FLAG rabbit polyclonal (1:1,000) antibodies, and 0.2% Tween-20. The 
membrane was incubated overnight at 4 °C. Membrane was then washed 5x5 minutes in 
1x PBS-T (0.1% Tween-20). Membrane was incubated for 1 hour at room temperature in 
10 ml blocking buffer supplemented with 0.2% Tween-20, 0.01% SDS, goat anti-mouse 
IR 680 RD (1:10,000), and goat anti-rabbit IR 800 CW (1:10,000). Membrane was 
washed again 5x5 minutes in 1x PBS-T and then 2x5 minutes in 1x PBS buffer. 
Membranes were visualized using a LICOR Odyssey SA using 100 µm resolution, and 
intensity level 7 for both 700 and 800 nm excitations. Images were processed using 
Image Studio Lite Version 4.0 and ImageJ. For the line scan analysis, a rectangle of 45 x 
120 pixels was drawn around the desired gel lane and set as First Lane under Analyze, 
30 
Gels, in ImageJ. The command ‘Plot Lanes’ was then selected with vertical and 
horizontal scale factors set to 1.0 with uncalibrated optical density. Using the magic 
wand, an area under the curve was selected and saved as x and y coordinates for 
replotting in GraphPad Prism 7. 
2.2.10  Fluorescence Correlation Spectroscopy Measurements 
Samples were loaded into # 1.5 glass bottom 96 well black plate (Senso plates, black, 384 
well reference number: 788892, 96-well plate reference number: 655892) and mounted in 
an inverted laser scanning confocal microscope LSM 780 (Zeiss). Alexa-488 was excited 
using an Argon 488 nm laser at 0.2% laser transmission. Laser excitation was focused 
into the sample by using a 40x C-Apochromat NA 1.2 water immersion objective. 
Correction collar was adjusted in the objective to 0.17 and room temperature. To prevent 
deformation of the PSF due to glycerol in the solution, the excitation volume was focused 
50 µm above the glass by performing a line scan using reflected light from the 488 nm 
laser line. For 488 nm excitation, a 488 only main beam splitter (MBS) was used. 
Emission from Alexa-488 was collected in the range of 516 – 596 nm using a GaAsP 
detector. Pinhole was set to 1.0 airy unit and aligned along the 𝑥𝑦 plane using a solution 
of free dye. Count-rate binning time was set to 1 ms and the correlator binning time was 
set to 0.2 µs. Count rates were never greater than 500 kHz and traces showing large 
deviations from the average or decaying/increasing fluorescence were manually removed 
from the analysis. Counts per molecule (CPM) values were between 1-16 kHz for all 
measurements to avoid optical saturation while maximizing counts above background. 
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For each single sample, data was collected in 10 repetitions of 10 seconds each and 
averaged after removing traces that contained large deviations from the average. FCS 
data analysis and concentration derivations were performed as described in section 3.2.2 
and 3.2.7 
 
2.3  Results 
 
2.3.1  CCR5-SNAP Cloning and Sequence 
 
CCR5-SNAP was successfully generated from the parent plasmid DNA containing 
CCR5. Our initial construct did not encode for the FLAG and signal peptide sequences. 
Also, we did not have restriction sites that we could use to swap the SP-FLAG sequence 
into CCR5-SNAP. We did not introduce new restriction sites since it would require 
various steps and the method would be time consuming. Instead, we employed a cloning 
method that does not rely on restriction enzyme or DNA ligation to introduce the SP-
FLAG sequence into CCR5-SNAP.[59] The method relies on PCR amplification of a 
‘megaprimer’ containing the desired sequence to be inserted and the parent DNA 
sequence. The parent DNA and ‘megaprimer’ sequences must have homologous end 
DNA sequences for the insertion to be successful. The PCR reaction is slightly modified 
from the Quickchange mutagenesis protocol to allow efficient insertion of the 
megaprimer sequence. We generated SP-FLAG-CCR5 from which we inserted the into a 
plasmid backbone to replace CCR5 and generate SP-FLAG-CCR5-SNAP. For this step, 
we employed restriction enzymes and DNA ligation since the sites between DNA 
32 
sequences were compatible. We sequenced both SP-FLAG-CCR5 and CCR5-SNAP 
(end-product) and we verified that the coding sequence remained intact. Figure 2.3.1 
shows a schematic of CCR5-SNAP and the functional tags fused to the N- and C-terminal 
ends of the receptor.  
Figure. 2.3.1. CCR5-SNAP sequence and functional tags fused to human CCR5. 
Schematic showing the different functional tags fused to the codon optimized human 
CCR5 gene (blue cylinder) and their amino acid positions. The signal peptide (violet 
ellipse) was incorporated for receptor cell surface trafficking, FLAG (cyan cylinder) and 
1D4 (green cylinder) epitopes for affinity purification, double OLLAS (orange cylinders) 
and Strep-III (red) tags for surface immobilization, and SNAP tag (yellow hexagon) for 
covalent attachment of fluorophores. 
2.3.2  CCR5-SNAP Cell Surface Expression Quantification 
We characterized CCR5-SNAP in HEK293T cells to demonstrate that the functional tags 
did not interfere with receptor cell surface expression. CCR5-SNAP and WT CCR5 cell 
surface expression levels were quantified by flow cytometry using different epitope 
recognizing antibodies conjugated to PE (Figure 2.3.2).  
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Figure 2.3.2 Cell surface quantification by flow cytometry of wild-type CCR5 and 
CCR5-SNAP in HEK293T cells stained with (a) anti-CCR5 (clone 2D7); (b) anti-FLAG 
or (c) anti-CCR5 (clone T21/8) coupled to phycoerythrin (PE). Data are mean of four 
independent experiments ± S.E.M. 
We employed the conformational sensitive 2D7 mouse monoclonal antibody, which 
recognizes the second extracellular loop (ECL2) of CCR5. 2D7-PE staining shows that 
wild-type CCR5 and CCR5-SNAP express at similar levels in HEK293T cells under the 
transfection conditions tested (a). Since the N-terminus of CCR5-SNAP is fused to the 
FLAG tag sequence, we tested the mouse monoclonal antibody T21/8-PE to show that 
the N-terminus could be recognized. T21/8-PE staining shows that the FLAG tag does 
not interfere with CCR5-SNAP recognition and that CCR5-SNAP express at similar 
levels as wild-type in agreement with the 2D7-PE detection (b). We also tested 
recognition of CCR5-SNAP with anti-FLAG-PE as a positive control since the antibody 
is not conformationally sensitive. Figure 2.3.2c shows that the anti-FLAG-PE does 
recognize CCR5-SNAP but not CCR5 as expected. 
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2.3.3  CCR5-SNAP Expression Characterization in Cells 
To validate the flow cytometry results, we performed TIRF imaging on HEK293T cells 
expressing CCR5 or CCR5-SNAP and stained with anti-1D4 antibody and Alexa-488 
conjugated secondary antibody. Figure 2.3.3 shows representative TIRF images for WT 
CCR5 and CCR5-SNAP stained in fixed HEK293T cells. 
Figure 2.3.3. Fluorescent images of HEK293T cells expressing wild-type CCR5 (i) or 
CCR5-SNAP (j) imaged using TIRF microscopy. CCR5 was detected using the anti-1D4 
mouse antibody and Alexa-488 conjugated anti-mouse secondary.  
We employed TIRF microscopy since only receptor at the plasma membrane will be 
excited by the evanescent wave. CCR5 and CCR5-SNAP both express at the cell 
membrane of HEK293T cells and show prototypical membrane distribution observed for 
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membrane receptors indicating that the functional tags do not perturb receptor cell 
surface trafficking. 
2.3.4  CCR5-SNAP Inhibits cAMP like WT CCR5 
We characterized the signaling properties of CCR5-SNAP in comparison to wild-type 
CCR5 to show that the intracellular tags did not affect coupling to intracellular partners. 
CCR5 is a Gαi coupled receptor whose activation reduces the levels of cAMP in cells. 
cAMP levels in cells can be measured using a BRET reporter based on the exchange 
protein directly activated by cAMP or (EPAC). In the absence of cAMP, the EPAC-
BRET reporter is in an open conformation that allows energy transfer between RLuc3 
and GFP. cAMP binding to the reporter induces a conformational change that prevents 
energy transfer and a reduction in BRET is observed. We generated dose response curves 
for CCR5 and CCR5-SNAP expressed in HEK293T cells with the EPAC-BRET reporter 
in response to different concentrations of chemokines (Figure 2.3.4) 
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Figure. 2.3.4 Percent inhibition of forskolin-induced cAMP production by wild-type 
CCR5 (d) and CCR5-SNAP (e) in response to increasing concentrations of MIP-1α 
(black), RANTES (red), 5P12 (blue), 5P14 (green), 6P4 (yellow), and PSC (violet).  Fits 
are only shown for wild-type CCR5 as a direct comparison (Lorenzen et al.). Data points 
are mean from 3 independent experiments performed in triplicate ± S.E.M. 
Dose response curves were fitted to a 3-parameter logarithmic equation to derive 
logEC50 and Emax values (Table 2.3.4). Chemokines inhibited cAMP production with 
similar efficacies and potencies in CCR5-SNAP and CCR5 expressing cells indicating 
that CCR5-SNAP can signal through Gαi as wild-type CCR5. We did observe that 6P4 
and PSC had higher ΔEmax values at CCR5-SNAP (34 ± 1 and 31 ± 7 respectively) than 
at wild-type CCR5 (20 ± 1 and 17 ± 3 respectively). 
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cAMP inhibition
Receptor Ligand N IC50 (nM) pIC50 ± S.E.M. Emax  ± S.E.M. 
CCR5 
RANTES 3 0.8 -9.2 ± 0.2 26 ± 2 
MIP-1 3 1.3 -9.3 ± 0.5 21 ± 4 
5P12-RANTES 3 2.4 -8.7 ± 0.1 17 ± 6 
5P14-RANTES 3 0.5 -9.4 ± 0.2 32 ± 3 
6P4-RANTES 3 0.1 -9.9 ± 0.1 20 ± 1 
PSC-RANTES 3 0.7 -9.2 ± 0.1 17 ± 3 
CCR5-SNAP 
RANTES 3 1.7 -9.8 ± 0.1 24 ± 5 
MIP-1 3 8.8 -8.2 ± 0.2 24 ± 7 
5P12-RANTES 3 1.9 -8.9 ± 0.3 15 ± 3 
5P14-RANTES 3 0.9 -9.2 ± 0.2 38 ± 6 
6P4-RANTES 3 0.2 -9.7 ± 0.1 34 ± 1 
PSC-RANTES 3 0.4 -9.4 ± 0.1 31 ± 7 
2.3.5  CCR5-SNAP Induces Calcium Mobilization Like WT CCR5 
We also tested CCR5-SNAP capability to induce calcium mobilization in HEK293T cells 
using the G-protein chimera Gαqi5 which has the last five C-terminal amino acids from 
Gαi in Gαq. Cells expressing CCR5 or CCR5-SNAP were treated with the FLIPR calcium 
6 dye which becomes fluorescent after chelating calcium ions. Dose response curves for 
CCR5 and CCR5-SNAP were generated in response to different concentrations of 
chemokines and fitted to a three-parameter logarithmic equation (Figure 2.3.5.)  
Table 2.3.4 Fitted parameters to the dose response curves generated for CCR5 and 
CCR5-SNAP to varying concentrations of chemokines. Dose response curves for cAMP 
inhibition were fitted in Origin with a three-parameter logistic equation. Values are the 
average from three independent experiments ± S.E.M.  
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Figure 2.3.5 Calcium flux by wild-type CCR5 (a) and CCR5-SNAP (b) in response to 
increasing concentrations of the indicated native and chemokine analogues. Data points 
represent the mean maximum fluorescence minus basal fluorescence from 3 independent 
experiments in triplicate ± S.E.M. 
CCR5 and CCR5-SNAP did not induce calcium mobilization when stimulated with 5P12 
or 5P14. CCR5-SNAP did not respond to MIP-1α and showed lower potencies to 
RANTES (40 nM) and PSC-RANTES (45 nM) as compared to wild-type CCR5 (14 and 
11 nM respectively, Table 2.3.5) Overall, CCR5-SNAP is capable of recognizing G-
proteins and activate different signaling pathways indicating that the intracellular tags do 
not affect G-protein coupling and activation. 
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Calcium flux
Receptor Ligand N EC50 (nM) pEC50 ± S.E.M. Emax  ± S.E.M. 
CCR5 
RANTES 3 14 -7.8 ± 0.2 13000 ± 1600 
MIP-1 3 96 -7.0 ± 0.3 20000 ± 3900 
5P12-RANTES 3 ND ND ND 
5P14-RANTES 3 ND ND ND 
6P4-RANTES 3 23 -7.6 ± 0.1 53000 ± 2600 
PSC-RANTES 3 11 -7.9 ± 0.1 38000 ± 2200 
CCR5-SNAP 
RANTES 3 40 -7.3 ± 0.4 12000 ± 3000 
MIP-1 3 ND ND ND 
5P12-RANTES 3 ND ND ND 
5P14-RANTES 3 ND ND ND 
6P4-RANTES 3 34 -7.5 ± 0.3 21000 ± 3400 
PSC-RANTES 3 45 -7.4 ± 0.2 26000 ± 3300 
2.3.6  CCR5-SNAP Tandem Affinity Purification 
To evaluate the tandem affinity purification procedure, we analyzed the purity of the cell 
lysate, 1D4, and FLAG elution fractions by near-infrared (NIR) fluorescent western 
immuno-blotting (Figure 2.3.7). We employed NIR detection because it provides higher 
sensitivity than chemiluminescence detection, signals are linearly proportional to protein 
amount, and multiple antibodies can be used simultaneously. The 680-nm emission, red 
color, is from detection of the 1D4 epitope and the 800-nm emission, green color, is from 
detection of the FLAG tag in the receptor.  
Table 2.3.5 Fitted parameters to the dose response curves generated for CCR5 and 
CCR5-SNAP to varying concentrations of chemokines. Dose response curves for calcium 
flux were fitted in Origin with a three-parameter logistic equation. Values are the average 
from three independent experiments ± S.E.M. ND (not determined) is reported for when 
the fit did not converge. 
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Figure 2.3.6 Reducing SDS-polyacrylamide gel electrophoresis and near-infrared 
fluorescent western blot of cell lysate (left lane), 1D4 elution (middle lane), and FLAG 
elution (right lane) from tandem affinity purification. Full-length CCR5-SNAP (~75 kDa, 
yellow band) was detected using antibodies against the 1D4 and FLAG epitopes and 680 
nm (middle panel) and 800 nm (right panel) fluorescent secondary antibodies. 
CCR5-SNAP runs with an apparent molecular weight of ~75 kDa which is the prominent 
yellow band in all 3 lanes. Cell lysate fraction shows the presence of several receptor N-
terminal truncations that are 1D4 only positive and run below 75 kDa. We also observe 
the presence of CCR5-SNAP dimers at 150 kDa and higher order oligomers around 250 
kDa. After 1D4 affinity purification, we observe that most receptor N-terminal 
truncations and oligomers co-elute with the monomeric receptor. However, we can purify 
away most of the receptor truncations after FLAG affinity purification as shown by their 
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absence in the FLAG elution fraction. We also observe CCR5 oligomers in the FLAG 
elution fraction and their presence can complicate the analysis of single molecule 
measurements. Therefore, we employed SEC to purify the monomeric receptor from 
these receptor oligomers.  
2.3.7  SEC Purification and Concentration Quantification by FCS 
We employed SEC to purify the monomeric receptor from these receptor oligomers.  
We injected the FLAG elution into a Superdex 200 10/300 GL column and protein 
elution was monitored by adding IgG- and detergent-free bovine serum albumin (BSA) to 
the sample. Figure 2.3.8 shows the 280 nm absorbance chromatograph (blue line) for 
fractions 20 to 30.  
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Figure 2.3.7 Size exclusion purification chromatograph (SEC) of CCR5-SNAP-488. 
Protein elution was monitored using 280 nm absorbance (blue). Fractions 20 to 30 were 
analyzed by FCS (top inset) to derive concentrations for each fraction (green). 
FCS autocorrelation traces for representative fractions are shown in the top inset. We 
averaged concentrations from 5 independent purifications and are shown alongside the 
280 nm absorbance chromatograph as the green line where the errors bars are the S.E.M. 
The FCS-derived chromatograph shows that the receptor peak fraction is in fraction 25 
and the average concentration is 4.5 ± 0.6 nM per purification. 
2.3.8  Western Immunoblot of CCR5-SNAP SEC Fractions. 
We also analyzed fractions 20 to 30 by NIR western immunoblotting to determine where 
monomeric CCR5-SNAP-488 eluted and the purity of the fraction. Figure 2.3.9 shows 
the overlay from 680 and 800 nm fluorescence and the independent fluorescence 
channels.  
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Figure 2.3.8 Reducing SDS-polyacrylamide gel electrophoresis and near-infrared 
fluorescent western blot of SEC fractions 20 to 30. CCR5-SNAP-488 was detected using 
antibodies against the 1D4 and FLAG epitopes and 680 nm (middle panel) and 800 nm 
(right panel) fluorescent secondary antibodies. 
Monomeric CCR5-SNAP-488 elutes in all fractions but CCR5-SNAP-488 oligomers are 
only present in fractions 20 to 24. Fractions 25 to 27 contain only monomeric CCR5-
SNAP-488 and these fractions were employed for single molecule FCCS ligand binding 
measurements. 
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2.4  Discussion 
2.4.1  CCR5-SNAP Cell Surface Expression 
We proceeded to characterize CCR5-SNAP in cell-based functional assays to determine 
if the functional tags affect receptor activity. We normalized receptor expression levels 
by varying the DNA amount used for transient transfection. We had previously observed 
that different expression levels resulted in shifts in efficacy and potency in cAMP 
inhibition experiments (data not shown). We found that 0.75 µg of CCR5-SNAP yielded 
similar receptor expression as 2.0 µg of CCR5. We employed these DNA quantities for 
all receptor characterization experiments. We expressed CCR5-SNAP and wild-type 
CCR5 for 24 hours in HEK293T cells since longer incubation times severely affected 
receptor expression and function. We were concerned that the FLAG tag may interfere 
with ligand recognition so we performed flow cytometry experiments using the 
conformationally sensitive 2D7 antibody to quantify CCR5-SNAP cell surface 
expression.[60] We did not observe any differences in CCR5-SNAP and wild-type CCR5 
cell surface expression in HEK293T cells with 2D7-PE. Chemokines also bind to the 
receptor N-terminus and the FLAG tag is positioned upstream the N-terminus.[61] Given 
this, we repeated the flow cytometry measurements but we used the T21/8 antibody, 
which recognizes the receptor N-terminus. As before, we did not observe any differences 
between CCR5-SNAP and wild-type CCR5 expression levels with the T21/8-PE 
antibody. We also did not observe any differences in total fluorescence between the 
T21/8-PE stained samples and the 2D7-PE samples. We also tested the FLAG-PE 
antibody on CCR5-SNAP and CCR5 expressing cells as a control experiment. We 
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detected CCR5-SNAP with the FLAG-PE antibody while we did not observe 
fluorescence above background from either the mock or wild-type CCR5 cells. 
2.4.2  CCR5-SNAP Coupling to G-Proteins 
We determined CCR5-SNAP capacity to inhibit cAMP production after chemokine 
stimulus. CCR5 couples to Gαi, which regulates adenylyl cyclase activity in cells. We 
employed the EPAC-BRET reporter to measure cAMP levels before and after chemokine 
stimulus.[62] We tested the RANTES analogues and the native chemokines RANTES 
and MIP-1α at increasing concentrations to generate dose-response curves for cAMP 
inhibition. To induce production of cAMP, cells were treated with the diterpene Forskolin 
that activates adenylyl cyclase. Lorenzen (2017) systematically analyzed biased agonism 
by the RANTES analogues on CCR5 and we based our wild-type CCR5 results from this 
study. CCR5-SNAP inhibited cAMP production with similar efficacy and potencies as 
wild-type CCR5 with the tested chemokines. The result shows that the intracellular 
functional tags do not interfere with receptor coupling and activation of Gαi in HEK293T 
cells. Surprisingly, 5P12 and 5P14 inhibited cAMP production even though they are 
presumed to not activate G-protein. Puzzled by these findings, we tested the chemokines 
in a different assay that measures calcium levels after ligand stimulation. We employed 
the G-protein chimera Gαqi5 which has the last five C-terminal amino acids from Gαi in 
Gαq. Gαq signaling activates calcium channels in the endoplasmic reticulum thereby 
increasing calcium levels in the cytosol. To measure calcium levels, cells were treated 
with the calcium cheater, FLIPR calcium dye 6, which becomes fluorescent upon calcium 
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binding. Dose response curves showed that the chemokines induce activation of Gαqi5. 
We observe that the chemokines induce calcium mobilization with similar efficacy and 
potency at CCR5-SNAP and wild-type CCR5. Our results with the cAMP inhibition and 
calcium flux assays show that CCR5-SNAP can couple and activate G-protein like wild-
type CCR5.  
2.4.3  CCR5-SNAP Functional Tags for Purification 
We purified Alexa-488 labeled, monomeric human CCR5 from receptor truncations and 
aggregates for single molecule ligand binding studies. Previous CCR5 purifications 
reports focused on optimizing detergent conditions to retain CCR5 activity and obtaining 
homogenous preparations in sufficient quantities for structural studies.[63-65] We 
focused on maximizing CCR5 homogeneity and purity and optimizing fluorescent 
labeling in an established detergent system. We employed a combined tandem affinity 
purification and size exclusion chromatography (SEC) step to yield highly pure 
monomeric CCR5. CCR5-SNAP expression in HEK293T cells yields several receptor C-
terminal truncations that are co-purified during one-step affinity purification. We based 
the tandem affinity purification method from Kobilka (1995) with two changes: 1) we 
swapped the hexa-histidine tag in the C-terminus for the 1D4 epitope and 2) we used the 
serotonin 5HT3A receptor signal peptide from guinea pig while Kobilka utilized the 
signal peptide from influenza hemagglutinin.[66] The 1D4 epitope is derived from the 
last 18 C-terminal amino acid residues of Rhodopsin.[67] We employed the 1D4 epitope 
because it has higher specificity than metal affinity purification and it is compatible with 
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several detergents types.[68] We chose the 5HT3A receptor signal peptide because 
Zebrafish odorant receptor expression was increased significantly in HEK293 cells.[56] 
Mirzabekov (1999) supplemented sodium butyrate in their cell medium to boost 
expression of CCR5. We tested the effect of sodium butyrate on CCR5-SNAP expression 
and found negligible expression enhancement (unpublished data).  
2.4.4  Analysis of Previous CCR5 Purification Reports 
We successfully purified full-length CCR5-SNAP from receptor truncations using the 
1D4/FLAG tandem affinity purification. SDS-PAGE and western immunoblot analysis 
shows that 1D4 affinity purification yields full-length receptor co-purified with FLAG-
insensitive truncations of various molecular weights. FLAG purification of CCR5-SNAP 
1D4 elution removes these C-terminal receptor truncations yielding only full-length 
CCR5-SNAP. In contrast, Mirzabekov (1999) and Nisius (2008) employed only C-
terminal epitopes for CCR5 affinity purification since they only observe two prominent 
species in their preparations. Mirzabekov (1999) observes two species that correspond to 
mature and precursor CCR5, while Nisius (2008) observes monomeric and dimeric 
CCR5. We attribute these differences in CCR5 preparations due to the different cell lines 
used by Mirzabekov, canine thymocytes (Cf2Th) cells, and Nisius, insect sf9 cells. We 
also observe CCR5 dimers and higher order oligomers in the FLAG fraction and we 
employed SEC to remove these species from monomeric CCR5. Nisius (2008) also 
employed SEC purification to separate CCR5 monomers and dimers with great 
success.[64] We differ from their approach in that we supplemented CCR5-SNAP with 
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BSA to monitor protein elution by 280 nm absorbance since we were working with very 
small receptor concentrations. Nisius (2008) observed that the total CCR5 population 
consisted of 50% dimer and 50% monomer species. In contrast, we observe one major 
peak fraction, fraction 25, in our FCS-derived chromatograph, which corresponds to 
monomeric CCR5-SNAP. Dimeric CCR5-SNAP elutes in fractions 20-24 but its 
concentration is too low to be observed as a separate peak by FCS. We speculate that the 
different monomer/dimer ratios observed are due to different detergents employed that 
can affect receptor aggregation. We should note that CCR5 oligomerization can also be 
dependent on cell line used and we cannot rule out an effect from the functional tags 
employed in both constructs.  
2.4.5  CCR5-SNAP Solubilization Conditions 
We employed a mixture of DDM, CHAPS, CHS, and the lipids DOPC and DOPS in our 
purification procedure that retains CCR5 ligand binding activity.[44] Mirzabekov (1999) 
and Nisius (2008) tested the same detergents for CCR5 solubilization but selected 
different ones based on conflicting results. They tested Cymal-5 and DDM, which are 
maltoside-derived detergents that differ in the alkyl chain. Cymal-5 and DDM solubilized 
CCR5 without affecting receptor binding. Mirzabekov (1999) chose Cymal-5 over other 
DDM because it has a lower critical micellar concentration than DDM. Nisius (2008) 
chose FosCholine-12 over Cymal-5 and DDM because it was better at solubilization and 
preparations were more homogeneous by electron microscopy. Mirzabekov (1999) tested 
FosCholine-14, which has a longer alkyl chain than FosCholine-12 by 2 carbons, and 
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observed that it was better at solubilizing CCR5 than Cymal-5 and DDM but it abolished 
CCR5 binding to 2D7. Nisius (2008) reported a 𝐾𝐷 value of 1 µM for RANTES binding 
to FosCholine-12 solubilized CCR5 by isothermal calorimetry titration (ITC). 
Navratilova (2005) also observed that CCR5 solubilization with DDM preserved binding 
to 2D7 better than any other detergent tested. Also, Navratilova (2005) discovered that 
addition of CHS, DOPC, and DOPS increased 2D7 binding by providing a more native 
environment than detergent alone. Thus, CCR5 solubilized in DDM containing buffers is 
in a more native environment which is suitable for single molecule ligand binding 
measurements.  
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CHAPTER THREE: FLUORESCENCE CROSS-CORRELATION SPECTROSCOPY 
3.1  Introduction 
We utilized FCCS to perform saturation and competition binding with Alexa-647 labeled 
RANTES analogues and CCR5-SNAP-488. Figure 3.1.1 illustrates the type of binding 
interactions analyzed by FCCS. The blue species represents the membrane receptor 
embedded in a detergent micelle represent by the yellow torus. On the site opposite 
ligand binding, the receptor has been fused with a labeling tag, in this case a SNAP tag, 
represented by the violet circle. The SNAP tag has been labeled with a green fluorophore 
represented by the green star. The ligand, represented by the orange species, has been 
labeled with a red fluorophore as shown by the red star. Ligand interacts with the receptor 
in a 1:1 stoichiometry leading to a double labeled complex. The labeled ligand can be 
displaced from the binding site by a competing ligand in this case the orange species 
without the red star. 
Figure 3.1.1 Schematic showing the binding interactions analyzed by FCCS. Fluorescent 
ligand (orange ellipse with red star) recognizes a lipid bound (yellow ellipse) membrane 
receptor (blue species) that has been fused to a functional tag (violet circle) labeled with a 
fluorophore (green star). Fluorescent ligand binds the receptor (saturation binding) but in 
the presence of unlabeled ligand it is displaced from the binding site (competition 
binding). 
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FCCS measurements are sensitive to refractive index mismatch. The point spread 
function (PSF) becomes distorted if the refractive index mismatch is large between the 
immersion solution and the sample. We optimized the imaging optical depth to ensure 
that we could obtain the maximum count rates from the sample. We also optimized the 
laser power used for FCCS measurements. Optical saturation distorts the PSF and the 
assumption that the PSF can be described as a 3D Gaussian is no longer valid. We 
measured count rates as a function of laser power for Alexa-647, Alexa-488, PSC-647, 
and CCR5-SNAP-488 to determine the linear range at which we could safely record 
fluorescence fluctuations. We also determined the cross-talk from the green channel into 
the red channel. Cross-talk would over-estimate the calculated number of particles for the 
receptor-ligand complex. We quantified the amount of cross-talk and we found negligible 
cross-talk in our system. We also quantified the size of the confocal volumes for 488 and 
633 nm excitations and the cross-correlation volume to derive concentrations for 
receptor, ligand, and complex. 
We then describe the fitting models we used to model the auto- and cross-correlation 
traces and the derivation for how 𝐾𝐷 and 𝐾𝑖 values can be determined from FCCS 
measurements under ideal situations. We performed saturation ligand binding with the 
RANTES analogues, native chemokines, and gp120. We show that the RANTES 
analogues bind with picomolar to nanomolar affinities. We found that 25% of the 
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receptor is active and within this fraction the analogues bind to 38% with high affinity 
and the remaining 62% with low affinity. We also performed homologous and 
heterologous competition binding and show that the unlabeled chemokines bind with 
similar affinities as the labeled chemokines. We also show that native chemokines and 
gp120 cannot displace the labeled RANTES analogues from CCR5-SNAP-488. We 
discuss plausible explanation for the two CCR5-SNAP species and the physiological 
implications of each hypothesis. 
3.2  Materials and Methods 
3.2.1  Correlation and Cross-Correlation Settings 
Samples were loaded into # 1.5 glass bottom 96 or 384 well black plates (Senso plates, 
black, 384 well reference number: 788892, 96 well plate reference number: 655892) and 
mounted in an inverted laser scanning confocal microscope LSM 780 (Zeiss). Alexa-488 
was excited using an Argon 488 nm laser at 0.2% or 0.8% laser transmission and Alexa-
647 was excited using a Helium-Neon 633 nm laser line at 1.0% laser transmission. Laser 
excitation was focused into the sample by using a 40x C-Apochromat NA 1.2 water 
immersion objective. Correction collar was adjusted in the objective to 0.17 and room 
temperature. To prevent deformation of the PSF due to glycerol in the solution, the 
excitation volume was focused 50 µm above the glass by performing a line scan using 
reflected light from the 488 nm laser line. For 488 nm excitation, a 488 nm only main 
beam splitter (MBS) was used, and for 633 nm and dual excitation a MBS 488/561/633 
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was used. Emission from Alexa-488 was collected in the range of 516 – 596 nm using a 
GaAsP detector and emission from Alexa-647 in the range of 650 – 694 nm using a 
separate GaAsP detector. Pinholes for both excitations were set to 1.0 airy units and 
aligned along the 𝑥𝑦 plane using a solution of free dye or the sample itself. Count-rate 
binning time was set to 1 ms and the correlator binning time was set to 0.2 µs. Count 
rates were never greater than 500 kHz and traces showing large deviations from the 
average or decaying/increasing fluorescence were manually removed from the analysis. 
Counts per molecule (CPM) values were between 1-16 kHz for all measurements to 
avoid optical saturation while maximizing counts above background. For single dye 
measurements, 10 repetitions of 10 seconds each were collected and averaged while for 
receptor-ligand binding experiments 50 repetitions of 30 seconds each were collected and 
averaged. 
3.2.2  Fitting Correlation Traces 
FCS and FCCS raw traces were fitted using the ZEN software. Auto- and cross-
correlations were analyzed from 2 µs to 10 s to remove after pulsing from the detectors. 
For the CCR5-SNAP-488 auto-correlation, a single 3D translational diffusing component 
undergoing triplet state transitions was chosen. The structural parameter was fixed to 8, 
the gamma factor to 0.35, and the triplet state relaxation time to 4 µs. The correlation 





























) + 1 (Equation 3.1) 
For the ligand-647 auto-correlation, we applied the previous fit with an included 
independent blinking term. The blinking term was only observed when the ligand was 
present with CCR5-SNAP-488. The structural parameter was fixed to 8 and the gamma 

































) + 1 (Equation 3.2) 
Triplet and blinking states correlation functions were set to be normalized to calculate the 
number of particles that are only in the fluorescent state. In some cases, 𝜏𝑡, was fixed to 7 
µs so that the fit will converge.  
Cross-correlation functions were analyzed by using a single component with 3D 
translational diffusion. Triplet states from Alexa-488 and Alexa-647 will not cross-



















+ 1 (Equation 3.3) 
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To derive errors for each measurement, the total repetitions were divided into 3 
independent sets of measurements and each set was averaged and analyzed using the 
equations above. From these 3 averages, the standard deviation was calculated for the 
number of particles. In cases where 𝜏𝐷𝑐𝑜𝑚𝑝𝑙𝑒𝑥 deviate significantly from previously 
measured values, it was fixed to 550 µs so that the fit would converge. 
3.2.3  Focal Depth Optimization for Measurements in Glycerol Solutions 
We employ a 40x immersion water objective to record correlation measurements. Buffer 
N contains 10% glycerol (v/v) to stabilize membrane proteins. FCS and FCCS 
measurements are best obtained at a focal depth from the glass slide at 200 µm. However, 
pilot FCS and FCCS measurements in Buffer N solution with fluorophores showed a 
decay in measured count rates and a larger PSF than the ones calculated on water 
solutions. We proceeded to optimize the focal depth at which FCS and FCCS 
measurements at recorded to minimize PSF distortion. We prepared solutions of Alexa-
488 and Alexa-647 in Buffer N and Millipore grade water at a final concentration of 1 
nM. We imaged the 4 samples per the settings listed in section 3.2.1. For Alexa-488, we 
used a 1% laser power transmission and Alexa-647 15% laser power transmission.  
3.2.4 Laser Power Optimization for 488 and 633 nm Excitations 
Triplet state transitions are dependent on laser power but the PSF becomes distorted at 
high laser powers. As such, the measured count rates will underestimate the true value 
56 
and the number of particles will overestimate the true number for the sample. To 
determine the optimal laser power for 488 and 633 nm laser excitations, we measured 
laser power as a function of % transmission for both Alexa-488 and Alexa-647. We 
employed 1 nM solutions of both dyes in Buffer N and Millipore grade water. Count-
rates were also measured for Buffer N and water alone to determine the background 
count-rates. For the CCR5-SNAP-488 and RANTES analogues, we employed 0.5 nM 
receptor and 1 nM PSC-647 and measure count rates at conditions identical for FCCS 
measurements. We employed PSC-647 since all the chemokines are labeled at the same 
site using the same chemistry. We measured count rates as described for the free dyes as 
well as just Buffer N to derive background count rates.  
3.2.5  Confocal Volume Determination 
Solutions of Alexa-488 and Alexa-647 were diluted in Buffer N at various concentrations 
from 25 nM to 0.8 nM. FCS measurements were performed per section 3.2.1 and fitted 
using the equations on section 3.2.2. Alexa-647 was fitted without the blinking 
component. Concentrations were plotted as a function of number of particles derived 
from the fits to the correlation traces. To correct for pipetting errors, Alexa-88 and Alexa-
647 stock solutions used for the dilutions (10 µM) were analyzed by UV-Vis to derive 
real concentrations. Concentrations for the diluted solutions were then corrected by a 
factor which accounts for deviations from the assumed valued. From the concentration 
vs. number of particles plot, we derived the slope using LINEST in Microsoft excel and 
divided the number by Avogadro’s number to derive the confocal volume. To calculate 
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the confocal volume for the CC channel, we employed a dual-labeled oligonucleotide 40 
base pairs long with Alexa-488 and Alexa-647 at both ends to minimize FRET. Single 
strand oligonucleotides were re-suspended in 10 mM Tris pH 8.0, 50 mM NaCl, 1 mM 
EDTA to a final concentration of 1 µM in 100 µl of buffer. Samples were added to a 
water bath at 94 °C in a Dewar flask and allowed to anneal until the temperature in the 
water bath reached less than 40 °C. Oligos were then placed at RT while a C4 column 
was equilibrated with 0.1 M ammonium acetate pH 6.6. Oligos were loaded into the 
column and eluted with 50% acetonitrile in water (v/v) by using a 50% gradient of 
acetonitrile. HPLC fractions were analyzed by UV-Vis absorbance for both Alexa-488 
and Alexa-647. The peak fraction was aliquoted into 50 µl aliquots and stored at -20 C 
for long-term storage. The final concentration of the oligo was 110 nM. Stock solutions 
were employed to dilute the oligonucleotide as done for the free dyes. The FCCS 
measurements were done per section 3.2.1, analyzed using the equations in sections 3.2.2 
and the confocal volume determined as described previously for Alexa-647 and Alexa-
488.  
 
3.2.6  Cross-Talk Determination 
 
Cross-talk from the green channel to the red channel was determined using the protocol 
by Bacia & Schwille (2007).[52] Briefly, Alexa-488 (25 nM) in Buffer N was excited 
using 488 nm laser line and the count rates were recorded in GaAsP 1. The same solution 
was excited with the same laser line but instead count rates were recorded on GaAsP 2, 
which is used for the red channels. Count rates from these two measurements were used 






𝐶𝑎𝑙𝑖𝑏𝑟𝑎𝑡𝑖𝑜𝑛 (Equation 3.4) 
In a sample containing dual-labeled oligonucleotide or CCR5-SNAP-488 and labeled 
chemokine, the ratio of the measured green and red count rates was taken and then 






) (Equation 3.5) 




Which is the relative cross-correlation not corrected for cross-talk. 
3.2.7  Determining Fractional Occupancy from FCCS Measurements 
In FCS, fluorescence fluctuations arise from diffusion through the confocal volume 
(𝑉𝑐𝑜𝑛𝑓𝑜𝑐𝑎𝑙) and changes in concentration. To derive diffusion coefficients and 
concentrations, a correlation analysis is performed on the fluorescence intensity profile. 





 (Equation 3.7) 
However, an analytical expression is needed to fit the autocorrelation function to derive 
parameters such as concentration and diffusion coefficients. For a single fluorescent 




















+ 1 (Equation 3.8) 
Where N is the number of fluorescent particles, 𝑤𝑥𝑦 is the radius along the 𝑥𝑦 plane for a 
3D Gaussian, 𝑧 is the radius along the z plane, and 𝜏𝐷 is the diffusion time through 






To derive concentrations from the autocorrelation data, 𝑉𝑐𝑜𝑛𝑓𝑜𝑐𝑎𝑙 for any excitation must 







2 𝑧 (Equation 3.10) 
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Concentrations are obtained using 
(𝑁)(𝑉𝑐𝑜𝑛𝑓𝑜𝑐𝑎𝑙)
𝑁𝐴
. Equation 1.1 is changed to account for 




 (Equation 3.11) 
In the case that the sample contains multiple fluorescent species, then the auto-correlation 
and cross-correlation amplitudes are given by  





2 (Equation 3.12) 
𝐺𝑋(0) =  
∑ 𝑁𝑖𝜂𝑖,𝑔𝜂𝑖,𝑟𝑖
(∑ 𝑁𝑖𝜂𝑖,𝑔𝑖 )(∑ 𝑁𝑖𝜂𝑖,𝑟𝑖 )
(Equation 3.13) 
Where 𝜂𝑖,𝑗 defines the molecular brightness for a specific fluorescent component. Let’s 
assume that the 𝑉𝐺 = 𝑉𝑅 = 𝑉𝑋, the molecular brightness 𝜂𝑖,𝑗 of all fluorescent 
components are identical, and the binding reaction is unimolecular.  Then the 
contributions of each fluorescent species to the auto- and cross-correlation amplitudes are 
given by  












Where 𝑁𝑅 is the number of red-labeled particles, 𝑁𝐺  is the number of green-labeled 
particles, and 𝑁𝐺𝑅 is the number of dual-labeled particles. If the red-labeled species is the 







The ratio shown above is also equal to the fractional occupancy, which is defined as 







Where [𝑅] is the concentration of receptor, [𝐿] is the concentration of ligand, and [𝑅𝐿] is 
the concentration of receptor-ligand complex. To derive 𝐾𝑖, we begin with equation 3.16 








 (Equation 3.18) 











Where 𝐿𝐹 is the free ligand concentration, 𝑅𝐹 is the free receptor concentration, 𝐶𝐹 is the 
free competitor concentration, and 𝑅𝐶 is the receptor-competitor complex concentration. 
From these relations, we can assume that free ligand is equal to total ligand concentration 
and that the free competitor concentration is also equal to the total competitor 
concentration to derive the following expression for [𝑅𝑇], 
 
𝑅𝑇 = 𝑅𝐹 + 𝑅𝐶 + 𝑅𝐿 (Equation 3.21) 
 













 (Equation 3.22) 
 










  (Equation 3.23) 
 
3.2.8  Ligand Binding Measurements 
 
Saturation ligand binding assays were set-up in PCR tubes by serially diluting the ligand 
in Buffer N supplemented with 0.1 mg/ml BSA (IgG free, detergent free). CCR5-SNAP-
A488 was then added in equal volume for a total reaction volume of 20 µl. Samples were 
equilibrated at room temperature for 4 hours protected from ambient light. 15 µl of each 
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sample were loaded into individual wells of a 384 well plate previously blocked with 1.0 
mg/ml BSA (IgG free, detergent free) in water for 15 minutes at room temperature. To 
prevent sample evaporation, 5 - 10 µl of paraffin oil was applied to the top of each 
sample. Competition binding assays were set-up in a similar fashion except that the 
labeled chemokine was kept at constant concentration and the competitor was serially 
diluted. 5 µl of the labeled chemokine was mixed with 5 µl of non-labeled chemokine 
and then 10 µl of CCR5-SNAP-A488 was added for a 20 µl total reaction volume. 
Samples were equilibrated for ≥16 hours at R.T. before imaging by FCCS. For 
competition with the sCD4-gp120 complex, sCD4 and gp120 were incubated for 1 hour 
at a molar ratio of 10:1 respectively and final complex concentration of 20 µM. Complex 
was then serially diluted in Buffer N prior to adding labeled 5P12- or 6P4-647 and 
CCR5-SNAP-488. Samples were then incubated for ≥ 16 hours at room temperature prior 
to FCCS measurements.  
3.2.9  Neuraminidase Treatment of CCR5-SNAP and SNAP-CCR5 
21 µl of 1D4 and FLAG purified CCR5-SNAP-488 and SNAP-CCR5-647 were mixed 
with 6 µl of GlycoBuffer1 and 3 µl of α2-3,6,8,9 neuraminidase A in individual PCR 
tubes. Control samples had 3 µl added of water instead of enzyme. Samples were 
incubated for 1 hour at RT and then analyzed by SDS-PAGE, NIR western 
immunoblotting, and line scan analysis in ImageJ as described previously.  
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3.2.10 Global Fitting Analysis of Binding Curves 

















Where 𝐾𝐷,𝐻 is the equilibrium dissociation constant for the high affinity site, 𝐾𝐷,𝐿 is the 
equilibrium dissociation constant for the low affinity site, 𝐾𝑖,𝐻 is the equilibrium 
inhibition constant for the high affinity site, 𝐾𝑖,𝐿 is the equilibrium inhibition constant for 
the low affinity site, 𝐶𝐹 and 𝐿𝐹 are the free concentrations of competitor and ligand, 
respectively, 𝑅𝐹.𝐻 and 𝑅𝐹,𝐿 are the free concentrations of receptor for the high and low 
affinity sites, respectively, 𝑅𝐿𝐻 and 𝑅𝐿𝐿 are the concentrations of receptor-ligand 
complex for the high and low affinity sites, respectively, and, 𝑅𝐶𝐻 and 𝑅𝐶𝐿 are the 
concentrations of receptor-competitor complex for the high and low affinity sites, 
respectively. We define the concentration of the high affinity site as 
𝑓𝐻 ∗ 𝑅𝑇 = 𝑅𝑇,𝐻 (Equation 3.28) 
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Where 𝑓𝐻 is a number from 0 to 1 to determine the high affinity receptor fraction, 𝑅𝑇 is 
the total receptor concentration, and 𝑅𝑇,𝐻 is the high affinity receptor fraction. We then 
define the concentration of the low affinity fraction as follows 
𝑓𝐿 =  1 − 𝑓𝐻  (Equation 3.29) 
𝑓𝐿 ∗ 𝑅𝑇 = 𝑅𝑇,𝐿 (Equation 3.30) 
Using these relations, we re-arrange equations 3.24 to 3.27 to yield the concentrations of 
𝑅𝑇,𝐻, 𝑅𝑇,𝐿, 𝐶𝑇, 𝐿𝑇, 𝑅𝐿𝑇, and 𝑅𝑇 
𝑅𝑇,𝐻 = 𝑅𝐹,𝐻 + 𝑅𝐿𝐻 + 𝑅𝐶𝐻 (Equation 3.31) 
𝑅𝑇,𝐿 = 𝑅𝐹,𝐿 + 𝑅𝐿𝐿 + 𝑅𝐶𝐿 (Equation 3.32) 
𝐶𝑇 = 𝐶𝐹 + 𝑅𝐶𝐻 + 𝑅𝐶𝐿 (Equation 3.33) 
𝐿𝑇 = 𝐿𝐹 + 𝑅𝐿𝐻 + 𝑅𝐿𝐿 (Equation 3.34) 
𝑅𝐿𝑇 = 𝑅𝐿𝐻 + 𝑅𝐿𝐿  (Equation 3.35) 
𝑅𝑇 = 𝑅𝑇,𝐻 + 𝑅𝑇,𝐿 (Equation 3.36) 

























We then define the following relations for the receptor-ligand complex 
𝑅𝐿𝑇 = 𝑅𝑇,𝐻 ∗ 𝜃𝐻 + 𝑅𝑇,𝐿 ∗ 𝜃𝐿 (Equation 3.41) 
Substituting in for the definitions of high and low receptor fractions we derive the 
following equation 
𝑅𝐿𝑇 = (𝑓𝐻 ∗ 𝜃𝐻 + (1 − 𝑓𝐻) ∗ 𝜃𝐿) ∗ 𝑅𝑇 (Equation 3.42) 
From equation 3.42, we derive the fractional occupancy as follows 
𝑅𝐿𝑇
𝑅𝑇
= 𝑓𝐻 ∗ 𝜃𝐻 + (1 − 𝑓𝐻) ∗ 𝜃𝐿 (Equation 3.43) 
Expanding the relation above yields the following expression 
𝑅𝐿𝑇
𝑅𝑇














We employed equation 3.44 to fit both saturation and competition binding isotherms. In 
the absence of competitor, the equation above reduces to the two binding sites saturation 
binding equation without ligand depletion. To correct for ligand depletion, we first fit the 
equation above by setting the concentration of free ligand and competitor equal to the 
total concentration of ligand and competitor. We then fit iteratively to correct for ligand 
depletion. The functional form above combined with the iterative fitting allows us to 
correct for ligand depletion without deriving an analytical solution. We define the chi 
squared function as follows 





− 𝑓(𝑝, 𝐶𝐹,𝑖, 𝐿𝐹,𝑖))
2𝑁
𝑖=1  (Equation 3.45) 
Where 𝑢 = {𝐶𝐹,𝑖}𝑖=1,2,3…𝑁 , {𝐿𝐹,𝑖}𝑖=1,2,3…𝑁. We minimize 𝛸2 with 𝑢 set to the 
concentration of ligand and competitor to get an initial solution for 𝑝: 𝑝𝑖. We then 
calculate a correction for 𝐶𝐹 and 𝐿𝐹 from 𝑝𝑖 and initial 𝐶 and 𝐿. We repeat the 
minimization until the correction is smaller than 𝜖. We fixed the total active receptor 
fraction to 25% and performed various binding fits to determine the optimal 𝑓𝑎value. We 
set 𝑓𝑎 to 38% for all fits since this value yielded the best fits from all the different 𝑓𝑎 
values tested. We set 𝐾𝐷,𝐻 and 𝐾𝐷,𝐿 to be free parameters and the values determined from 
saturation binding are fixed to determine 𝐾𝑖,𝐻 and 𝐾𝑖,𝐿 from competition binding assays.  
To determine errors associated with each affinity, we performed bootstrapping with data 
re-sampling by replacement. Global analysis with non-linear least square fitting of the 
binding isotherms yields parameters that describe the complete data set. We repeated the 
bootstrap resampling 100 times and eliminated cases, 14 out of 100, where the affinities 
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were for the high and low binding sites are switched. Saturation and competition binding 
isotherms were normalized and binding isotherms were plotted as a 2D function (𝜌, 𝐿) or 
the 3D surface (𝜌, 𝐶, 𝐿) for saturation and competition binding respectively.  
3.3  Results 
3.3.1  Optical Focus Depth Optimization 
We measured count rates for Alexa-488 and Alexa-647 in Buffer N and water to 
determine at which optical depth we measured the most count rates. Figure 3.3.1 shows 
plots for Alexa-488 and Alexa-647 as a function of optical depth for solutions containing 
glycerol (Buffer N) and solutions not containing glycerol (water). 
Figure 3.3.1 Optical focus depth optimization for Alexa-488 and Alexa-647 count rates as 
a function of optical depth.  
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Alexa-647 is brighter than Alexa-488 at the conditions tested. We did not exceed count 
rates above 15 kHz because of optical saturation. We observed that the Alexa dyes are 
brighter in glycerol-containing solutions than water. At depths below 50 µm, we 
observed no fluorescence from either Alexa dye. We started to observe fluorescence 
above 25 µm. For both dyes, we observed constant count rates from 50 to 100 µm depth 
indicating that at this range the PSF was not affected by glycerol. From there on, count 
rates started to decrease only for the fluorophores in glycerol solutions but not 
fluorophores in water. Based on these results, we performed all FCS and FCCS 
measurements at an optical depth of 50 µm. 
3.3.2  Laser Power Optimization for 488 and 633 nm Excitations 
Count rates were measured for Alexa-488, Alexa-647, CCR5-SNAP-488, and PSC-647 at 
various laser powers. We also measured background count rates at identical laser powers 
for Buffer N and/or Millipore grade water. Figure 3.3.2 shows the 4 plots obtained for 
each experiment conducted where count rates are plotted as a function of laser power.  
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Figure 3.3.2 Count rates determined for Alexa-488, Alexa-647, CCR5-SNAP-488, and 
PSC-647 at various laser powers and buffer conditions. (a) Alexa-488 count rates for 
solutions containing glycerol or water. (b) Alexa-647 count rates for solutions containing 
glycerol or water. (c) CCR5-SNAP count rates determined in Buffer N (d) PSC-647 
count rates determined in Buffer N. 
We observed a general trend where Alexa-488 or Alexa-647 count rates are linearly 
dependent on laser power in the range of 0.2-1% laser transmission. The labeled receptor 
and chemokine saturate faster than the free dyes. We chose laser powers of 0.2% 
transmission for CCR5-SNAP-488 and 1.0% transmission for PSC-64. At these values, 
we maximize brightness from the fluorophores without optical saturation. We also chose 
these values because background contribution to the total fluorescence signal was less 
than 10%.   
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3.3.3  Confocal Volume Determination for 488 and 633 nm Excitations 
We determined the confocal volumes for 488 nm, 633 nm, and their volume overlap 
(cross-correlation) using dilution series of Alexa 488, Alexa 647, and a dual labeled 
oligonucleotide.[69] We plotted the fitted number of particles for each sample vs. the 
corrected concentration determined from UV-Vis measurements (Figure 3.3.3). To derive 
the concentration volume, the slope from each curve is divided by Avogadro’s number. 
For each channel, we observed that the number of particles is a linear function of 
concentration. We did not observe any deviations from the linear trend at low or high 
concentrations. Deviations at low concentrations are due to background fluorescence 
overestimating the calculated number of particles. Deviations at high concentrations are 
due to optical saturation that arise from PSF distortion. We chose this method to 
determine the confocal volumes over 𝑥𝑦𝑧 scan of fluorescent beads because we perform 
FCS measurements at 50 µm into the sample and not at the glass surface. We also chose 
this method over calculating the confocal volume from 𝜏𝐷 because this method is 
dependent on the model employed to fit the autocorrelation functions. We derived for 488 
nm excitation a confocal volume of 0.18 fl, for 633 nm excitation a confocal volume of 
0.35 fl, and for the cross-correlation volume 2.16 fl. 
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Figure 3.3.3 Linear plots of Alexa-488, Alexa-647, and CC number of particles as a 
function of concentration. (a) Alexa-488 plot, (b) Alexa-647 plot, and (c) cross-
correlation plot.  
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3.3.4  Cross-Talk Quantification 
We determine the cross-talk contribution from the green channel into the red channel 
using the method by Bacia & Schwille (2007). [52] In this method, the bleed-through 
ratio is determined from a solution of Alexa-488 excited with 488 nm excitation. The 
excitation is recorded on either the green (GaAsP 1) or the red channel (GaAsP 2) and the 
ratio is taken from these count rates. We determined these values using the FCCS 
acquisition parameters we used for the ligand binding assays. Table 3.3.4 shows the 
calculated count rates for Alexa-488 detected in both channels using two different main 
beam splitters.  
Table 3.3.4 Cross-talk quantification values determined from a solution of Alexa-488. 
Alexa-488 (MBS 488) Bleed-through Ratio 
Count Rate (GaAsP 1) Count Rate (GaAsP 2) 
93.292 0.569 0.00609913 
 A488 Count Rate (MBS 488/561/633) Bleed-through Ratio 
Count Rate (GaAsP 1) Count Rate (GaAsP 2) 
80.169 0.574 0.007159875 
  Dual-labeled Oligo (MBS 488/561/633) Corrected Ratio Gx/Gg 
Count Rate (GaAsP 1) Count Rate (GaAsP 2) 
 1.551 3.383 0.003282579 0.875908 
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We observe that regardless of the MBS used, we observe no difference in the bleed-
through ratio for Alexa-488. We use MBS 488 exclusively for 488 nm excitation and we 
use MBS 488/561/633 for both 633 nm excitation and CC measurements. To determine if 
cross-talk made a significant contribution to the CC amplitude, we recorded count-rates 
for the dual-labeled oligonucleotide at concentrations similarly used for ligand binding 
measurements. We took the ratio of these count rates and multiplied the ratio by the 
bleed-through ratio. In comparison to the relative cross-correlation, the cross-talk 
contribution to the CC is less than 1% indicating that cross-talk makes no contribution to 
the CC amplitude.  
3.3.5   Calculating 𝐾𝐷 and 𝐾𝑖 values from FCCS measurements 
We calculated theoretical curves showing the dependency of 𝐺(0), the correlation 
amplitudes, on the concentrations of labeled and competitor ligands. Curves were 
calculated under the assumptions that the ligands interacted with a 1 to 1 stoichiometry 
with the receptor, ligand and receptor are 100% labeled, the confocal volumes for green 
and red excitation are the same volume, there are no chromatic aberrations, and cross-talk 
is negligible. For saturation binding, we analyzed the behavior of 𝐺(0) for two different 
dissociation constants of 5 and 0.5 nM (Figure 3.3.5)  
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Figure 3.3.5a Dependency of correlation amplitudes on concentrations of receptor (green, 
𝐺𝑅(0)), ligand (red, 𝐺𝐿(0)), and complex (blue, 𝐺𝑋(0)) for saturation binding at 𝐾𝐷 
values of 5 (a) and 0.5 nM (b). (c) Saturation binding isotherms for 𝐾𝐷 = 5 nM (orange) 
and 𝐾𝐷 = 0.5 nM (yellow) derived from the ratio of 𝐺𝑋(0)/𝐺𝐿(0) as a function of total 
fluorescent ligand. 
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Receptor concentration is kept constant in saturation binding so 𝐺𝑅(0), the correlation 
amplitude from labeled receptors (green line), does not change with varying ligand 
concentration. In the other hand, 𝐺𝐿(0) the correlation amplitude from ligand (red line), 
increases as ligand concentration decreases with equal magnitude for both 5 and 0.5 nM 
binding affinities. 𝐺𝑋(0), the cross-correlation amplitude from the ligand-receptor 
complex (blue line), shows a sigmoidal behavior for both binding constants analyzed. At 
low ligand concentrations, 𝐺𝑋(0) reaches a plateau since ligand is the limiting reagent in 
complex formation. At high ligand concentrations, receptor concentration becomes the 
limiting reagent and 𝐺𝑋(0) reaches another plateau since no more complex can be formed 
with more ligand added. At 𝐾𝐷 =  0.5 nM, 𝐺𝑋(0)  has a higher amplitude than 𝐾𝐷 =  5 
nM because there is more ligand-receptor complex at higher ligand affinities. Since the 
correlation amplitudes are inversely proportional to the concentration of labeled species, 
the ratio of 𝐺𝑋(0) / 𝐺𝐿(0) gives the fractional occupancy. Figure 3.3.5a (c) shows the 
saturation binding isotherms for 𝐾𝐷 =  0.5 nM (orange) and 5 nM (yellow) as a function 
of total concentration of labeled ligand. The saturation binding isotherms show the 
expected hyperbolic behavior with the 𝐾𝐷 values being at the right place. 
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Figure 3.3.5b Dependency of correlation amplitudes on concentrations of receptor, 
ligand, and complex for competition binding at 𝐾𝐷 = 0.5 nM; 𝐾𝑖 = 0.5 nM (a), 𝐾𝐷 = 0.5 
nM; 𝐾𝑖 = 5 nM  (c), 𝐾𝐷 = 5 nM; 𝐾𝑖 = 5 nM (b), and 𝐾𝐷 = 5 nM; 𝐾𝑖 = 0.5 nM  (d). (e) 
Competition binding isotherms for 𝐾𝐷 = 0.5 nM; 𝐾𝑖 = 0.5 nM (purple), 𝐾𝐷 = 0.5 nM; 
𝐾𝑖 = 5 nM (green), and (f) 𝐾𝐷 = 5 nM; 𝐾𝑖 = 0.5 nM (black), and 𝐾𝐷 = 5 nM; 𝐾𝑖 = 5 
nM (magenta) derived from the ratio of 𝐺𝑋(0)/𝐺𝐿(0) as a function of total competitor.  
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For competition binding, we analyzed both 𝐾𝐷 =  0.5 nM and 5 nM and we assumed that 
the inhibition constants of the unlabeled ligand were 𝐾𝑖 =  0.5 nM and 5 nM (Figure 
3.3.5b) Like saturation binding, 𝐺𝑅(0) remains constant for all concentrations of 
competitor tested. 𝐺𝐿(0) also remains constant since a fixed concentration of labeled 
ligand is used for all tested concentrations of competitor. 𝐺𝑋(0) shows similar sigmoidal 
behavior as with saturation binding for all competition cases analyzed. The amplitude of 
𝐺𝑋(0) is dependent on the concentration of labeled ligand and the dissociation constant 
such that higher affinities have higher amplitudes. At high competitor concentrations, 
ligand is displaced from the receptor binding site such that the complex concentration 
decreases and 𝐺𝑋(0) goes to 0. In that cases that 𝐾𝑖 =  0.5 nM, the inflection point is 
shifted towards left since less concentration of competitor is required to displaced the 
labeled ligand. In the other hand, the inflection point for 𝐺𝑋(0) is shifted to the right for 
𝐾𝑖 =  5 nM since higher concentrations of competitor are required to displaced the 
labeled ligand. Figure 3.3.5b shows the competition binding isotherms for the cases 
where 𝐾𝐷 = 0.5 nM and 𝐾𝑖 was set to either 0.5 or 5 nM (e). (f) shows the competition 
isotherms for 𝐾𝐷 = 5 nM and 𝐾𝑖 was set to either 0.5 or 5 nM. For 𝐾𝐷 = 0.5 nM, the 
fractional occupancy is higher than for 𝐾𝐷 = 0.5 nM since higher complex will be found 
for the higher affinity ligand at equal competitor concentrations. For 𝐾𝑖 = 5 nM, the 
inflection point is shifted to the right since higher concentration of competitor is required 
to displaced the labeled ligand.  
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3.3.6  Saturation Ligand Binding with RANTES Analogues 
 
We performed saturation binding experiments with Alexa-647 labeled RANTES 
analogues and purified CCR5-SNAP-488 by FCCS to determine their equilibrium 
dissociation constants. Figure 3.3.6a (a) shows representative auto-correlation traces for 
5P12- and 6P4-647 in the presence of CCR5-SNAP-488. Correlation traces were fitted to 
a 1 3D translational diffusion component undergoing independent blinking and triplet 
state transitions. Triplet and blinking states were normalized to derive the total number of 
fluorescent particles. Figure 3.3.6a (b) shows the auto-correlation traces for CCR5-
SNAP-488 for different concentrations of 5P12- and 6P4-647 tested and their associated 
fits. CCR5-SNAP-488 auto-correlation traces were fitted to 1 component with 3D 
translational diffusion undergoing triplet state transitions with 𝜏𝑇𝑟𝑖𝑝𝑙𝑒𝑡 fixed to 4 µs. 
Figure 3.3.6a (b) shows the cross-correlation traces obtained for the 5P12- and 6P4-
647/CCR5-SNAP-488 complexes at the different ligand concentrations tested. Cross-
correlation traces were fitted to 1 translational component with no triplet or blinking 




Figure. 3.3.6a (a) 5P12-647 (left) and 6P4-647 (right) auto-correlation traces and fits for 
all concentrations tested. (b) CCR5-SNAP-488 auto-correlation traces and fits for 
different concentrations of 5P12-647 (left) and 6P4-647 (right). (c) Receptor-ligand 
complex cross-correlation traces and fits for different concentrations of 5P12-647 (left) 
and 6P4-647 (right).  
Figure 3.3.6b shows the saturation binding isotherms derived for 5P12- and 6P4-647 by 
plotting 𝑅𝐿/𝑅 as a function of labeled chemokine.  
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Figure 3.3.6b. Normalized saturation binding isotherms for 5P12- and 6P4-647 binding to 
CCR5-SNAP-488 in solution. Data points represent individual points for different 
concentrations of labeled chemokine. The blue solid line represents the global fit 
performed on the data points.  
Qualitatively, 5P12 shows higher affinity than 6P4-647, which is different from the 
affinities calculated by Gaertner (2008). We repeated the same FCCS measurements on 
5P14- and PSC-647 to determine their 𝐾𝐷 values. Figure 3.3.6c shows auto-correlation 
traces for 5P12- and 6P4-647 (a) for CCR5-SNAP-488 (b) and the cross-correlation 
traces obtained for the ligand-receptor complex (c) at the different ligand concentrations 
tested. Auto- and cross-correlation traces were fitted the same way as done for 5P12- and 
6P4-647 saturation binding measurements. 
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Figure 3.3.6c (a) 5P14-647 and PSC-647 auto-correlation traces and fits for all 
concentrations tested. (b) CCR5-SNAP-488 auto-correlation traces and fits for different 
concentrations of 5P14-647 and PSC-647. (c) Receptor-ligand complex cross-correlation 
traces and fits for different concentrations of 5P14-647 and PSC-647.  
Likewise, we derived concentrations for each fluorescent component and derived binding 
isotherm for 5P14- and PSC-647. Figure 3.3.6d shows the saturation binding isotherms 
derived for 5P14- and PSC-647 by plotting 𝑅𝐿/𝑅 as a function of labeled chemokine.  
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Figure 3.3.6d. Normalized saturation binding isotherms for 5P14- and PSC-647 binding 
to CCR5-SNAP-488 in solution. Data points represent individual points for different 
concentrations of labeled chemokine. The blue solid line represents the global fit 
performed on the data points.  
To derive 𝐾𝐷 values, we performed global fitting on the saturation binding isotherms 
employing two binding sites with ligand depletion (Table 3.3.6) We assumed that the 
binding sites were non-interchangeable since computations where the sites could 
interchange yielded one observable affinity. We also fixed the active CCR5-SNAP-488 
fraction to 25% of the total receptor concentration and within this fraction we fixed the 
high affinity fraction, 𝑓𝐴,𝐻, to 38% and low affinity fraction, 𝑓𝐴,𝐿, to 62%. To derive errors 
for each value, we performed bootstrapping. The data are resampled with replacement.  
Global analysis with non-linear least squares fitting of the binding isotherms gives fitting 
parameters that describe the complete data set.  The bootstrap resampling is repeated 100 
times and analysis of the means and standard deviations of the fitting parameters 
describes their distribution.  I eliminate few cases (14 out of 100) where the fitting 
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resulted in fits with high and low affinities switched after the fit for any of the 4 
competition experiments (5P12, 5P14, 6P4, or PSC). 
Table 3.3.6. Equilibrium dissociation constants for the CCR5-SNAP-488 high affinity 
state (𝐾𝐷,𝐻) and low affinity state (𝐾𝐷,𝐿) derived from saturation binding with the 
RANTES analogues labeled with Alexa-647. Units are in nanomolar and errors were 
derived using global analysis with non-linear least square fitting of the binding isotherms 
with bootstrapping. 
Chemokine 𝑲𝑫,𝑯 (𝒏𝑴) 𝑲𝑫,𝑳 (𝒏𝑴) 
5P12-647 0.05 ± 0.05 1.3 ± 0.5 
5P14-647 0.04 ± 0.03 2.2 ± 0.9 
6P4-647 3.8 ± 0.5  43 ± 11 
PSC-647 4.8 ± 1.5 16 ± 29 
We calculated similar dissociation and bound fraction values for 5P14- and PSC-647 as 
5P12- and 6P4-647 respectively indicating that 5P12/5P14 and PSC/6P4 bind similarly to 
the two CCR5-SNAP-488 species. We did not observe any changes in the molecular 
brightness for the RANTES analogues and CCR5-SNAP across the concentrations tested 
(Figure 3.3.6e). We also did not observe any effect Alexa-647 and Alexa-488 triplet state 
transitions (Figure 3.3.6f) and Alexa-647 blinking transitions (Figure 3.3.6g). Likewise, 
we did not observe any effect from increasing ligand concentration on the diffusion time 
of the three fluorescent species (Figure 3.3.6h).  
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Figure 3.3.6e Brightness Dependency on Ligand Concentration. Average brightness 
values measured as counts per molecule (kHz) for the RANTES analogues labeled with 
Alexa-647 (a) and CCR5-SNAP-488 (b) as a function of labeled chemokine. Values are 
averages from at least 3 independent experiments and errors are the S.E.M. 
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Figure 3.3.6f Average triplet state fraction determined from fitting auto-correlation 
curves for the RANTES analogues labeled with Alexa-647 (a) and CCR5-SNAP-488 (b) 
as a function of labeled chemokine. Triplet state fraction are fitted such that they are a 
percent of total fluorescent and non-fluorescent species in solution. Average triplet state 
relaxation time in µs determined from fitting auto-correlation curves for the RANTES 
analogues labeled with Alexa-647 (c) as a function of labeled chemokine concentration. 
CCR5-SNAP triplet relaxation time was fixed to 4 µs in all experiments and was not 
plotted. Values are averages from at least 3 independent experiments and errors are the 
S.E.M. 
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Figure 3.3.6g Average blinking state fraction (a) and blinking state relaxation time (b) 
determined from fitting auto-correlation curves for the RANTES analogues labeled with 
Alexa-647 from saturation binding experiments as a function of labeled chemokine 
concentration. Blinking state fractions are fitted such that they are a percent of total 
fluorescent and non-fluorescent species in solution. Values are averages from at least 3 
independent experiments and errors are the S.E.M. 
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Figure 3.3.6h Average diffusion times (𝜏𝐷) in µs determined from fitting auto- and cross-
correlation curves for the RANTES analogues labeled with Alexa-647 (a), CCR5-SNAP-
488 (b), and the receptor-ligand complex (c) as a function of labeled chemokine 
concentration. Values are averages from at least 3 independent experiments and errors are 
the S.E.M. 
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3.3.7  Competition Binding with 5P12- and 6P4-647 
We performed homologous competition binding experiments with 5P12- and 6P4-647 
using non-labeled 5P12 and 6P4 to determine the affinity of the non-labeled chemokines. 
We only employed 5P12- and 6P4-647 for the competition binding experiments since 
5P14- and PSC-647 are like 5P12- and 6P4-647 in their binding affinities respectively. 
Auto- and cross-correlation traces were fit as described previously for the saturation 
binding experiments. Figure 3.3.7a shows representative auto-correlation traces and 
associated fits for 5P12- and 6P4-647 (a), auto-correlation traces and fits for CCR5-
SNAP-488 (b), and cross-correlation traces and fits for the 5P12- and 6P4-647 bound to 
CCR5-SNAP-488 in the presence of various concentrations of competing 5P12 and 6P4. 
Figure 3.3.7a (a) 5P12-647 (left) and 6P4-647 (right) auto-correlation traces and fits for 
all concentrations of competitor tested. (b) CCR5-SNAP-488 auto-correlation traces 
and fits in the presence of 5P12-647 (left) and 6P4-647 (right) at different 
concentrations of competitor. (c) Receptor-ligand complex cross-correlation traces and 
fits for 5P12-647 (left) and 6P4-647 (right) at different concentrations of competitor.  
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We derived binding isotherms for the competition data using the same principles as the 
saturation binding fits. We performed a global fit with the Cheng-Prusoff equation using 
the calculated 𝐾𝐷 values from the saturation binding experiments. To account for ligand 
depletion, we fitted the equation iteratively until the fit converged. Fits were plotted in a 
3D surface with fluorescent ligand concentration as the 3rd axis. Figure 3.3.7b shows the 
3D surface plots for homologous competition binding of 5P12 and 6P4. 
Figure 3.3.7b 3D surface plots for homologous competition binding of 5P12- and 6P4-
647. 5P12-647 homologous curves are shown on the right while 6P4 homologous 
competition curves are shown on the right. 3D surfaces were generated by plotting the 
normalized global fits and individual data points as a function of labeled chemokine 
concentration.  
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We also performed heterologous competition binding experiments using 5P12- and 6P4-
647 with 6P4 and 5P12 respectively to validate the two-binding site model. Figure 3.3.7c 
shows the autocorrelation traces and associated fits for 5P12- and 6P4-647 (a), auto-
correlation traces and CCR5-SNAP-488 (b) and cross-correlation traces and for the 5P12- 
and 6P4-647 bound to CCR5-SNAP-488 in the presence of various concentrations of 
competing 6P4 and 5P12 respectively.  
Figure 3.3.7c (a) 5P12-647 and 6P4-647 auto-correlation traces and fits for all 
concentrations of competitor tested. (b) CCR5-SNAP-488 auto-correlation traces and fits 
in the presence of 5P12-647 and 6P4-647 at different concentrations of competitor. (c) 
Receptor-ligand complex cross-correlation traces and fits for 5P12-647 and 6P4-647 at 
different concentrations of competitor.  
92 
We also derived 3D surface plots for heterologous competition binding of 5P12 and 6P4. 
Figure 3.3.7d shows the 3D surface plots for 5P12- and 6P4- heterologous competition. 
Surface plots were generated using the same method as for the homologous competition 
surface plots.  
Figure 3.3.7d 3D surface plots for heterologous competition binding of 5P12- and 6P4-
647. 5P12-647 heterologous curves are shown on the right while 6P4 heterologous 
competition curves are shown on the right. 3D surfaces were generated by plotting the 
normalized global fits and individual data points as a function of labeled chemokine 
concentration.  
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Table 3.3.7 Equilibrium constants of inhibition for the CCR5-SNAP-488 high affinity 
state (𝐾𝑖,𝐻) and low affinity state (𝐾𝑖,𝐿) derived from competition binding with the 
RANTES analogues labeled with Alexa-647 and unlabeled analogues. Units are in 
nanomolar and errors were derived using global analysis with non-linear least square 
fitting of the binding isotherms with bootstrapping.  
Labeled/Unlabeled 𝑲𝒊,𝑯 (𝒏𝑴) 𝑲𝒊,𝑳 (𝒏𝑴) 
5P12-647/5P12 0.007 ± 0.005 0.8 ± 0.4 
5P12-647/6P4  0.9 ± 0.7 56 ± 22 
6P4-647/6P4 1.3 ± 0.3 N.D. 
6P4-647/5P12 0.02 ± 0.01 N.D. 
We did not observe any changes in the molecular brightness for the RANTES analogues 
and CCR5-SNAP across the concentrations tested (Figure 3.3.7e). We also did not 
observe any effect Alexa-647 and Alexa-488 triplet state transitions (Figure 3.3.7f) and 
Alexa-647 blinking transitions (Figure 3.3.7g). Likewise, we did not observe any effect 
from increasing ligand concentration on the diffusion time of the three fluorescent species 
(Figure 3.3.7h). For some of the values, we observe a sharp increase or decrease in the 
plots, which is caused by replenishing the immersion water to avoid evaporation during 
data collection.  
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Figure 3.3.7e Brightness Dependency on Competitor Concentration.   
Average brightness values measured as counts per molecule (kHz) for the RANTES 
analogues labeled with Alexa-647 (a) and CCR5-SNAP-488 (b) as a function of 
competitor. Values are averages from at least 3 independent experiments and errors are 
the S.E.M. 
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Figure 3.3.7f Average triplet state fraction determined from fitting auto-correlation 
curves for the RANTES analogues labeled with Alexa-647 (a) and CCR5-SNAP-488 (b) 
as a function of competitor. Triplet state fractions are fitted such that they are a percent of 
total fluorescent and non-fluorescent species in solution. Average triplet state relaxation 
time in µs determined from fitting auto-correlation curves for the RANTES analogues 
labeled with Alexa-647 (c) as a function of competitor concentration. CCR5-SNAP triplet 
relaxation time was fixed to 4 µs in all experiments and was not plotted. Values are 
averages from at least 3 independent experiments and errors are the S.E.M. 
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Figure 3.3.7g Average blinking state fraction (a) and blinking state relaxation time (b) 
determined from fitting auto-correlation curves for the RANTES analogues labeled with 
Alexa-647 from saturation binding experiments as a function of competitor 
concentration. Blinking state fractions are fitted such that they are a percent of total 
fluorescent and non-fluorescent species in solution. Values are averages from at least 3 
independent experiments and errors are the S.E.M. 
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Figure 3.3.7h Average diffusion times (𝜏𝐷) in µs determined from fitting auto- and cross-
correlation curves for the RANTES analogues labeled with Alexa-647 (a), CCR5-SNAP-
488 (b), and the receptor-ligand complex (c) as a function of competitor concentration. 
Values are averages from at least 3 independent experiments and errors are the S.E.M. 
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3.3.8  Competition Binding with Native Chemokines and Env 
We proceeded to calculate the affinity of gp120 with CCR5-SNAP-488. We performed 
competition binding experiments with the human soluble CD4 (sCD4) and 2G12 purified 
monomeric gp120 complex in the presence of 5P12- and 6P4-647. Figure 3.3.8a shows 
the auto-correlation traces for 5P12- and 6P4-647 (a), CCR5-SNAP-488 (b), and cross-
correlation traces for receptor-ligand complex (c) at different concentrations of 
competing sCD4-gp120.  
Figure 3.3.8a (a) 5P12-647 and 6P4-647 auto-correlation traces and fits (b) CCR5-SNAP-
488 auto-correlation traces and fits (c) Receptor-ligand complex cross-correlation traces 
and fits for 5P12-647 and 6P4-647 at different concentrations of sCD4-gp120 complex. 
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Auto- and cross-correlation traces were fitted using the same models and assumptions as 
done previously. We calculated 𝑅𝐿/𝑅 and 𝐿 to determine how the fractional occupancy 
for 5P12- and 6P4-647 change with increasing concentrations of viral complex. Figure 
3.3.8b shows the plots of 𝑅𝐿/𝑅 as a function 𝐿 for 5P12- and 6P4-647 in the presence of 
increasing sCD4-gp120 concentration. sCD4-gp120 concentrations up to 1,000 nM had 
no effect on 5P12- or 6P4-647 binding to CCR5-SNAP-488 indicating that the complex 
has low affinity to CCR5-SNAP-488. 
Figure 3.3.8b Competition binding isotherms for 5P12-647 and 6P4-647 at various 
concentrations of sCD4-gp120 complex. Data points represent the mean from at least 30 
individual FCCS measurements and their associated errors. 
We then performed competition binding experiments with the native chemokines, 
RANTES and MIP-1α, to determine their 𝐾𝑖 values. Competition binding experiments 
were performed using the same conditions as with the RANTES analogues competition 
binding experiments. Figure 3.3.8c shows the auto-correlation traces for 5P12- and 6P4-
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647 (a), CCR5-SNAP-488 (b), and cross-correlation traces for receptor-ligand complex 
(c) at different concentrations of competing RANTES.  
Figure 3.3.8c (a) 5P12-647 and 6P4-647 auto-correlation traces and fits (b) CCR5-SNAP-
488 auto-correlation traces and fits (c) Receptor-ligand complex cross-correlation traces 
and fits for 5P12-647 and 6P4-647 at different concentrations of RANTES. 
We observed that 𝐺𝑋(0) varies slightly in comparison to the curves obtained for 
competition binding with the RANTES analogues. We plotted 𝑅𝐿/𝑅 and 𝐿 from the 
correlation traces to determine the effect increasing concentrations of RANTES had on 
5P12- and 6P4- 647 binding to CCR5-SNAP-488. Figure 3.3.8d shows the plots of 𝑅𝐿/𝑅 
as a function 𝐿 for 5P12- and 6P4-647 in the presence of increasing RANTES 
concentrations.  
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Figure 3.3.8d Competition binding isotherms for 5P12-647 and 6P4-647 at various 
concentrations of RANTES. Data points represent the mean from at least 30 individual 
FCCS measurements and their associated errors. 
Surprisingly, RANTES did not displace 5P12- or 6P4-647 from CCR5-SNAP-488. Given 
this remarkable result, we proceeded to test if MIP-1α could compete with 5P12- and 
6P4-647. Figure 3.3.8e shows the auto-correlation traces for 5P12- and 6P4-647 (a), 
CCR5-SNAP-488 (b), and cross-correlation traces for receptor-ligand complex (c) at 
different concentrations of competing MIP-1α.  
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Figure 3.3.8e (a) 5P12-647 and 6P4-647 auto-correlation traces and fits (b) CCR5-
SNAP-488 auto-correlation traces and fits (c) Receptor-ligand complex cross-correlation 
traces and fits for 5P12-647 and 6P4-647 at different concentrations of MIP-1α. 
Figure 3.3.8f shows the shows the plots of 𝑅𝐿/𝑅 as a function 𝐿 for 5P12- and 6P4-647 
in the presence of increasing MIP-1α concentrations. MIP-1α did not displace 5P12- or 
6P4-647 from CCR5-SNAP-488. We were surprised by these findings since we expected 
the native chemokines to completely displace the analogues up to 10 µM concentrations. 
Given this, we hypothesize that the native chemokines either have very low affinity for 
CCR5-SNAP-488 or that the chemokines recognize a different receptor state. We have 
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also observed very little binding of RANTES-647 to CCR5-SNAP-488 in saturation 
binding experiments and by single molecule TIRF-FRET (data not shown). 
Figure 3.3.8f Competition binding isotherms for 5P12-647 and 6P4-647 at various 
concentrations of MIP-1α. Data points represent the mean from at least 30 individual 
FCCS measurements and their associated errors. 
3.3.9  Line Scan Analysis of CCR5-SNAP 
We performed line-scan analysis FLAG purified CCR5-SNAP-488 resolved by SDS-
PAGE and NIR western immunoblotting. We analyzed the lanes using Gel Analyzer in 
ImageJ. Figure 3.3.9a shows the NIR western immunoblotting results for CCR5-SNAP 
and the corresponding line scan plots for 680 and 800 nm fluorescence.  
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Figure 3.3.9a (a) Line scan analysis performed in ImageJ of the corresponding 
fluorescent gel lanes in (b). (b) Reducing SDS-polyacrylamide gel electrophoresis and 
near-infrared fluorescent western blot of FLAG elution from tandem affinity purification 
of CCR5-SNAP. Full-length CCR5-SNAP was detected using antibodies against the 
1D4 and FLAG epitopes and 680 nm (top) and 800 nm (bottom) fluorescent secondary 
antibodies. 
Line scan analysis of FLAG purified CCR5-SNAP-488 fraction reveals two species that 
are very close in molecular weight. The two overlapping bands are observed in both the 
680 and 800 nm emission channels. SNAP-CCR5 also shows similar split band by line-
scan analysis (data not shown). We hypothesized that differential O-linked glycosylation 
yields the split band pattern observed in both CCR5-SNAP and SNAP-CCR5. To test this 
hypothesis, CCR5-SNAP and SNAP-CCR5 were treated with or without α2-3,6,8,9 
Neuraminidase A for 1 hour and then analyzed as described previously. Figure 3.3.9b 
shows the NIR western immunoblotting results for SNAP-CCR5 treated with and without 
α2-3,6,8,9 neuraminidase A and the corresponding line scan plots for 680 and 800 nm 
fluorescence.  
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Figure 3.3.9b Reducing SDS-polyacrylamide gel electrophoresis and near-infrared 
fluorescent western blot of FLAG elution from tandem affinity purification of SNAP-
CCR5. SNAP-CCR5 was treated with α2-3,6,8,9 neuraminidase A for 1 hour. Full-length 
CCR5-SNAP was detected using antibodies against the 1D4 and FLAG epitopes and 680 
nm (a) and 800 nm (b) fluorescent secondary antibodies. Line scan analysis performed in 
ImageJ of the control lanes for 680 nm (c) and 800 nm (d) emission. Line scan analysis 
performed in ImageJ of the neuraminidase treated samples for 680 nm (e) and 800 nm (f) 
emission. 
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SNAP-CCR5 Neuraminidase treatment reduced the observed receptor heterogeneity but 
did not yield a single band. The result indicates that SNAP-CCR5 is sialylated to some 
degree. Given this, we cannot exclude the possibility of other post-translational 
modifications that yield the observed receptor heterogeneity. We observed similar results 
for CCR5-SNAP (data not shown) indicating both receptors are similarly sialylated in
vitro.  
3.4  Discussion 
3.4.1  Ligand Binding by FCS 
We successfully employed FCCS to determine the equilibrium dissociation and 
competition affinities for the RANTES analogues with CCR5-SNAP-488. Antoine (2016) 
performed saturation and competition binding by FCCS on several GFP-GPCR fusion 
proteins, such as β2-AR and CXCR4, with fluorescently labeled small molecules and 
antibodies. Unlike Antoine et al. (2016), we employed the SNAP-tag to label CCR5 with 
Alexa-488. The SNAP-tag is advantageous to traditional labeling methods such as 
fluorescent proteins in that it allows different fluorophores and functional tags to be 
attached. Also, FCCS derived affinities are affected by the number of GFP dark states, 
which influence the detected number of particles. Foo (2012) showed that the GFP dark 
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states are caused by combination of misfolded and photobleached protein.[70] Addition 
of 1 mM DTT and 50 µM SNAP substrate during the labeling step yields stoichiometric 
receptor labeling. Antoine et al. (2016) did not purify the GPCRs from the cell lysate to 
remove heterogeneities which can complicate the ligand binding analysis. In our case, we 
purify away G-proteins and other intracellular partners that can contribute to receptor 
heterogeneity.  For example, live cell ligand binding studies on GPCRs have revealed the 
existence of different receptor-ligand complexes. Ligand binding to GPCRs was 
determined by changes in the diffusion of the labeled ligand. In addition to observing the 
receptor-ligand complex, the reports also observed a second ligand-receptor species with 
slower diffusion but there is no consensus on the nature of this species. For example, 
Hegener (2004) investigated binding of fluorescent labeled Arterenol to β2-AR expressed 
in neuronal or alveolar epithelial cells (A549).[71] The Arterenol/β2-AR complex 
displayed a diffusion coefficient of 5.23x10-8 cm2/s in neurons and 2.88x10-8 cm2/s in 
A549 cells. 5 minutes after ligand treatment, 38% of receptor sites displayed a diffusion 
coefficient of 6.05x10-10 cm2/s in neurons. On the other hand, 15 to 20 minutes after 
ligand treatment 40% of receptor sites displayed a diffusion coefficient of 1.01x10-9 
cm2/s in A549 cells. Forskolin addition shifted the receptor-ligand complex ratio from the 
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faster component to the slower component. We assume that the slower component arises 
from G-protein coupling to the Arterenol-receptor complex. Briddon (2004) and Corriden 
(2014) observed similar results as Hegener (2004) with a fluorescent xanthine analogue 
binding to the adrenergic 1 receptor (A3R) and CA200645 binding to the A3R 
respectively.[72, 73] Briddon (2004) showed that the fraction of ligand bound to the fast 
diffusing component could be reduced by competition with non-fluorescent ligands. Yet, 
Briddon (2004) could not compete the ligand from the slowly diffusing species and 
attributed this effect to ligand non-specific binding. Corriden (2014) assumed that the fast 
diffusing species arise from triplet state transitions and the slowly diffusing species was 
the receptor-ligand complex. Like Briddon (2004), Corriden (2014) shows that the 
fluorescent ligand can be competed with a non-fluorescent antagonist. Surprisingly, 
Corriden (2014) observes that the fluorescent ligand, CA200645, cannot be competed 
with a different antagonist indicating different receptor species.  
3.4.2  CCR5-SNAP Species 
We report the observation that the RANTES analogues bind to 25% of CCR5-SNAP-488 
with picomolar to nanomolar affinity. GPCR solubilization with detergents is known to 
reduce the number of active sites. For example, Kuszak (2009) designed a µ-opioid 
receptor fusion with yellow fluorescent protein (YFP) in the N-terminus. Saturation 
binding with a µ-opioid receptor agonist revealed that the DDM/CHS solubilized receptor 
had only 20% of active sites of receptor in cell membranes.[74] We speculate that the 
remaining 75% of CCR5-SNAP-488 is irreversibly denatured during the purification 
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procedure. Within this 25% active fraction, the RANTES analogues bind with high 
affinity to 38% of active receptor and the remaining 62% fraction with low affinity. We 
assumed that these two receptor species corresponded to two interconvertible 
conformations described by the cyclic model of receptor activation.[75] We assumed 
these conformations were interconvertible based on structural data that shows TM6 
movement is coupled to different receptor-ligand conformations.[76] We performed 
simulations with the data set and found that such models yield one observable 𝐾𝐷 value 
indicating that the two conformations must be non-interconvertible. Previous studies by 
Alves showed that the neurokinin-1 receptor, another GPCR, also exhibits two non-
interconvertible binding sites.[77-79] Alves (2006) conducted ligand binding 
measurements on purified NK-1R by SPR and calculated that substrate P had 𝐾𝐷,𝐻 =
0.14 nM and 𝐾𝐷,𝐿 =  1.4 nM while neurokinin A displayed 𝐾𝐷,𝐻 =  5.5 nM and 𝐾𝐷,𝐿 =
620 nM.[77] The two NK-1R species also couple to different intracellular pathways. The 
high affinity receptor species activates cAMP pathway while the low affinity receptor 
species activates the phospholipase C pathway. Further studies by Alves (2007) showed 
that the purified NK-1R consisted of several species with varying degrees of 
glycosylation and palmitoylation.[80] Yet, they were not able to identify which species 
were responsible for the pharmacology observed by SPR and cell-based functional 
assays. To our knowledge, we report the second study on GPCRs that detect two distinct 
non-interconvertible receptor species.   
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3.4.3  RANTES Analogues Affinities 
We compared the FCCS determined 𝐾𝐷 and 𝐾𝑖 values to previous literature reports and 
we could not find any calculated 𝐾𝐷 values for the RANTES analogues. Colin (2013) 
calculated 𝐾𝑖 values for the RANTES anslogues from 125I-MIP-1α competition in CCR5 
expressing HeLa P4C5 cells.[81] In contrast to our results, Colin (2013) reports that 6P4 
has a 𝐾𝑖 of (0.055 + 0.02) nM and 5P12 a 𝐾𝑖 of (0.26 + 0.13) nM. In contrast, Gaertner 
(2008) reported that the RANTES analogues displayed similar affinities of ~ 1 nM in 
competition binding experiments with 125I-MIP-1β in CCR5 expressing CHO cells.[40] 
To complicate things further, Colin (2013) also performed competition binding with 
sCD4-(35S-gp120) and report for 6P4 𝐾𝑖 = (2.93 + 0.23) nM and for 5P12 𝐾𝑖 = (3.51 + 
1.8) nM. The results above illustrate the issue of deriving ligand affinities with different 
radiolabeled ligands and across different cell types. Affinities are dependent on the 
ligand, assay conditions, cell type, and radioactive nuclei employed. To circumvent this 
problem, we used purified CCR5-SNAP in a well-defined buffer-detergent system. We 
labeled the receptor and chemokines with Alexa fluorophores, which are inexpensive, 
compared to radiolabeling and they allow for simpler reaction conditions. We calculated 
from saturation binding experiments that 5P12-647 had a 𝐾𝐷,𝐻 = (0.05 ± 0.05) nM and 
𝐾𝐷,𝐿 = (1.3 ± 0.5) nM and for 6P4-647 we calculated 𝐾𝐷,𝐻 = (3.8 ± 0.5) nM and 𝐾𝐷,𝐿 = 
(43 ± 11) nM. We obtained similar results for 5P14- and PSC-647 so we classified 
5P12/5P14 as ultra-high affinity binders and 6P4/PSC as high affinity binders. It is 
interesting 5P12 and 5P14 do not activate Gαq while 6P4 and PSC activate Gαq better 
than RANTES. However, we cannot directly correlate the calculated 𝐾𝐷 values with the 
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pharmacological properties of the RANTES analogues. To validate the saturation binding 
derived affinities, we performed competition binding measurements with 6P4- and 5P12-
647 since PSC- and 5P14-647 bind to CCR5 similarly as 6P4- and 5P12-647 respectively. 
Homologous competition binding with 6P4- and 5P12-647 revealed that the non-labeled 
chemokines bind with similar affinities as the labeled chemokines. We performed 
heterologous competition binding to determine if 6P4 and 5P12 were binding to the same 
CCR5-SNAP-488 species. 6P4 was capable of displacing 5P12-647 and 5P12 displaced 
6P4-647 from CCR5-SNAP-488. We calculated a higher affinity for 6P4 when 
competing 5P12-647 than in the homologous competition binding case.  
3.4.4 Env Does Not Compete 5P12- and 6P4-647 
We tested competition of the RANTES analogues with soluble CD4 (sCD4) in complex 
with gp120. The RANTES analogues were specifically designed to be potent anti-HIV 
therapeutics. Doranz (1999) calculated that the association half-life for sCD4 and gp120 
was less than 1 minute meaning that the complex equilibrates readily at room 
temperature. Doranz et al. also calculated that the sCD4/gp120 complex association half-
life to CCR5 in cells was 5.8 min and the dissociation half-life was 32 minutes. We 
incubated sCD4 and gp120 for 30 minutes at R.T. before adding the complex to CCR5 
and the entire components were incubated for 16 hours at R.T. sCD4 was obtained from 
the NIH AIDS reagent program and BG505.SOSIPgp120 was a gift from Dr. John 
Moore. BG505.SOSIP was developed from BG505 by introducing several stabilizing 
mutations. BG505 was truncated at residue 41 in gp41 and residue 559 was mutated from 
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proline to isoleucine. Also, a disulfide bridge was introduced between residues 501 and 
605.[82] Hoffenberg (2013) identified BG505 from a native Env sequence that preserves 
the most epitopes neutralized by broadly neutralizing antibodies.[83]  
Competition binding with 5P12- or 6P4-647 showed that the sCD4/gp120 complex did 
not displace the chemokines from CCR5-SNAP-488. Garcia-Perez (2011) performed 
saturation binding with 35S-gp120 and calculated gp120 𝐾𝐷 = 9.9 ± 1.2 nM. Doranz 
(1999) obtained similar results, 𝐾𝐷 = 4.35 ± 0.75 nM, from saturation binding of 125I-
gp120 to CCR5.[84] In contrast, Garcia-Perez (2011) performed competition binding 
with 125I-MIP-1α and non-labeled gp120 and derived 𝐾𝑖 = 103 ± 18 nM. Colin (2013) 
also performed competition binding with native chemokines and RANTES analogues on 
35S-gp120 and 125I-MIP-1α discovered two CCR5 species. 125I-MIP-1α displacement with 
native and chemokine analogues revealed the existence of a single class of CCR5 
receptors. In contrast, 35S-gp120 displacement with the RANTES analogues show a 
single binding receptor site while the native chemokines, RANTES and MIP-1α, bound 
to two CCR5 binding sites. Colin et al. calculated that RANTES and MIP-1α bound to 
the low affinity site with 𝐾𝑖 values greater than 1,000 nM. Gpp(NH)p treatment, a non-
hydrolysable GTP analogue, decreased the fraction of MIP-1α high affinity sites without 
changing MIP-1α affinity. RANTES and MIP-1α bind with high affinity to the G-protein 
pre-coupled receptor. Nucleotide addition or pertussin toxin treatment abolishes high 
affinity binding of the native chemokines. In contrast, gp120 binds with high affinity the 
G-protein pre-coupled and un-coupled receptor. Doranz (1999) also discovered that 
gp120 binding to CCR5 did not depend on receptor coupling to G-protein. These findings 
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help explain why the RANTES analogues are potent HIV-1 inhibitors but the native 
chemokines are not.  
3.4.5 Native Chemokines Do Not Compete 5P12- and 6P4-647 
We proceeded to perform competition binding with 5P12- and 6P4-647 and non-
fluorescent RANTES and MIP-1α using the same equilibration conditions as before. 
FCCS measurements revealed that RANTES and MIP-1α could not displace the 
RANTES analogues from CCR5-SNAP-488. We were surprised since we tested 
competitor concentrations of 10 µM and the native chemokines could not bind to CCR5-
SNAP-488. Pilot saturation binding experiments with RANTES-647 showed that the 
affinity of RANTES must be greater than 20 nM. We were not able to derive a precise 
value because the cross-correlation signal was too low given the very small concentration 
of receptor-ligand complex. Single molecule TIRF-FRET experiments with the N-
terminal SNAP-CCR5-647 fusion and RANTES- and MIP-1α-555 have shown little 
complex formation over several hours imaging time (data not shown in this report). 
Based on these results, we hypothesize the following: 1) RANTES and MIP-1α 
equilibrium dissociation constants must be greater than 10 µM, 2) RANTES and MIP-1α 
recognize a different CCR5-SNAP-488 species than the 38% active fraction or 3) 
RANTES and MIP-1α bind with high affinity to the G-protein pre-coupled receptor. 
Evidence from Colin (2013) and Garcia-Perez (2011) indicates that RANTES and MIP-
1α recognize two different CCR5 binding sites with different affinity for gp120. G-
protein coupling to the low affinity site shits the site to high affinity indicating that 
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RANTES and MIP-1α are sensitive to CCR5 coupling to G-protein. Therefore, we can 
reasonably assume that high affinity binding of RANTES and MIP-1α requires G-protein 
coupling. Given this, the RANTES analogues recognize a CCR5 binding site that is high 
affinity for gp120 but is low affinity for the native chemokines. Alternatively, the 
RANTES analogues modify the RANTES binding site by changing the receptor 
conformation. CCR5 coupling to G-protein allows the native chemokines to bind the 
gp120 high affinity site.  Given this, we propose to conduct future studies with CCR5-
SNAP reconstituted into nanoscale apolipoprotein bound bilayers (NABBs). NABBs are 
phospholipid bilayers encapsulated by two apolipoprotein belt proteins.[85, 86] 
Rhodopsin, the visual GPCR, has previously been incorporated into POPC NABBs and 
rhodopsin NABBs can activate the G-protein transducing in solution. CCR5 has also 
been incorporated into NABBs where thermal stability studies have shown that CCR5 is 
more stable in NABBs than in detergent.[85] We propose to employ NABBs to 
incorporate CCR5 to perform ligand-binding studies in the presence and absence of 
reconstituted Gαiβγ to determine if G-protein affect measured affinities and the fraction 
of low and high affinity receptors.  
3.4.6  Structural Determinants of RANTES Binding to CCR5 
To understand the differences from 5P12-/5P14-647 and 6P4-/PSC-647, we analyzed the 
N-terminus sequence of the RANTES analogues to determine which resides may be 
responsible for their binding affinities. We observed that PSC and 6P4 contain an 
aspartate residue that is not present in 5P12 and 5P14. Aspartate 6 is also conserved in 
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the native chemokines RANTES and MIP-1α indicating an important role of this residue 
on CCR5 recognition.[61] Crystal structure of RANTES bound to CCR5 is not available 
but Tamamis et al. (2014) reported a computational model of RANTES bound to CCR5 
based on previous NMR data, previous chemokine receptor crystal structures, and 
mutational data.[87] The model shows that aspartate 6 forms a salt bridge with lysine 191 
in CCR5. Interestingly, NMR mapping studies did not reveal changes in the chemical 
environment of asparate 6 during RANTES ligand binding.[88, 89] Instead, Schnur et al. 
(2013) and Duma et al. (2007) show that chemical shift from threonine 8 changes 
significantly during ligand binding. Tamamis et al. (2014) observed that threonine 8 
forms hydrogen bonds with glycine 21 and asparagine 24 in CCR5. Glutamine replaces 
threonine 8 in both 5P12 and 5P14 so we don’t expect large disruption in the hydrogen 
bond network. The model from Tamamis et al. also shows that serines 5 and 4 make 
important hydrogen bonds with aspartate 276 and lysine 22 respectively. Serines 4 and 5 
are replaced by leucine 4 and methionine 5 in both 5P12 and 5P14 indicating a major 
disruption of the hydrogen bond network in these analogues. Given this, one might have 
naively assumed that 5P12 and 5P14 are weaker binders than 6P4 and PSC. Chemokine 
binding to CCR5 also requires several contacts with the CCR5 N-terminus and ECL2 
domain.[61] Thus, we cannot exclude other contributions from CCR5 that are required 
for dictating chemokine affinity. Choi et al. (2012) revealed that glutamine 283 plays a 
fundamental role in the RANTES analogues binding and pharmacological properties.[90] 
Choi et al. tested the anti-HIV potencies of the RANTES analogues on wild-type CCR5 
and CCR5E283A and discovered that 5P12 had 80 fold reduction in potency while both 
PSC and 6P4 showed enhanced potency up to 100 fold. Interestingly, 5P14 was not 
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affected by the E283A mutation but its potency was enhanced by the N252A mutation in 
CCR5. Choi et al. showed that the RANTES analogues affinities were not severely 
affected by the mutation ruling out that their different affinities were responsible for the 
changes in PIC50. Tamamis et al. in their molecular model also shows that E283 makes 
an important salt bridge with Ser1 of RANTES and this residue has also been shown to 
interact with the tropane nitrogen in Maraviroc by Tan (2013). Future NMR and x-ray 
crystallography experiments will shed light on the binding mode of the RANTES 
analogues with CCR5 and explain their different measured affinities. 
3.4.7  Partial Signal Peptide Cleavage 
Partial signal peptide cleavage may explain the two observed CCR5 species by FCCS and 
SDS-PAGE. The 5HT3a receptor signal peptide is predicted to be a cleavable signal 
peptide but it is possible that the FLAG tag and other receptor components can interfere 
with signal peptidase cleavage. We performed line-scan analysis of FLAG purified 
CCR5-SNAP from a representative NIR western blot to confirm if two distinct species 
are present in the ‘monomeric’ band (data not shown). Line scan analysis shows that 
CCR5 is composed of two distinct bands with a molecular weight difference of 2 kDa. 
This molecular weight difference corresponds to the molecular weight of the signal 
peptide. Similar band splitting has been observed for another GPCR, the glucagon-like 
peptide-1 receptor (GLP-1R) , which encodes for a cleavable signal peptide.[91] Ge et al. 
(2014) showed that although the signal peptide from GLP-1R is strongly predicted to be 
cleaved, the receptor undergoes partial cleavage with two distinct bands observed by 
western immunoblotting. Yet, expression of a GLP-1R mutant lacking the signal peptide 
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showed only reduction in cell surface expression with no perturbations in ligand binding 
or cAMP response. In comparison, Kobilka (1995) also reports a split band for a fusion 
protein of the β2-adrenergic receptor (β2-AR) where the signal peptide from 
hemagluttinin followed by a FLAG tag were fused upstream the receptor.[66] However, 
Kobilka reports that addition of PNGase collapses the dimer into a single band indicating 
that glycosylation, and not partial signal cleavage, could be responsible for the observed 
splitting. Furthermore, Guan et al. (1992) emphasizes that if the signal peptide is partially 
cleaved, then recognition by the M1 FLAG agarose would not be possible since the 
antibody does not recognize internal FLAG tags.[92] In our case, we employ a rabbit 
polyclonal FLAG antibody for NIR western immunoblotting, which does not recognize 
internal FLAG tags. Further experiments such as mass spectrometry will be required to 
assess whether the 5HT3a signal peptide is fully or partially cleaved. 
3.4.8  Post-Translational Modification of FLAG Epitope 
We also consider the possibility that the FLAG tag in CCR5-SNAP could be modified by 
phosphate or sulfate groups. The FLAG tag contains several aspartic acid residues, two 
lysines, and one tyrosine, all which can be phosphorylated, and/or tyrosine sulfated. 
Schmidt et al. (2012) and Hunter et al. (2016) have shown that the FLAG tag can be 
tyrosine sulfated in E. coli and mammalian cells.[93, 94] FLAG tag tyrosine sulfation 
decreases the binding affinity for the FLAG antibody. FLAG tag tyrosine sulfation can 
also perturb chemokine binding to CCR5 since CCR5 is also tyrosine sulfated in the N-
terminus. We could not find any literature reports on FLAG tag phosphorylation but 
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phosphorylation can mimic tyrosine sulfation. We treated FLAG purified CCR5-SNAP 
with phosphatase I and analyzed the reaction product by NIR western immunoblotting 
(data not shown). We observed no difference in mobility between the phosphatase treated 
sample and the non-treated sample indicating that CCR5-SNAP is not phosphorylated. 
We could not test if the FLAG tag tyrosine is sulfated since there are no commercially 
available tyrosine-O-sulfatases.  
 
3.4.9 Disulfide Bridge Reduction 
 
We also considered the possibility that DTT treatment during the SNAP tag labeling step 
with Alexa-488 could potentially disrupt the disulfide bridges in CCR5. SNAP tag 
contains a catalytic cysteine, cysteine 145, that undergoes nucleophilic addition at the 
benzyl guanine to form a covalent bond.[55, 95] DTT addition reduces cysteine 145 so 
that it can undergo nucleophilic addition. However, CCR5 has two extracellular 
conserved disulfide bridges between cys20-cys269 and cys101-cys178.[96] The disulfide 
bridges are required for CCR5 proper folding. We speculate that CCR5 reduction by DTT 
proceeds through a long-lived intermediate capable of ligand binding. This receptor long-
lived intermediate would bind with low affinity to the RANTES analogues. Rummel et 
al. (2013) investigated the effect of disulfide bridge reduction in CCR5 ligand binding 
and signaling by alanine mutagenesis.[96] Disulfide bridge removal completely abolished 
CCR5 ligand binding to MIP-1α and inositol phosphate (IP) accumulation in COS-7 cells 
indicating that the disulfide bridges are necessary for CCR5 function. In contrast, CCR1 
retained ligand binding to MIP-1α with no changes in maximal binding or affinity but 
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(IP) accumulation was abrogated. Blanpain et al. (1999) published similar results but 
employed DTT treatment instead of alanine mutagenesis to abolish the disulfide bridges 
in CCR5.[97] Blanpain et al. treated CCR5 expressing CHO-K1 cells with 100 mM DTT 
for 1 hour at 37 °C and observed that MIP-1β binding was abolished. The results above 
show that the disulfide bridges in CCR5 are essential for ligand binding and activity but 
are not the case for other chemokine receptors. As such, the possibility that a long lived 
CCR5 intermediate that retains CCR5 conformational integrity without the disulfides is 
not likely otherwise binding would have been retained in the CCR5 alanine mutants or 
CCR5 treated with DTT. We should note that during our labeling step, we employ 1 mM 
DTT well below the threshold for complete denaturation observed by Blanpain et al. 
(1999). We have observed a small decrease in active receptor sites from DTT treatment 
but the DTT addition allows quantitative labeling of the SNAP tag (unpublished data). 
We did observe that prolonged DTT treatment on SNAP-CCR5 completely abolished 
chemokine binding.  
3.4.10 Long-Lived Proline Conformers 
GPCRs contain several conserved prolines in the transmembrane region that have been 
shown to be important for cell surface expression, ligand binding, and signal 
transduction.[98] Proline is known to undergo cis-trans isomerization where the two-
receptor conformers could be long-lived species with distinct ligand binding profiles. 
Proline cis-trans isomerization has been shown to mediate channel opening in the 5-
HT3A receptor but its role in GPCRs is less understood.[99-101] Mutagenesis analysis 
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on CCR5 demonstrated that proline P84 in the transmembrane 2 (TM2) was important for 
differentiating chemokines.[102] Govaerts et al. (2001) tested a CCR5 proline mutant, 
CCR5P84A, and observed reduced MIP-1α binding but no changes in RANTES binding. 
Govaerts et al. (2001) also observed that RANTES could signal through the mutant but 
not MIP-1α. This indicates that proline is required for differentiating chemokines but we 
would like to emphasize that alanine is not an appropriate replacement for proline. Van 
Arman et al. (2011) introduced several unnatural amino acids in the dopamine 2 receptor 
(D2R) to probe directly the effect of N-H bonding and cis-trans isomerization in receptor 
function. Incorporation of ester analogues showed that lack of N-H bonding was required 
for functional activity while amino acids that restored N-H bonding had perturbed 
activity. Furthermore, N-cyclic proline analogues with different propensities for cis-trans 
isomerization did not have major effects on D2R function. Thus, we can exclude that the 
two CCR5-SNAP-488 species are proline cis-trans isomers.  
3.4.11 CCR5 Tyrosine Sulfation 
CCR5 is sulfated at tyrosines 3, 10, 14, and 15 from which tyrosines 10 and 14 are 
important for chemokine and gp120 high affinity binding.[103, 104] Tyrosine 
replacement with aspartate shows inefficient ligand binding indicating that charge is not 
responsible high affinity chemokine binding. In contrast, phenylalanine receptor mutants 
showed higher viral entry than the aspartate mutants.[104] Thus, hydrophobic 
interactions may play a larger role in chemokine binding affinity than ionic interactions. 
Furthermore, it is unknown if CCR5 is heterogeneously or homogeneously sulfated at all 
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4 tyrosine residues. Elegant studies by Seibert et al. (2002) using a CCR5 peptide 
comprising of amino acid residues 2 to 18 (CCR5 2-18) point to the possibility that  
CCR5 can be heterogeneously sulfated.[103] CCR5 is sulfated by TPST-1 and TPST-2 
but the two proteins show different sulfation kinetics and residue preferences. TPST-1 
primarily sulfates tyrosine 14 while TPST-2 sulfates tyrosine 15. Subsequently, TPST-1 
sulfates tyrosine 15 and TPST-2 sulfates tyrosine 14. TPST-1 incorporates sulfate to all 
the tyrosine residues but the major receptor species in the double-sulfated at tyrosines 14 
and 15. On the other hand, TPST-2 incorporates 3 distinct sulfates to CCR5. At 24 hours 
post-transfection, CCR5 would be comprised of the double- and triple-sulfated species 
assuming that the in vitro kinetics observed for both TPST proteins hold in HEK293T 
cells. Yet, it is unclear to what extent CCR5 is sulfated in HEK293T cells or in vivo.  
Further experiments will be required to assess whether CCR5 is heterogeneously sulfated 
in HEK293T cells and in vivo and whether these species have different ligand binding 
properties. 
3.4.12 CCR5 Glycosylation 
CCR5 contains several amino acid residues that can be N-linked or O-linked -
glycosylated. Farzan (1999) showed that treatment with N-glycosidase or tunicamycin 
did not affect CCR5 mobility in SDS-PAGE. In contrast, CCR5 treatment with O-
glycosidase cocktail treatment or neuraminidase shifted CCR5 mobility by SDS-
PAGE.[104] Bannert (2001) showed that CCR5 is O-linked glycosylated in the N-
terminus since a CCR5 mutant lacking the first 17 amino acids could not incorporated 
122 
3H-sugars. Serine 6, serine 7, threonine 16, and serine 17 in CCR5 are possible residues 
that can be glycosylated. Bannert (2001) showed that alanine mutations in serines 6 and 7 
displayed similar mobility as the fully de-glycosylated receptor. Also, CCR5 de-
glycosylation abolished MIP-1α binding in competition binding experiments. In contrast, 
de-glycosylation did not affect HIV-1 infection indicating that glycosylation is not 
required for viral binding to CCR5. Western immunoblotting analysis of CCR5 
expression in macrophages showed two CCR5 species that correspond to the 
glycosylated and non-glycosylated species. Doring (2014) expressed CCR5 in myeloid 
cells deficient of alpha2,3-sialyltransferase IV (STE3Gal-IV) and discovered that 
RANTES binding was severely reduced.[105] Doring (2014) also showed that leukocytes 
deficient on STE3Gal-IV adhered poorly to carotid arteries in response to RANTES. 
Thus, CCR5 glycosylation is important for chemokine high affinity binding. Hauser et al. 
(2016) also investigated the physiological role of glycosylation in the closely related 
chemokine receptor CCR7. Native T cells showed marginal CCR7 sialylation while a 
fraction of CD45RO+ cells show strong sialylation. Likewise, CCR7 was sialylated in 
almost all CD3/CD28 activated T cells indicating that T cell regulates CCR7 
glycosylation in vivo. Hauser (2016) further showed that murine cells with de-
glycosylated CCR7 migrated more rapidly in response to the chemokines CCL19 and 
CCL21 in 2D and 3D chemotactic assays. Hauser et al. also observed that PNGaseF 
treated human T cells migrated better than non-treated cells in response to chemokine 
stimulus. Also, cells expressing de-glycosylated cells showed prolonged calcium flux 
responses than wild-type CCR7 expressing cells. In contrast, CCR7 alanine mutants that 
could not be glycosylated internalized poorly in response to chemokine stimulus. The 
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results demonstrate that receptor activation of different signaling pathways can be 
regulated by the addition or removal or post-translational modifications.  Thus, we 
hypothesize that the two CCR5 species are the fully glycosylated and de-glycosylated 
species. To test this hypothesis, we treated SEC purified CCR5-SNAP and SNAP-CCR5 
with α2-3,6,8,9 neuraminidase A for 1 hour at room temperature and analyzed the 
reaction products by SDS-PAGE. Neuraminidase treatment reduced CCR5-SNAP and 
SNAP-CCR5 heterogeneity but did not completely reduced the observed bands to a 
single band. Thus, CCR5-SNAP and SNAP-CCR5 are sialylated but receptor sialylation 
is not the only covalent modification present in these constructs. Future experiments, 
such as MALDI-TOF, will help us discern the covalent modifications present in CCR5-
SNAP. Future FCCS ligand binding measurements will also help us assess whether these 
covalent modifications, such as sialic acid, affect chemokine binding. Also, we propose 
to perform experiments to assess whether CCR5 is heterogeneously modified in the 
immune system and the role of these modifications on receptor physiology. We have 
shown that FCCS is a powerful technique to discern receptor species that are averaged in 
cell-based functional assays. These CCR5 species are non-interconvertible and 
differentially recognize the RANTES analogues. Future studies with purified G-protein 
and CCR5-SNAP reconstituted in nanoscale apolipoprotein bound bilayers (NABBs) will 
show if the native chemokines can bind to CCR5-SNAP. The experiments will also help 
us determine the effect of G-protein on the RANTES analogues affinities and their 
residence on the two-receptor species. Our methodology is applicable to studying other 
GPCR-ligand interactions and can be generalized to broader receptor-ligand, and protein-
protein interactions in solution at the single molecule scale.  
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Chapter 4: NANOSCALE APOLIPOPROTEIN AI BOUND BILAYERS (NABBs) 
4.1  Introduction 
GPCRs are highly susceptible to their lipid environment. Detergents decrease interhelical 
packing in the transmembrane domain and increase unfolding of the alpha helices.[106]  
Detergent solubilization also cause GPCRs to aggregate to minimize hydrophobic 
contacts with water.[107] DDM, the detergent of choice to solubilize GPCRs, maintains 
good interhelical packing and stabilizes GPCR flexibility. Yet, GPCRs solubilized in 
DDM or other detergents cannot activate G-protein and the detergents can alter the 
kinetics of GDP-GTP exchange. [108, 109] Given this, several methods have been 
devised to study GPCRs in more native hydrophobic environments that maintain receptor 
structure and function and allow coupling of effector proteins such as G-protein.[110] 
Nanoscale apolipoprotein bound bilayers (NABBs) is an example of a phospholipid 
bilayer system devised to solubilize GPCRs without detergents. NABBs are soluble 
phospholipid bilayers encircled by apolipoprotein A-I derived from zebrafish (Zap1). 
NABBs offer several advantages over detergent micelles and liposomes, such native 
bilayer environment, retention of wild-type stability and function, and control of 
oligomeric state and lipid environment. Rhodopsin incorporated into POPC NABBs 
showed thermal stability comparable to Rhodopsin in rod outer segments (ROS) and 
greater than Rhodopsin solubilized in DDM.[86] Also, Rhodopsin incorporated in 
NABBs can activate the visual G-protein, transducin. Further studies on CCR5 revealed 
similar thermal stability from CCR5 solubilized in micelles. CCR5 NABBs denatured at 
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the temperature of 54.5 °C while CCR5 in Buffer N denatured at 47.1 °C.[85] Small 
molecules such as Maraviroc and Vicriviroc also stabilized CCR5 by shifting the melting 
temperature of the receptor. Thus, NABBs are a suitable lipid system to study GPCRs in 
a native environment. 
However, NABBs are expensive to work with since Zap1 does not express well in 
bacterial cultures with protein yields around 10 mg/L culture. Given this, we 
systematically optimized the expression and purification conditions for Zap1 to increase 
protein yield and purity. We designed a codon optimized construct, ZapN1, for higher 
expression in E. coli and performed single colony screening for protein expression. We 
found that double-screened colonies expressed ZapN1 at higher quantities than the single 
screened colonies. We optimized induction time for single and double-screened colonies 
and monitored ZapN1 expression every hour after induction. We observed that induction 
at O.D.600 0.8 and 3 hours incubation time gave the highest ZapN1 expression. We tested 
ZapN1 expression at 16, 23, 30, and 37 ° C for 3 hours and discovered that ZapN1 
expressed better when cultures where incubated for 3 hours at 30 °C. We also optimized 
purification of ZapN1 in batch to increase yield and purity. Large-scale expression of 
ZapN1 using the optimized expression and purification conditions yielded 250 mg/L 
culture of ZapN1.  
NABBs assembly is also limited by the number of reactions that can be performed 
simultaneously. To address this problem, we designed and built a custom platform to 
support mini-scale batch columns for high-throughput chromatography at RT and 0 °C. 
NABBs assembled with POPC are heterogeneous and this heterogeneity can complicate 
single molecule analysis and NABBs stability over time. Given this, NABBs assembly 
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with DLPC yielded near-homogeneous NABB preparations. We optimized NABBs 
assembly with DLPC and showed that 95 lipids/ZapN1 give near-homogeneous 
preparations and the assembly conditions are compatible with the detergents and 
additives used in GPCR solubilization. We reconstituted Rhodopsin labeled with 
Fluorescein (Rho-Fl) into DLPC NABBs and showed that Rho-Fl is successfully 
incorporated into NABBs and the particles have the expected size. We then show that 
CCR5 incorporated into DLPC NABBs (CCR5-NABBs) can bind 2D7-Cy5 and we 
calculated a 𝐾𝐷 value of 5.5 nM. Future experiments will employ CCR5-NABBs to 
perform saturation and competition binding with the RANTES analogues to validate the 
results obtained in micelles. We will also reconstitute CCR5-NABBs with purified Gαiβγ 
to determine if G-protein pre-coupling affects chemokine affinity and the ratio of the high 
and low affinity receptor fractions. 
4.2  Materials and Methods 
4.2.1 SDS-PAGE Analysis 
Cell pellets were solubilized in 100 μl of lysis buffer A (150 mM NaCl, 1% Triton X-
100, 50 mM Tris pH 8.0) and sonicated for 10 seconds in a Branson 1200 sonicator. 
Samples were centrifuged at 17,800 rpm for 5 minutes in an IEC Micromax 
microcentrifuge. 6.5 μl of cell lysate supernatant or Ni fraction was added to 2.5 μl of 
NuPAGE loading dye buffer and 1 μl of NuPAGE reducing agent in a 1.0 ml Eppendorf 
microcentrifuge tube. Samples were heat-denatured by placing them in a boiling water 
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bath for 10 minutes. The denatured samples were then applied to individual wells of a 4-
12% Bis-Tris NuPAGE gel (1.0 mm) in MES-SDS buffer (50 mM MES, 50 mM Tris 
Base, 0.1% SDS, 1 mM EDTA, pH 7.3). Electrophoresis was carried out with a voltage 
of ≤ 200 V. The gel was then stained for 30 minutes in Coomassie Brilliant Blue-R G250 
staining solution and destained by several washes of destaining solution and water.  
4.2.2 Double Screening for Apolipoprotein Expression 
BL21-Gold (DE3) cells (Agilent Technologies, Catalog # 230132) were aliquoted (10 μl) 
with 50 ng of plasmid DNA and incubated in ice for 30 minutes. Cells were then 
transformed by heat-shocking at 42 ͦ C for 20 seconds in a water-bath. 190 μl of SOC 
media was added to each sample and incubated at 37 ͦ C with shaking at 1,100 rpm for 1 
hour in a Thermomixer compact (Eppendorf, Order # 022670051). Bacterial samples (20 
and 180 μl per sample) were then plated onto LB-agar kanamycin plates (50 μg/ml final 
concentration) and incubated at 37 ͦ C for 12-16 hours. Single colonies were selected to 
inoculate 10 ml of Terrific Broth (TB) media in 13 ml polypropylene culture tubes 
(Sarstedt, Item I.D. 368625). Bacterial cultures were incubated at 37 ͦ C and induced with 
1 mM IPTG when the O.D.600 reached a value of ~ 0.6. Cultures were then incubated for 
an additional 3 hours at 37 ͦ C. 5 ml of each culture were collected in individual 1.5 ml 
Eppendorf microcentrifuge tubes. Also, 1 ml of each culture was used to make glycerol 
stocks by adding an equal part of sterile 50% glycerol in water (v/v) in a cryogenic vial 
(Thermo Scientific, Catalog # 375418). 
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4.2.3 Generation of Bacterial Growth Curves 
A 5 ml LB culture with kanamycin (50 μg/ml final concentration) was inoculated from a 
glycerol stock of BL21-Gold (DE3) cells previously transformed with ZapN1 that were 
either randomly selected or double-screened for protein expression. The culture was 
incubated at 37 ͦ C for ≤ 16 hours with shaking at 200 rpm. Then, 100 ml TB cultures 
with kanamycin (in 250 ml Pyrex Flasks) were inoculated with 500 μl of the starter 
culture (1:200 dilution) and incubated at 37 ͦ C with shaking at 200 rpm. Every hour or 30 
minutes, 1 ml sample of each culture was removed for O.D.600 measurements in 
methacrylate, 4.5 ml cuvettes with a 10 mm light path (Fisherbrand, Catalogue # 14-955-
130). O.D.600 measurements were obtained using a SmartSpec 3000 spectrophotometer 
(Bio-Rad, Catalogue # 170-2501) before and after addition of IPTG. Bacterial cultures 
were induced with 100 μl of 1M IPTG when they reached O.D.600 values of 0.5, 0.8, and 
1.2. Every hour after induction, 1 ml samples of each culture were collected in 1.5 ml 
Eppendorf tubes and stored at – 20 ͦ C.  
4.2.4 Temperature Effects on Expression of ZapN1 
8 ml LB cultures with kanamycin (50 μg/ml final concentration) were inoculated from 
glycerol stocks of BL21-Gold (DE3) cells previously transformed with ZapN1 that were 
either randomly selected or double-screened for protein expression. The starter cultures 
were incubated at 37 ͦ C for ≤ 16 hours with shaking at 200 rpm. Then, 100 ml TB 
cultures with kanamycin (in 250 ml Pyrex Flasks) were inoculated with 500 μl of each 
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starter culture (1:200 dilution) and incubated at 37 ͦ C with shaking at 200 rpm. When 
cultures reached an O.D.600 value of ~0.8, ZapN1 expression was induced by the addition 
of IPTG (1 mM final concentration). Then, cultures were incubated at four different 
temperatures (37, 30, 23, and 16 ͦ C) for a span of 3 hours each. Each hour after induction, 
1 ml samples per culture were collected in 1.5 ml Eppendorf tubes and O.D.600 values 
were recorded as mentioned previously.  
4.2.5 Small Scale Purification of ZapN1 
100 ml TB cultures that were previously inoculated with single or double-screened 
samples were incubated at 37 ͦ C until the O.D.600 reached ~0.8 at which then IPTG (1 
mM final concentration was added). Cultures were then incubated at 30 ͦ C for 3 hours 
with shaking at 200 rpm. Cells were harvested every hour post-induction by centrifuging 
at 3,000 rpm, 4 ͦ C in 250 ml ultracentrifuge conical tubes (Corning, Catalogue # 25350-
250) in a Beckman CS-6R Centrifuge. Cell pellets were thawed from – 80 ͦ C on ice and 
then solubilized in 5 ml of lysis buffer B (40 mM Tris, 0.3 M NaCl, 5 mM 2-
mercaptoethanol, 2 mM phenylmethanesulfonyl fluoride (PMSF), 10 μg/ml aprotinin, 5 
μg/ml leupeptin, 1% Triton X-100, 1 EDTA-free protease inhibitor-table (1 tablet per 50 
ml of buffer), pH 8.0). Cell samples were then incubated on ice for 30 minutes with 
vortexing every 15 minutes. Samples were then spun for 30 minutes at 4 ͦ C, 30,000xg in 
polypropylene ultracentrifuge clear tubes, using a JA-17 rotor in a Beckman Avanti J-25 
centrifuge. 600 μl of His60 Ni Superflow resin (Clontech, Catalogue # 635660) was 
loaded into a Poly-Prep chromatography column (Bio-Rad, Catalogue # 731-1550, 6 
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columns total) and equilibrated with 5 ml of Equilibration buffer (50 mM sodium 
phosphate, 300 mM NaCl, 20 mM imidazole, pH 7.4). After centrifugation, the 
supernatant from each sample was loaded into the equilibrated resin. ZapN1 was allowed 
to bind the resin by gravity flow. The resin was then washed with 5 ml of wash buffer (50 
mM sodium phosphate, 300 mM NaCl, 40 mM imidazole, pH 7.4). To elute ZapN1 from 
the columns, 1.5 ml of elution buffer (50 mM sodium phosphate, 300 mM NaCl, 300 mM 
imidazole, pH 7.4) was added twice to the resin and collected in 2 ml Eppendorf tubes. 
To analyze the efficiency of ZapN1 purification, 6.5 μl of the flow through, wash elution, 
and fractions were aliquoted for SDS-PAGE analysis as described previously. 
4.2.6 Large Scale Expression and Purification of ZapN1 
1 L TB cultures (with kanamycin at 50 μg/ml final concentration) were inoculated (1:200 
dilution) with a previously grown culture of BL21-Gold (DE3) cells that were double-
screened for ZapN1 expression. The 1 L cultures were then incubated at 37 ͦ C with 
shaking at 200 rpm. ZapN1 expression was induced by the addition of IPTG (1 mM final 
concentration) when the cultures reached an O.D.600 of ~0.8. Then, the 1 L cultures were 
incubated for 3 hours at 30 ͦ C with shaking at 200 rpm. Cells were harvested by 
centrifuging the samples at 2,000 rpm for 20 minutes in a J6-HC Beckman centrifuge. 
Cell pellets were then stored at – 80 ͦ C. Cell pellets were thawed to 4 ͦ C before 
solubilizing in 50 ml total of lysis buffer B. The cell mixture was then incubated on ice 
for 30 minutes. The cell lysate was then sonicated on ice by using a Misonix Sonicator 
3000 with an output level of 10, ON time 10 seconds, OFF time 10 seconds, for a total 
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time of 1.2 minutes. After sonication, the cell lysate was placed into polypropylene tubes 
and centrifuged at 30,000xg for 30 minutes at 4 ͦ C using a JA-17 rotor in an Avanti J-25 
centrifuge (Beckman). The supernatant was then applied to 15 ml of His60 Ni Superflow 
resin previously equilibrated with 10 CVs (150 ml) of equilibration buffer and incubated 
overnight at 4 ͦ C. The resin was then applied to a column and washed with 10 CVs of 
wash buffer. ZapN1 was then eluted with 10 x 5 ml of elution. To analyze the ZapN1 
content of each fraction, SDS-PAGE analysis was performed as described previously. 
Fractions containing ZapN1 were concentrated and desalted using an Amicon Ultra-15 
centrifuge filter unit with a molecular weight cutoff of 10,000 Da (Millipore, Catalogue # 
UFC901024). ZapN1 was dialyzed twice against 50 mM ammonium acetate in a Slide-A-
lyzer Dialysis cassette with a molecular weight cutoff of 3.5 kDa (Pierce, Product # 
66130). Samples were then aliquoted, lyophilized using a SpeedVac SC100, and stored at 
-80 ͦ C.  
4.2.7 Triton X-100 Removal from Purified ZapN1 
250 mg lyophilized ZapN1 is solubilized in 5 milliliters 6 M guanidinium hydrochloride 
for 1 hour at 4 °C. Meanwhile, 1 ml of His60 Superflow Ni resin is washed with 10 ml 
Millipore grade water and then equilibrated with 10 ml buffer (50 mM sodium phosphate, 
300 mM NaCl, 10 mM imidazole, 6M GuHCl, pH 7.4). ZapN1 is added to the resin and 
allowed to bind overnight at 4 °C in a 50 ml vessel. The resin is added onto a disposable 
Poly-prep and allowed to settle by gravity flow. The resin is then washed with 50 mM 
sodium phosphate, 300 mM NaCl, 10 mM imidazole, pH 7.4 with decreasing 
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concentrations of guanidinium hydrochloride (4, 2, 1, and 0.5 M) in steps of 5 ml. The 
resin is then washed in 10 ml of 50 mM sodium phosphate, 300 mM NaCl, 10 mM 
imidazole, pH 7.4) to remove remaining traces of guanidinium hydrochloride. The resin 
is then washed with another 10 ml of the same buffer as above supplemented with 1% 
sodium cholate followed by another 10 ml buffer without detergent. ZapN1 is eluted from 
the resin 8 1 ml fractions using 50 mM sodium phosphate, 300 mM NaCl, 300 mM 
imidazole, pH 7.4. Fractions were analyzed by SDS-PAGE and the peak fractions were 
pooled together, aliquoted, and snap frozen in liquid N2 for long term storage at -80 °C. 
4.2.8 Construction of High Throughout Chromatography Platforms 
We designed a platform that allows for simultaneous, high-throughput, mini-scale 
chromatography at either RT or 0 °C. Platform was designed so that any 96-well plate 
could be placed below for sample collection. We took dimension measurements from a 
96 well plate (Fisher Scientific, Round Bottom 96 well plate, Natural, Polypropylene, 
Catalogue Number 12-565-502) as a basis for the platform. We also acquired 
measurements for the pins in the B2 position in the EpMotion 5070 so that the platform 
could fit between pins. We took this approach since we could automate fluid dispensing 
with the EpMotion. The measured distance between pins was 102 mm (width) and 54 
mm (height) for the inside distances. For the external distances, a 96 well plate was 
measured and obtained a width of 127.3 mm and a height of 85 mm. Based on the 
dimensions of the 96 well plate, an adobe illustrator file was made for the plate (Figure 
4.2.8a)  
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Figure 4.2.8a. Dimensions of a 96-well plate. The red lines indicate the distance between 
two points and the numbers adjacent to the red lines indicate the length in mm.  
To design the platform, we used a box design and modify the dimensions to fit the 96 
well plate and the pins in the Eppendorf 5070 (Figure 4.2.8b). We designed two different 
models that would accommodate mini-scale chromatography purifications at different 
temperatures. We designed a top that accommodates 24 simultaneous purifications for 0 
°C. We designed a second top that accommodates 96 simultaneous purifications for RT. 
We made the tops compatible with the walls of the platform so that they could be 
interchanged.  
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Figure 4.2.8b Dimensions of the high-throughput chromatography platform. The red lines 
indicate the distance between two points in inches.  
For the top of the box, we imposed the drawing made in illustrator for the 96-well plate 
into the corresponding section of the box. For the 24-sample holder, every other well was 
deleted such that the top could slide into three different positions in the box and allow 
fractions to be collected in the same plate. To determine the height of the box, we 
determined the height of the disposable columns (Extract Clean 1.5 ml reservoir part# 
210001/5122381) to be used with the platform to be 65 mm. The height of the column 
was then added to that of the 96 well plate and 5 mm were added to allow space between 
the column and the plate for a total height of 78.72 mm. Adobe illustrator files were 
converted into AutoCAD files for printing the files into plastic. To design the RT box, we 
employed a VLS 6.60 Laser Cutter and used Cast Colorless Acrylic plastic from 
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McMaster Carr. To print the 0 °C platform, we employed a 3D PROJET 3510 HD (Plus) 
printer and used M3 crystal as the material. The RT platform was assembled manually 
using epoxy glue to hold the individual pieces together.  
4.2.9  Assembly of NABBs 
1.5 ml columns (Extract Clean 1.5 ml reservoir part# 210001/5122381) are washed with 
1 ml 100% ethanol to prime the membrane and allow aqueous solutions to pass through. 
The columns are then washed with 2 x 1 ml Millipore grade water to wash residual 
ethanol. Re-suspended detergent removal resin (Pierce Detergent Removal Spin 
Columns, 4 ml, Prod #97779) is added to each column until 1 ml of packed resin has 
filled the column. Resin is then equilibrated in 2 ml of Buffer G (10 mM Tris, 0.15 M 
NaCl, pH 8.0, for empty NABBs) or Buffer C (20 mM HEPES pH 7.4, 0.1 M (NH4)2SO4, 
1 mM CaCl2, 5 mM MgCl2, 10% glycerol, for GPCR-loaded NABBs). NABBs samples 
are then added onto the resin and allowed to enter by gravity flow. NABBs are eluted in 4 
x 150 µl fractions of buffer and collected in polystyrene 96 well plates. Fractions are 
analyzed by measuring the 280 nm absorbance to determine the NABB peak fractions. 
Peak fractions are pooled and utilized for SEC and native PAGE.  
NABBs reaction were assembled by mixing all the components in 1.5 ml Eppendorfs and 
incubating the reactions on ice for 30 minutes prior to detergent removal. Reagent 
concentrations were determined based on the concentration of ZapN1 used for the 
reactions. For 75 and 55 POPC NABBs, ZapN1 was added to a final concentration of 90 
µM and 1.5% sodium cholate (w/v). For all other NABBs assembly except for receptor 
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loaded NABBs, ZapN1 was added to a final concentration of 200 µM and 2% (w/v) 
sodium cholate for total reaction volume of 150 µl. Lipid stocks were made in 7.5% (w/v) 
sodium cholate which is known to yield more homogeneous preparations than CHAPS or 
DDM. Lipids are added at a stoichiometric factor relative to the concentration of ZapN1. 
For example, for 95 DLPC NABBs, DLPC is added to a final concentration of 95 x 200 
µM or 19 mM for a total reaction volume of 150 µl. Buffer G or Buffer C is then added 
to each reaction to bring the final volume to 150 µl. Additives such as DDM, CHS, and 
glycerol are added to each NABB reaction at a final concentration (w/v) relative to the 
final volume of 150 µl. For Rhodopsin-Fluorescein loaded NABBs, ZapN1 was added to 
a final concentration of 100 µM and Rhodopsin-Fluorescein 2 µM in 6 mM DLPC (60 
DLPC per ZapN1) in a total reaction volume of 150 µl. Sodium cholate was kept at 2% 
(w/v) total concentration for Rhodopsin-Fluorescein NABBs. Rhodopsin-Fluorescein 
NABBs were eluted in Buffer G. For CCR5-SNAP-488 NABBs, ZapN1 and sodium 
cholate concentration was kept the same as the Rhodopsin-Fluorescein NABBs. CCR5-
SNAP-488 was 1D4/FLAG purified as described previously and added directly to the 
NABB reaction without SEC purification step. 70 µl CCR5-SNAP-488 FLAG elution 
was added to the DLPC/ZapN1/sodium cholate mixture to bring the final volume to 150 
µl. CCR5-SNAP-488 NABBs were eluted in Buffer C and then used for 2D7-Cy5 
binding studies or analyzed by SEC and SDS-PAGE.  
137 
4.2.10  Native PAGE Analysis 
16 µl sample is mixed with equal parts native sample buffer (Bio-rad, catalog# 161-0738, 
62.5 mM Tris-HCl, pH 6.8, 40% glycerol, 0.01% bromophenol blue) in individual 1.0 ml 
Eppendorfs. Samples are loaded into a 4-20% Mini Protean TGX gel immersed in 1x 
TBE buffer (90 mM Tris base, 80 mM boric acid, 3 mM EDTA, pH close to 8.35) at 16 
°C. To analyze NABB particles, the following voltage sequence is used  
1. 20 V for 15 minutes.
2. 70 V for 20 minutes.
3. 150V for 12 hours.
Gels are removed from the cassette and stained in Coomassie Brilliant Blue solution 
(50% methanol, 10% glacial acetic acid, 0.1% Coomassie Brilliant Blue) for 30 minutes 
at RT and destained with several washes of destaining solution (50% methanol, 10% 
glacial acetic acid).  
4.2.11  Size Exclusion Chromatography 
Superdex 200 10/300 GL column is equilibrated with at least 1 CV of Buffer G or Buffer 
C prior to addition of the NABB samples. NABBs are injected into the column and then 
eluted over 1 CV in the appropriate buffer with a flow rate of 0.25 ml/mn. 0.5 ml 
fractions are collected in 1.0 ml tubes and protein elution is monitored using 280 nm 
absorbance. Fractions are analyzed by native PAGE to determine the peak fractions. If 
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the column would be used subsequently for more NABB purifications, then the column is 
washed with 1 CV of the appropriate buffer before loading the NABB sample.  
4.2.12  Rhodopsin Purification from Rod Outer Segments 
ROS membranes are thawed on ice for 1 hour in the dark and then 500 µl 1% DDM 
solution in 1x PBS supplemented with protease inhibitor tablets is added to the 
membranes. Samples are incubated for 2 hours at 4 °C and then centrifuged using the 
TLA 100.3 rotor at 100,000xg for 30 minutes at 4 °C using the Optima TL 
ultracentrifuge. Supernatant is transferred to a 15 ml vessel containing 1 ml 50% 1D4 
mAb Sepharose 2B resin and 4 ml 1x PBS. Sample is then incubated for 16 hours at 4 °C 
to allow Rhodopsin to bind the resin. Resin is transferred to a clean 1.5 ml Eppendorf and 
0.5 ml reaction buffer (0.1% DDM (w/v) in 1x PBS, pH 7.2) is added to the resin. Sample 
is incubated with constant nutation for 30 minutes at 4 °C and then spun down to pellet 
the resin at 5,500 rpm. Supernatant is removed from the resin and the resin is washed one 
more time with reaction buffer as before. Resin is re-suspended in 1.0 ml reaction buffer 
and 1.5 µl of 23 mM Fluorescein-maleimide is added to the sample. Rhodopsin is labeled 
with Fluorescein at 25 °C for 20 hours with constant vortexing. To stop the reaction, resin 
is pelleted at 4 °C for 2 minutes and the supernatant is discarded. Resin is re-suspended in 
1.0 ml reaction buffer and washed for 30 minutes at 4 °C with constant nutation. Resin is 
pelleted as above and the supernatant removed from the resin. Resin is washed 4 more 
time in reaction buffer as above to remove any trace fluorophore. Resin is re-suspended 
in 1.0 ml low salt buffer (0.1% (w/v) DDM, 2 mM sodium phosphate, pH 6.0) and 
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washed for 30 minutes at 4 °C with constant nutation. Resin is pelleted as above and then 
Rhodopsin-Fluorescein (Rho-Fl) is eluted from the 1D4 resin by adding 500 µl elution 
buffer (0.33 mg/ml 1D5 peptide in 0.1% DDM (w/v), 2 mM sodium phosphate, pH 6.0) 
and incubating on ice for 1 hour. Sample is pelleted as above and the supernatant is 
collected in a separate 1.5 ml Eppendorf. Elution buffer is added one more time as above 
and Rho-Fl is eluted one more time. 1D4 elution fractions are pooled together and 5 M 
NaCl is added to a final concentration of 0.15 M. Rho-Fl is characterized by UV-Vis 
spectroscopy.  
4.2.13  FCS and FCCS Measurements 
For antibody binding to CCR5-SNAP-488 NABBs, CCR5-NABBs were mixed with 
2D7-Cy5 at various antibody concentrations (1, 2, 4, 8, 16, and 32 nM) for a total 
reaction volume of 100 µl. Samples were incubated for 30 minutes at RT protected from 
ambient light. Samples were loaded into # 1.5 glass bottom 96 well black plates and 
mounted in an inverted laser scanning confocal microscope LSM 780 (Zeiss). Alexa-
488/Fluorescein was excited using an Argon 488 nm laser at 0.8% or 1.0% laser 
transmission and Cy5 was excited using a Helium-Neon 633 nm laser line at 4.0% laser 
transmission. Laser excitation was focused into the sample by using a 40x C-Apochromat 
NA 1.2 water immersion objective. Correction collar was adjusted in the objective to 0.17 
and room temperature and focal depth set at 50 µm (CCR5 NABBs) or 200 µm (Rho-Fl 
NABBs) above the glass by performing a line scan using reflected light from the 488 nm 
laser line. For 488 nm excitation, a 488 only main beam splitter (MBS) was used and for 
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633 nm and dual excitation a MBS 488/561/633 was used. Emission from Alexa-488 or 
Fluorescein was collected in the range of 516 – 596 nm using a GaAsP detector and 
emission from Cy5 in the range of 656 – 750 nm using a PMT detector. Pinholes for both 
excitations were set to 1.0 airy units and aligned along the 𝑥𝑦 plane using a solution of 
free dye or the sample itself. Count-rate binning time was set to 1 ms and the correlator 
binning time was set to 0.2 µs. Count rates were never greater than 500 kHz and traces 
showing large deviations from the average or decaying/increasing fluorescence were 
manually removed from the analysis. Counts per molecule (CPM) values were between 
1-16 kHz for all measurements to avoid optical saturation while maximizing counts 
above background. For Rho-Fl NABBs, 10 repetitions of 10 seconds each were collected 
and averaged while for CCR5-SNAP-488 NABBs binding to 2D7-Cy5 50 repetitions of 
10 seconds each were collected and averaged. For 2D7-Cy5 binding to CCR5-SNAP-488 
NABBs, cross-correlation curves were fitted using equation 3.3 and the auto-correlation 













































Where the second translational component is to account for NABB aggregates that are 
present in the solution or the 2D7-Cy5 bound to CCR5-SNAP NABBs. To fit the Rho-Fl 

































) + 1 (Equation 4.2) 
Where we included a rotational component that is dependent on translational diffusion. 
𝑅𝑎 is the rotational amplitude and 𝜏𝑟 is the rotational diffusion time. Concentrations for 
the fluorescent species were derived as described previously.  
4.2.14  Negative Stain Transmission Electron Microscopy 
SEC purified DLPC NABBs (empty or with CCR5-SNAP) were diluted in Buffer G or 
Buffer C at the following concentrations: 10 µg/ml, 5 µg/ml, and 1 µg/ml for EM sample 
staining. Carbon-coated 200 mesh copper grids were glow discharged for 20 seconds and 
then 10 µl of was applied directly to the copper grid and incubated for 2 minutes at R.T. 
Excess sample was blotted using a kimwipe and the grid was washed twice with 10 µl of 
Millipore water. The grid was stained in 10 µl of 1% aqueous uranyl acetate previously 
filtered using a 0.45 µm membrane. The staining was repeated twice and in the last 
staining step the stain was allowed to sit on the grid for 2 minutes at R.T. Excess stain 
was removed using a kimwipe making sure to leave behind a thin film of stain.  Grids 
were air-dried for 10 mns and then stored at R.T. until imaging. Images were acquired 
using a JEOL 1400 Plus transmission electron microscope with Gatan 2K x 2K digital 
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camera. Electron beam energy was set at 120 kV and images were acquired at 25,000x 
magnification with size of 2048 x 2048 pixels and exposure time of 1 second. 
4.2.15 Atomic Force Microscopy on NABBs 
Fluid imaging of SEC purified empty NABBS or SNAP-CCR5 NABBs was performed 
using a Cypher ES AFM (Asylum Research), with a silicon probe (nominal spring 
constant, k = 2 N/m) in tapping mode at RT. 45 µl of buffer G or buffer C was plated on 
freshly cleaved mica substrate (SPI) for ~10 seconds before adding 5 µl of the NABBs 
solution for a final dilution of 1:10. The mixture was incubated for ~ 30 seconds, and 
then washed with 5 ml of the same buffer to remove excess NABBs in solution. The scan 
size was 500 nm x 500 nm. Raw data was exported into tiff images using the Asylum 
Research’s Igor Pro software for analysis. 
Tiff exported images were then imported into FIJI/ImageJ (NIH) for quantification of 
height, volume, and diameter of NABBS. A FFT bandpass filter was first applied to the 
image, and then an unsharp mask filter was applied to allow for segmentation of 
individual NABB structures. An auto threshold was applied to the image and the 
thresholded image was converted into a binary image. Using the watershed irregular 
features plugin in the BioVoxxel Toolbox in FIJI, the NABBs were segmented. An 
average intensity measurement was converted into an average height measurement for 
each individual NABB. A Feret’s diameter measurement was used to get the diameter of 
individual NABBs. Volume measurements were calculated using equation 4.3 
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𝑉 = 𝐼𝑎𝑣𝑔 ∙ 𝑍𝑐𝑜𝑛𝑣𝑒𝑟𝑠𝑖𝑜𝑛 ∙ 𝐴𝑝 ∙ 𝑋𝑌𝑐𝑜𝑛𝑣𝑒𝑟𝑠𝑖𝑜𝑛
2 (Equation 4.3) 
where 𝐼𝑎𝑣𝑔 is the average intensity, 𝑍𝑐𝑜𝑛𝑣𝑒𝑟𝑠𝑖𝑜𝑛is the conversion of one gray scale unit of 
intensity into height in nanometers,  𝑋𝑌𝑐𝑜𝑛𝑣𝑒𝑟𝑠𝑖𝑜𝑛 is the pixel to nanometer conversion for 
the image in xy, and 𝐴𝑝 is the area of particles or NABBs in pixels. In addition, images 
were exported with a 3x3 median filter to reduce the noise seen in images for the figures. 
4.2.16 Receptor SDS-PAGE Analysis and Western Immunoblotting 
SEC purified CCR5-SNAP-488 NABB fractions were mixed with DTT at 150 mM final 
concentration and NuPAGE loading buffer. Samples were loaded into a NuPAGE 4-12% 
Bis-Tris gel in MES-SDS buffer. Electrophoresis was conducted at a constant voltage of 
100V. The gel was removed from the cassette and rinsed in water for 5 minutes at RT. 1 
piece of Immobilon PVDF membrane was incubated for 1 minute at room temperature in 
100% methanol. The PVDF membrane and 2 pieces of extra thick blot papers (Bio-rad) 
were rinsed in 1x Fast Semi-Dry transfer buffer for 10 minutes at RT. Western transfer 
was performed in a semi-dry apparatus for 7 minutes with a constant voltage of 25V. 
After electrophoresis, the membrane was placed in 10 ml of 5% Milk in 1x TBST for 1 
hour at room temperature. The membrane was then placed in 10 ml of blocking buffer 
with anti-1D4 mouse monoclonal (1:3,000). The membrane was incubated overnight at 4 
°C. Membrane was then washed 3x5 minutes in 1x TBST. Membrane was incubated for 
30 minutes at RT in 10 ml blocking buffer supplemented with anti-mouse horseradish 
peroxidase (HRP) conjugated secondary antibody (1:10,000). Membrane was washed 
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again 3x5 minutes in 1x TBST.  Solution was removed and the membrane was treated 
Femto substrate (Thermo Scientific) for 1 minute at RT. Excess solution was removed 
and the autoradiography film was exposed to the membrane in the dark at various time 
intervals. Images were scanned using a scanner and analyzed using ImageJ. 
4.2.17 Data Analysis and Processing 
All Coomassie stained gels were analyzed using a BioSpectrum 500 Imaging System 
(Ultra-Violet Products) with a LED white illuminator. Images were acquired with an 
exposure time of 4 seconds and a gain of 581. Data analysis was performed using 
Microsoft Excel 2010 unless stated otherwise. Figures were made using Adobe 
Photoshop CC and Illustrator. To fit the saturation binding isotherm of 2D7-Cy5 binding 




 (Equation 4.4) 
Where 𝑦 is the fractional occupancy and 𝐿 is the concentration of free labeled antibody. 
Equation 4.4 was fitted using GraphPad Prism.  
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4.3 Results 
4.3.1 Double Screening of Cultures for ZapN1 Expression 
Double selection or screening relies on performing two rounds of antibiotic pressure on 
single colonies plated on LB agar plates. Single colonies are screened for protein 
expression in small-scale cultures. The highest expressing culture is then re-plated onto a 
fresh LB agar plate and then single colonies are re-screened for protein expression. We 
performed double screening on BL21 (DE3) transformed with ZapN1, Zap1, and the 
commercially available membrane scaffold protein MSP1D1. Transformed bacterial 
cultures were plated onto LB agar-kanamycin plates and single colonies were grown in 5 
ml LB cultures. Cultures were pelleted, lysed, and analyzed by SDS-PAGE to determine 
which colonies expressed the proteins at the highest levels. Cultures were then screened 
twice as described previously. Figure 4.3.1 shows the SDS-PAGE analysis of the 3 
highest colonies from the 1st and 2nd rounds of screening. 
Figure 4.3.1 Screening for Apolipoprotein Expression in BL21-Gold (DE3) Single 
Colonies. Coomassie Brilliant Blue-stained polyacrylamide gels showing BL21-Gold 
(DE3) cell lysates that expressed the highest levels of apolipoproteins from n ≥ 3 
screened colonies. The first panel shows cell lysates from the first round of screening 
while the second panel shows samples that underwent a second screening. The double-
screened samples were selected from the glycerol stocks of the highest expressing 
colonies of the first panel.  
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ZapN1 and Zap1 run as a single molecular species of 30 kDa molecular weight. MSP1D1 
runs at a molecular weight of 25 kDa. The 3 apolipoproteins express in BL21 (DE3) cells 
but ZapN1 expresses higher than the non-codon optimized construct Zap1 and MSP1D1. 
Double screening increased expression of all 3 apolipoproteins but ZapN1 increased 
more than Zap1 and MSPS1D1. For subsequent expression optimization experiments, we 
employed the single and double-screened ZapN1 colonies that had the highest protein 
expression.  
4.3.2 Optimization of Induction and Incubation Time 
ZapN1 expression was assessed on single and double-screened BL21 (DE3) cultures that 
were induced with IPTG at different O.D600 values of 0.5, 0.8, and 1.2. We monitored 
bacterial growth before and after induction by taking O.D600 measurements periodically. 
After induction, 1 ml samples were taken from each culture to determine ZapN1 
expression at every hour by SDS-PAGE analysis. Figure 4.3.2 shows the bacterial growth 
curves for single and double-screened cultures induced with IPTG at various O.D600 
values. Figure 4.3.2 also shows the Coomassie blue stained SDS-PAGE gels for bacterial 
samples taken every hour post-induction to assess ZapN1 expression.  
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Figure 4.3.2 Induction of ZapN1 Expression at Various Time Points in BL21-Gold 
(DE3) Cultures. Growth curves of BL21-Gold (DE3) cells (100 ml cultures of TB media) 
expressing ZapN1 induced by 1 mM IPTG at various O.D. 600 values (0.5, 0.8, and 1.2). 
As a control, cultures were incubated without the addition of IPTG to monitor any effect 
on cell growth after IPTG addition (A). Growth curves of BL21-Gold (DE3) cells (100 
ml cultures of TB media) that were double-screened for ZapN1 expression. ZapN1 
expression was induced at the same O.D. 600 values as in A and bacterial growth was also 
monitored in cultures were no IPTG was added (B). The data points correspond to the 
mean O.D. 600 values from 3 cultures and the error bars correspond to the standard 
deviations of each mean. Coomassie Brilliant blue-stained polyacrylamide gels showing 
the expression of ZapN1 over time from BL21-Gold (DE3) cultures (no screening) 
induced at various O.D. 600 values (C). Coomassie Brilliant blue-stained polyacrylamide 
gels showing the expression of ZapN1 over time from double-screened BL21-Gold 
(DE3) cultures induced at the same O.D. 600 values as in C (D).  
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We optimized induction time for single and double-screened colonies and monitored 
ZapN1 expression every hour after induction. We observed that induction at O.D.600 0.5 
reduced bacterial growth when compared to bacterial cultures induced when the value 
O.D.600 was 0.8 or 1.2. However, we observed no difference in ZapN1 expression over 4 
hours between cultures induced at either O.D.600 0.5 or 0.8. In contrast, bacterial cultures 
induced at O.D.600 1.2 showed severe ZapN1 expression reduction in comparison to the 
cultures induced at either O.D.600 0.5 or 0.8. We observed the same trend n ZapN1 
expression for the single screened colony. We did not observe any differences in bacterial 
growth between the single and double-screened cultures indicating that the higher ZapN1 
expression in the double-screened colony is not due to higher bacterial growth. For 
subsequent expression experiments, we chose induction at O.D.600 0.8 and 3 hours 
incubation.  
4.3.3 Temperature Effects on ZapN1 Expression 
Bacterial cultures can be incubated at different temperatures post-induction, which affects 
protein expression. We proceeded to determine ZapN1 expression at 16, 23, 30, and 37 
°C in small-scale LB cultures. ZapN1 expression was induced with 1 mM IPTG at 
O.D.600 0.8 and cultures were incubated for 3 hours at the 4 temperatures mentioned 
previously. 1 ml samples were taken every hour to assess ZapN1 expression by SDS-
PAGE analysis. Figure 4.3.3 shows the Coomassie blue stained SDS-PAGE gel for single 
and double screened bacterial cultures incubated at different temperatures and assessed 
every hour post-induction.  
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Figure 4.3.3 Temperature Effects on ZapN1 Expression on Single and Double-Screened 
Colonies. Coomassie Brilliant Blue-stained polyacrylamide gel showing expression of 
ZapN1 from BL21-Gold (DE3) cultures (single vs. double expressed) at various time 
points. Cultures were subjected to different temperatures (37, 30, 23, and 16 ͦ C) 
following addition of IPTG for 3 hours each. Each hour after induction, 1 ml samples 
were taken for SDS-PAGE analysis. Expression of ZapN1 was highest when induction 
was carried out at 30 ͦ C (in both single and double-screened samples) but higher in the 
double-screened samples than the single-screened cultures after 3 hours incubation.  
As expected, ZapN1 expression in the double-screened cultures was higher than in the 
single screened cultures. ZapN1 expression was the highest in both single and double-
screened cultures at 30 °C. Surprisingly, ZapN1 expression was lower when cultures 
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were incubated at 37 °C than either 30 or 23 °C. ZapN1 expression was the lowest when 
cultures where incubated at 16 °C. For all cases, ZapN1 expression was highest when 
incubated for 3 hours. Based from these results, ZapN1 expression for future expression 
experiment will be conducted at 30 °C for 3 hours. 
4.3.4 Batch Purification of ZapN1 from Single and Double Screened Cultures 
We proceeded to test ZapN1 purification using a batch method to simplify the 
purification from previous FPLC methods using a novel Nickel affinity resin. We 
employed the His60 Superflow nickel resin for its high binding capacity and claimed 
higher purity obtained. ZapN1 was expressed in 100 ml TB cultures of single or double-
screened BL21 (DE3) cells. ZapN1 expression was induced with 1 mM IPTG at O.D.600 
0.8 and cultures were incubated 3 hours at 30 °C. Cultures were pelleted and processed as 
described in the methods for Nickel affinity purification. To assess the nickel affinity 
purification, samples from the cell lysate, wash, and elution fractions were analyzed by 
SDS-PAGE. Figure 4.3.4 shows the Coomassie stained SDS-PAGE gels for single and 
double screened cultures expressing ZapN1 and the different nickel affinity purification 
fractions.  
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Figure 4.3.4 Purification of ZapN1 from cell cultures harvested at various time points. 
ZapN1 expression in single and double-screened samples was analyzed by purifying the 
protein from total cell pellets (100 ml). Cell pellets were collected from samples at 
various time points and processed equally to look for any differences in protein yield. 
ZapN1 was purified using the His60 Ni superflow resin each step assessed by SDS-
PAGE analysis. The figure above shows the Coomassie Brilliant Blue stained gels of 
each flowthrough (lysate, wash, and eluate) from each sample.  
ZapN1 purification using the His60 superflow resin yielded ZapN1 with very little co-
contaminants eluting in the imidazole gradient. We observed no differences in the time 
point at which cultures were harvested and between the single and double screened 
cultures. We also observed that most bacterial proteins observed in the cell lysate are 
washed away during the purification method. We do observe a small amount of ZapN1 
that elutes in the wash fraction but the amount is minimal compared to the ZapN1 present 
in the elution fractions. The batch procedure took only a few hours to complete and yield 
highly pure ZapN1. In contrast, FPLC based ZapN1 purification takes on average 1 day 
or longer which adds considerable time to the purification method. Based on these 
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results, we proceeded to perform a large-scale ZapN1 expression using the previously 
optimized expression and purification methods.  
4.3.5 Large-Scale Expression of ZapN1 
We expressed ZapN1 using the double screened BL21(DE3) culture in 8 L TB media 
using the previously optimized expression and purification parameters. ZapN1 was 
collected over 5 fractions from the nickel affinity resin and each fraction was analyzed by 
SDS-PAGE to determine ZapN1 purity. ZapN1 yield was determined by measuring the 
280 nm absorbance from the pooled elution fractions. Figure 4.3.5 shows the Coomassie 
blue stained SDS-PAGE gel for fractions 1 – 5 from the nickel resin. Figure 4.3.5 also 
shows the combine fractions diluted 100x for clarity.  
Figure 4.3.5 Large-scale purification of ZapN1. Coomassie Brilliant Blue stained 
polyacrylamide gel with fractions obtained from the His60 purification of ZapN1. The 
right panel shows the combined fractions (1- 4) that have been diluted 100x in the same 
buffer without imidazole. ZapN1 was mainly contained in fractions 2-3 with very little 
proteolysis products found in the fractions. The total yield of ZapN1 from the 8 L culture 
was 1.8 grams.  
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ZapN1 elutes primarily in fractions 2 and 3 with some protein eluting in fractions 1 and 
5. We only observed lower molecular weight contaminants in fraction 3. From the
combine fraction, we observe that the contaminants, which we believe are ZapN1 
truncations, are negligible relative to the concentration of ZapN1. We purified ~250 mg/L 
culture of ZapN1 which is a massive improvement from the previous method which 
yielded in average 10 mg/L culture. Given this, we have successfully purified ZapN1 in 
high purity and yield from BL21 (DE3) cells.  
4.3.6  Construction of High Throughput Chromatography Platforms 
Initial NABB assembly experiments with ZapN1 revealed several limitations in the set-
up employed to remove detergent and collect NABB fractions. We found that the old set-
up did not allow for temperature control and only up to 4 purifications could be 
performed simultaneously. To address this problem, we designed and constructed with 
aid of the Rockefeller Precision Facility two platforms made from Acrylic (for RT 
purifications), and M3 crystal (for 0°C purifications) for high-throughput, minis-scale 
chromatography. Figure 4.3.6 shows photographs of the assembled platforms viewed 
from different angles. We designed the 96 samples holder in Acrylic to be compatible for 
RT purifications. For the 24 samples holder, we designed the top with a reservoir 
surrounding the individual column holders where ice-water mixture will be placed to cool 
down the samples. Both platforms are compatible with the walls of the box so that they 
can be freely interchanged. We have employed both platforms in NABBs assembly using 
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manual or automated Elutions using the EpMotion 5070. Samples are collected in a 96 
well plate underneath the platforms in 4 steps. The platforms are compatible with any 
batch chromatography method, which allow for faster purification optimization.  
Figure 4.3.6 Photographs showing the HTCPs built at the Rockefeller Precision 
Fabrication Facility. The top panels show the top view for the three different adapters 
designed. The lower panels show each adapter in conjunction with the HTCP. The 
adapters have been designed to hold 96 samples or 24 samples at either RT or at 0 °C. 
4.3.7 Assembly of NABBs with POPC 
We assembled NABBs using the phospholipid POPC at a stoichiometry ratio of 75 or 55 
POPC per 1 ZapN1. Previous NABBs assemblies with Rho and CCR5 employed POPC 
for receptor reconstitution. Thus, we assembled NABBs using ZapN1 and POPC and 
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characterized the complexes by SEC and Native PAGE. Figure 4.3.7 shows the 280 nm 
absorbance chromatographs for POPC NABBs assembled at either 75 or 55 lipids per 
ZapN1. Figure 4.3.7 also shows the Coomassie blue stained Native PAGE for the two 
NABB assemblies.  
Figure 4.3.7 Size-exclusion chromatographs of NABBs assembled with 75 or 55 POPC 
lipids per ZapN1. The chromatographs show that the NABBs elute as two distinct peaks 
corresponding to NABBs of 16 and 11 nm in diameter. The SEC data also shows two 
other peaks, which correspond to vesicles and free-ZapN1. The inset shows the same 
samples analyzed by native gel stained in Coomassie blue.  
The SEC chromatographs shows that POPC NABBs are highly heterogeneous since we 
observed 4 distinct species at either 75 or 55 lipids. The peak eluting at 8 ml corresponds 
to NABBs aggregates that form during the detergent removal procedure. The peaks 
eluting at 11.5 and 13.5 ml correspond to NABBs of different diameter. We calculated 
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the size of the assemblies and determined that the NABBs are 16 and 11 nm in diameter. 
The 4th peak eluting at 16 ml corresponds to either NABBs that are lipid deficient of free 
ZapN1. The Native page shows similar heterogeneity since the NABBs run as a smear 
with one singe defined band. Based on these results, we proceeded to find a suitable lipid 
for NABB assembly that yielded more homogeneous preparations than POPC. 
4.3.8 Assembly of NABBs with Various Lipids 
We assembled NABBs using various saturated and unsaturated lipids at 75 lipids per 
ZapN1. We tested SOPC which is like POPC but it is two carbons longer in the alkyl 
chains and has a transition temperature closer to 0 °C. We also tested the saturated lipids 
DLPC, DMPC, and DPPC, which differ only in the length of the alkyl chain. NABBs 
were assembled as described before using identical conditions. NABBs were analyzed by 
SEC and Native-PAGE. Figure 4.3.8 shows the 280 nm absorbance chromatographs for 
NABBs assembled with the lipids tested and the Coomassie Blue stained Native PAGE 
gel.  
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Figure 4.3.8 Chromatographs obtained for ZapN1 NABBs assembled with different lipids 
at 0 °C and 75 lipids per ZapN1. DLPC NABBs show the greater degree of homogeneity 
than any other lipid tested. The inset shows the Coomassie Blue stained native gel.  
The SEC results show DLPC yields the most homogeneous preparations from the all the 
lipids tested. All the lipids tested from NABBs of approximate diameter 10 – 11 nm with 
varying degrees of larger NABBs and aggregates present in the sample. DMPC NABBs 
are also more homogeneous than the other lipids tested but this lipid has a transition 
temperature of 24 °C which is not compatible for GPCR reconstitution. DPPC proved 
difficult to solubilize in aqueous solutions due to its longer alkyl chain and yielded 
heterogeneous preparations. Native PAGE shows no difference between POPC and 
SOPC indicating that their difference transition temperature has no effect on NABBs 
homogeneity. DLPC NABBs run as a single major band while DMPC and DPPC show 
increasing degree of heterogeneity probably because of increasing alkyl chain length. We 
also ran the proteins thyroglobulin and catalase for which Stokes’ radii are known. 
Except for DPPC, the NABBs assembled with the other lipids run similarly as catalase 
indicating that they must also have a Stokes radius close to 5 nm. Based from these 
results, we proceeded to optimize assembly of DLPC NABBs using varying lipid/ZapN1 
ratios. 
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4.3.9  Assembly of DLPC NABBs With Different Lipid to ZapN1 Ratios 
POPC NABBs are assembled at 75 lipids per ZapN1 based on previous optimization 
performed by Banerjee (2008). We discovered that DLPC yields near-homogeneous 
preparations by SEC and Native PAGE. Given this, we optimized the lipid to ZapN1 ratio 
for the DLPC NABBs. We assembled NABBs at 65, 75, 85, and 95 lipids per ZapN1 
using identical conditions as described in the methods section. DLPC NABBs were 
analyzed by SEC and Native PAGE to determine the homogeneity of the preparations. 
Figure 4.3.9 shows the 280 nm absorbance chromatographs for the DLPC NABBs 
assembled with varying lipid to ZapN1 ratios and the Coomassie Blue stained Native 
PAGE gel.  
Figure 4.3.9 NABBs assembled at various DLPC to ZapN1 ratios. The size exclusion 
chromatographs shows that the DLPC NABBs assembled at 95 DLPC/ZapN1 are 
homogeneous to other stoichiometries tested. The inset show the native gel obtained for 
the NABBs tested. 
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SEC chromatographs shows that DLPC NABBs assembled at 95 lipids per ZapN1 are the 
most homogeneous compared to other stoichiometric ratios tested. For all cases, we 
observed one prominent peak eluting at 11.5 ml, which corresponds to NABB particles of 
10 – 11 nm in diameter. We observed small amounts of aggregate, larger NABBs, and 
free ZapN1 in the preparations. As the amount of lipid per ZapN1 decreases, we observed 
that the peak corresponding to free ZapN1 increases. Native PAGE analysis showed that 
the DLPC NABBs assembled run at the same molecular size as a single sharp band. 
Given this, we chose the optimal DLPC to ZapN1 ratio to be 95 lipids per ZapN1.  
4.3.10  Assembly of DLPC NABBs with GPCR Solubilization Agents 
CCR5-SNAP is purified in a detergent mixture comprising of DDM, CHAPS, CHS, and 
glycerol, which may affect the assembly of DLPC NABBs. We have routinely employed 
CHAPS in the assembly of NABBs and we have not observed any detrimental effect if 
sodium cholate is present. Sodium cholate at a concentration of 2% (w/v) is required to 
yield near-homogeneous preparations. Yet, We have not tested addition of DDM, CHS, 
or glycerol to the NABB assembly reaction. We assembled DLPC NABBs at a ratio of 95 
lipids per ZapN1 with 5% glycerol, 0.15% DDM, 0.15% DDM + 0.015% CHS, and 
0.15% DDM + 0.015% CHS + 5% glycerol. NABBs were analyzed by SEC and Native 
PAGE as described before. Figure 4.3.10 shows the 280 nm absorbance chromatograph 
for the DLPC NABBs and the Coomassie Blue stained Native PAGE gel.  
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Figure 4.3.10 Size exclusion chromatographs for DLPC NABBs assembled with different 
GPCR solubilization reagents. NABB elution was monitored by 280 nm absorbance from 
ZapN1. Inset shows the Coomassie Blue stained Native-PAGE gel with the different 
NABB samples tested. Thyroglobulin and catalase are added in a separate lane as 
molecular size standards.  
SEC chromatographs show DLPC NABBs are not affected by the addition of DDM, 
CHS, or glycerol. Likewise, we observed no differences on the assemblies by Native 
PAGE indicating that DLPC NABBs are robust to the addition of detergents and glycerol. 
Based from these results, we proceeded to characterize DLPC NABBs by negative stain 
electron microscopy (EM) and atomic force microscopy (AFM).  
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4.3.11 Characterization of DLPC NABBs by Negative Stain EM 
DLPC NABBs are near homogeneous by SEC and Native-PAGE but it is unclear if they 
form discoidal particles. To characterize NABBs morphology, we imaged negative 
stained NABBs on copper grid using transmission electron microscopy. Empty NABBs 
and CCR5-SNAP NABBs were stained in 1% uranyl acetate solution and imaged as 
described in the materials and methods section. Figure 4.3.11 shows two representative 
images from NABBs and CCR5-SNAP NABBs obtained in the JEOL 1400 Plus electron 
microscope with beam energy set at 120 kV and 25,000x magnification.  
Figure 4.3.11 Negative stained electron microscopy images obtained for empty NABBs 
and CCR5-SNAP NABBs loaded onto carbon coated copper grids and stained with 1% 
uranyl acetate. Images were acquired using an electron beam energy of 120 kV and 
25,000x magnification. Arrows point to Rouleaux formation indicative of HDL particle 
formation.  
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Rouleaux formation, the stacking of discoidal particles into rows, is observed in both the 
empty and CCR5-SNAP NABBs samples. We observed discoidal particles of varying 
sizes in the peak fractions indicating that the NABBs are heterogeneous in diameter. We 
also observed NABB aggregates that result from the fusion of Rouleax formations into a 
single highly branched species (data not shown). NABB dilution also affected NABB 
stability since SUVs were also present in the peak fraction. We cannot rule out that the 
heterogeneity observed is a result from NABBs interacting with the copper grid and 
affecting NABB morphology. Given this, we proceeded to image the NABBs in solution 
using AFM and derive quantitative information about NABB diameter and height 
distribution.  
4.3.12  Characterization of DLPC NABBs by AFM 
Negative stain EM images on empty NABBs and CCR5-SNAP NABBs revealed high 
degree of heterogeneity in the SEC peak fraction. We attribute the observed NABB 
heterogeneity to sample dilution, which precipitates NABB fusion to form SUVs. We 
also hypothesize that the NABBs are not interacting with homogenously with the copper 
surface, which contributes to the non-uniform NABB distribution and morphology. Given 
this, we imaged empty and SNAP-CCR5 NABBs using AFM. Pilot experiments revealed 
that NABBs imaged on air deflated and lost structural stability on the mica surface 
requiring the need for AFM imaging in fluid. NABBs were imaged in either Buffer G or 
Buffer C using a Cypher ES AFM with a silicon probe. Figure 4.3.12 shows 
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representative AFM images for SNAP-CCR5 and empty NABBs. Figure 4.3.12 also 
shows histograms for NABBs diameter and height.  
Figure 4.2.13 AFM imaging and analysis of SEC fractions containing empty and SNAP-
CCR5 NABBs made with DLPC. a) AFM image for SNAP-CCR5 and b) for empty 
NABBs. 𝑥𝑦 Coordinates are in nanometers and the color scheme reflect the height of the 
sample in nanometers. c) NABBs diameter histogram and d) height histogram derived for 
SNAP-CCR5 and empty NABBs.  
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AFM images show that the NABBs are uniformly distributed on the mica surface with no 
Rouleaux formation present. We observe a small number of bright spots, which we 
attribute to NABB particle freely diffusing in solution. We also observe large NABBs, 
which are more prevalent in the SNAP-CCR5 NABBs than the empty NABBs. The larger 
discoidal structures have the same color as the NABBs indicating that they are the same 
height. Based from this, we attribute these larger particles to be NABBs of larger 
diameter. We observe that the NABBs are densely packed on the mica surface. The 
higher NABB density helps to prevent dilution induced NABB fusion. We calculated 
height and diameter for individual NABB particles and derived histogram distributions 
for both parameters. Table 4.3.12 shows the mean height and diameter calculated for 
SNAP-CCR5 and empty NABBs.  
Table 4.3.12 Average height and diameter for SNAP-CCR5 and empty NABBs derived 
from AFM images. Errors are the standard deviation.  
 
Height (nm) Diameter (nm) 
SNAP-CCR5 NABBs 2.8 ± 0.2 14 ± 5 
Empty NABBs 2.8 ± 0.1 16 ± 5 
We observe no difference in particle diameter between the SNAP-CCR5 and empty 
NABBs. We also do not observe any statistically significant difference between the 
height of SNAP-CCR5 NABBs and empty NABBs. The calculated diameters from AFM 
images agree with the calculated values from SEC and Native-PAGE experiments. 
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4.3.13 Assembly and Characterization of Rho-Fl NABBs 
We incorporated the prototypical GPCR, Rhodopsin, into DLPC NABBs and 
characterized the assemblies by SEC and FCS. We obtained Rhodopsin from bovine rod 
outer segments that were previously reconstituted with 11-cis retinal. We purified 
Rhodopsin from bovine ROS using DDM and labeled Rhodopsin with the fluorophore 
Fluorescein-maleimide that forms a covalent bond with solvent accessible cysteine 
residues. We labeled Rhodopsin with Fluorescein so we could monitor Rhodopsin by 
SEC and FCS. After Rho-Fl purification, we performed UV-Vis measurements on the 
1D4 elution to determine the yield and the labeling stoichiometry. Fluorescein has a 
maximum absorption at 500 nm so we used the 380 nm absorbance from the dark-light 
spectrum of Rhodopsin to measure the amount of recovered Rhodopsin. We measured an 
absorbance of 0.019494 at 380 nm and calculated rhodopsin concentration to be 0.1834 
mg/ml using an extinction coefficient of 36,143 and dilution factor of 10. To determine 
the concentration of Fluorescein, we determined an absorbance of 0.088203 at 500 nm in 
the light spectrum of Rhodopsin. From this value, we calculated a concentration of 11.47 
µM using an extinction coefficient of 76,900 and a dilution factor of 10. We determined 
the labeling stoichiometry to be 2.2 Fluorescein per Rhodopsin. We employed this 
labeled protein for reconstitution into DLPC NABBs. Rho-Fl NABBs were loaded into a 
previously equilibrated Superdex 200 10/300 column and NABBs elution were monitored 
by absorbance at 280 and 494 nm. Figure 4.3.13a shows the SEC chromatograph 
obtained by monitoring sample absorbance at 280 and 494 nm.  
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Figure 4.3.13a Rho-Fl NABBs eluting from Superdex 200 10/300 GL column in Buffer 
G. Fluorescein absorbance was monitored at 494 nm and protein absorbance at 280 nm. 
The SEC chromatographs show two distinct peaks in the 280 nm absorbance elution 
profile. In the other hand, we observe only one peak in the 494 nm absorbance elution 
profile from the Rho-FL. This second peaks elutes at ~ 10.5 ml and aligns with one peak 
observed in the 280 nm absorbance profile. We attribute this peak to be the Rho-Fl 
NABBs since calculating the Stokes’ radius for this species yields a value of (6.1 ± 0.6) 
nm. We did not further characterize the second peak which elutes at ~13 ml but we 
attribute this peak to be empty NABBs. We also characterized the Rho-Fl NABBs by 
FCS as described in the methods section. Figure 4.3.13b shows the auto-correlation trace 
and associated fit for Rho-Fl NABBs. 
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Figure 4.3.13b FCS traces obtained for Rho-Fl NABBs. Autocorrelation was fitted to a 1 
component with 3-D translational and dependent rotational diffusion and triplet state 
fluctuations. The inset in the left panel shows the calculated Stokes radii for Rho-FL 
NABBs from the FCS and SEC data. For comparison, The Stokes radius 
bacteriorhodopsin incorporated into nanodiscs is shown in the bar graph.  
FCS curves were fitted using a 1 3D translational component with dependent rotational 
diffusion and independent triplet state transitions. We calculated a (25 ± 1) % triple state 
fraction with a relaxation time of (3.1 ± 0.4) µs for Rho-Fl NABBs. We also calculated a 
rotational relaxation time of (27 ± 5) µs and a translational diffusion time of (380 ± 7) µs. 
Using the calculated confocal volume for 488 nm excitation, we calculated a 
concentration of (29.8 ± 0.3) nM for Rho-Fl NABBs. Lastly, we employed the 
translational diffusion time and derived a Stokes radius of (5.1 ± 0.2) nm, which is not 
that different from the SEC derived value of (6.1 ± 0.6) nm. For comparison, 
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bacteriorhodopsin incorporated into DMPC nanodiscs had a Stokes radius of (3.9 ± 1.4) 
nm.[111]  
4.3.14 Characterization of CCR5-SNAP NABBs 
After successfully incorporating Rhodopsin into DLPC NABBs, we proceeded to 
incorporate CCR5-SNAP-488 into NABBs and characterize the assemblies by SEC. 
Since CCR5-SNAP-488 concentration is too low for detection by 280 or 496 nm 
absorption, we analyzed SEC fractions by SDS-PAGE to detect CCR5. We employed 
1D4/FLAG purified CCR5-SNAP-488 for NABB assembly with DLPC. Figure 4.3.14a 
shows the SEC chromatograph from 280 nm absorption. Figure 4.3.14a also shows the 
western immunoblot of SEC fractions 20 – 24 where CCR5 was detected using the 1D4 
epitope. The SEC chromatographs shows 4 distinct peaks and a shoulder around the main 
peak. The peak at 7 ml corresponds to NABB aggregates eluting in the void volume. The 
main peak at 12 ml corresponds to the NABB particles and the shoulder centered on 10 
ml represents NABBs of larger diameter than 11 nm. The peak at 14 ml corresponds to 
free ZapN1 or lipid deficient ZapN1. The peak at 18 ml corresponds to the salt front from 
the sample.  
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Figure 4.3.14a 280 nm absorbance chromatograph for CCR5-SNAP NABBs eluting in 
the Superdex 200 10/300 GL column. Inset shows the western immunoblot of SEC 
fractions 20 – 24. CCR5-SNAP was detected using the 1D4 monoclonal antibody.  
To detect CCR5-SNAP in fractions 20 – 24, we performed SDS-PAGE analysis and 
western immunoblotting to determine the elution of CCR5-SNAP in the NABBs. CCR5-
SNAP is present only in fractions 21 – 23. The results indicate that CCR5-SNAP 
successfully incorporated into DLPC NABBs. We performed saturation binding with the 
conformationally sensitive antibody 2D7 conjugated to Cy5, which is spectrally like 
Alexa-647. Figure 4.3.14b shows auto-correlation traces for CCR5-SNAP (a) 2D7-Cy5 
(b) and cross-correlation traces obtained for the antibody-receptor complex (c) at the 
different antibody concentrations tested. Auto-correlation traces were fitted using 2 
components with 3D translational diffusion and triplet state transitions. Cross-correlation 
traces were fitted using a single component with 3D diffusion.  
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Figure 4.3.14b (a) CCR5-SNAP-488 auto-correlation traces and fits for different 
concentrations of 2D7-Cy5. (b) 2D7-Cy5 auto-correlation traces and fits for all 
concentrations tested. (c) Receptor-ligand complex cross-correlation traces and fits for 
different concentrations of 2D7-Cy5. 
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We calculated concentrations for each fluorescent component and derived the binding 
isotherm for 2D7-Cy5. Figure 4.3.14c shows the saturation-binding isotherm derived for 
2D7-Cy5 by plotting 𝑅𝐿/𝑅 as a function of free antibody.  
Figure 4.3.14c Saturation binding isotherms for 2D7-Cy5 binding to CCR5-SNAP-488 in 
DLPC NABBs. Data points represent individual points for different concentrations of 
labeled antibody. The red solid line represents the fit performed on the data points using 
equation 4.4.  
We did not account for ligand depletion in this binding experiment since we did not 
observe any appreciable differences between the concentrations of total and free 2D7-
Cy5. We calculated a 𝐾𝐷 (5 ± 1) nM for 2D7-Cy5 which is similar to the value calculated 
in cell-based saturation assays of 4.5 nM.[112] We conclude that CCR5-SNAP 
reconstituted into DLPC NABBs is functional.  
172 
4.4  Discussion 
4.4.1 Zapn1 Expression and Purification Optimization 
We successfully expressed and purified D. rerio apolipoprotein AI (ZapN1) from E. coli 
in high yield and purity. From an 8 L culture, we purified 2 grams of ZapN1 using an 
optimized expression protocol and batch nickel affinity purification. In contrast, Zap1, 
the non-codon optimized gene, yielded ~ 50 mg total protein from a 13 L culture using 
the previously published protocol.[86] We assemble NABBs with a total of 1 mg ZapN1 
per 150 µl reaction volume limiting the amount of NABB reactions that can performed. 
Our initial approach was to optimize the Zap1 codon usage to generate a construct that 
could be expressed in non-Rosetta 2 cell lines. Zap1 was expressed in BL21 (DE3) 
Rosetta 2 cells, which encode for 7 rare tRNAs to enhance eukaryotic protein expression. 
We generated ZapN1 in the pET28 plasmid backbone and transformed BL21 (DE3) cells 
to induce protein expression with IPTG. Pilot expression experiments using a Fermenter 
to achieve high cell density did not yield higher ZapN1 quantities than cell cultures 
grown in flasks (data not shown). Given this, we opted to optimize ZapN1 expression in 
bacterial cultures grown in flasks. Sivashanmugam (2009) discovered that double-
selected E. coli colonies expressing truncated apolipoprotein E yielded higher protein 
expression than single selected colonies.[113] We replicated the double-selection 
protocol using ZapN1 transformed BL21 (DE3) cells and indeed we show that after two 
rounds of selection, ZapN1 expression increases. We also show that Zap1 and MSP1D1 
express higher in double-selected colonies than single selected colonies.  
173 
We proceeded to optimize ZapN1 expression induction time by adding 1 mM IPTG at 
optical densities of 0.5, 0.8, and 1.2. We did not observe any difference in cell growth 
between the single and double-selected cultures. Thus, the higher ZapN1 expression 
observed in double-selected colonies cannot be a result of higher cell expression in the 
double-selected colonies. We also found that IPTG induction at O.D600 1.2 yielded very 
low ZapN1 expression relative to the cultures induced at 0.5 or 0.8. We postulate that the 
lower ZapN1 expression observed in these cultures is a result of nutrient depletion in the 
media. We also tested ZapN1 expression at various temperatures in both the single and 
double-selected colonies. ZapN1 expression was the highest when single and double-
selected colonies were incubated for 3 hours at 30 °C. SDS-PAGE analysis of cultures 
lysed with guanidium hydrochloride shows that a fraction of ZapN1 precipitates as 
inclusion bodies (data not shown). Triton X-100 cannot solubilize ZapN1 in inclusion 
bodies and higher incubation temperatures precipitate ZapN1 aggregation. Given this, we 
postulate that ZapN1 aggregates less at 30 °C than at 37 °C and we observe higher 
expression because there is more soluble ZapN1.  
For ZapN1 purification, we decided to employ a batch method over the traditional FPLC 
method because in the past FPLC ZapN1 purification was time consuming and protein 
loss was significant. We chose the His60 Superflow nickel resin (Clontech) because of its 
higher binding capacity, higher protein purity, and better compatibility with detergents 
such as sodium cholate than Ni-NTA resins. We performed small-scale purification using 
the His60 superflow resin and observed that the purification method is robust and yields 
highly pure ZapN1 from single and double-screened colonies. We proceeded to scale 
ZapN1 expression to 8 L using the previously optimized expression and purification 
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parameters. We purified 2 grams of ZapN1, which is an improvement from the previous 
protocol which yielded 50 mg of Zap1.  
4.4.2 NABBs Lipid Optimization 
NABBs assembled with POPC showed 4 different peaks by SEC indicating that the 
preparations were heterogeneous and not suitable for single molecule analysis. Given 
this, we assembled NABBs with different lipid compositions to determine which lipid 
yielded homogeneous preparations. Figure 4.4.2 shows the chemical structures of the 
different lipids tested and their phase transition temperatures from the ordered gel phase 
to the liquid crystalline phase.  
Figure 4.4.2 Chemical structure of the lipids employed to assemble NABBs and their 
phase transition temperatures. 
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We hypothesized that NABBs assembled with POPC were heterogeneous because 
reactions were incubated above the phase transition temperature of POPC. Given this, we 
chose SOPC as an alternative to POPC because it is chemically like POPC but the phase 
transition temperature is higher than POPC. Surprisingly, SOPC NABBs yielded 
similarly heterogeneous NABBs by SEC and identical band pattern by Native-PAGE. 
Thus, we rule out the possibility that POPC NABBs were heterogeneous because of the 
phase transition temperature being lower than the NABB assembly temperature. We 
tested 3 different saturated lipids to determine if NABBs made with these lipids yielded 
better preparations. DPPC has previously been employed with membrane scaffold 
proteins to generate homogeneous discs.[114, 115] We chose DLPC and DMPC since 
they are chemically like DPPC but with different alkyl chain lengths. SEC and Native-
PAGE analysis show that DLPC NABBs are near-homogeneous and increasing alkyl 
chain length decreases sample homogeneity. Bavishi (2016) assembled discs using a lipid 
mixture of DLPC:DLPG:NBD-PE (73/25/2 mol %) and SEC analysis showed that the 
discs were near-homogeneous.[116] Similarly, Skar-Gislinge (2010) using small angle 
neutron scattering (SANS) and small angle x-ray scattering (SAXS) showed that the 
scattering data for DLPC discs was best fit using a monodisperse elliptical model.[117]  
We optimized the lipid per ZapN1 stoichiometry and discovered that NABBs assembled 
with 95 DLPC lipids per 1 ZapN1 yielded homogeneous preparations by SEC. In 
contrast, Skar-Gislinge (2010) calculated from SANS data that DLPC discs had a 
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stoichiometry of 76 lipids per 1 membrane scaffold protein. The difference in 
stoichiometry can be attributed to the fact that MSP is N-terminally truncated. Skar-
Gislinge (2010) noted that the DLPC discs had a smaller circumference than the maximal 
circumference allowed if the MSP was fully extended in the discs. Given this, the MSP in 
the DLPC discs was not fully stretched and could potentially allow for higher lipid 
incorporation. We also tested the effect of adding DDM, CHS, and glycerol to DLPC 
NABBs to determine if they affected sample homogeneity. We did not observe any 
adverse effect from adding DDM, CHS, and glycerol to DLPC NABBs indicating that 
GPCRs solubilized in solutions containing those components are compatible with NABB 
assembly conditions.  
We employed EM and AFM imaging of DLPC empty and CCR5-SNAP loaded NABBs 
to determine their morphology. EM imaging of DLPC NABBs showed that the NABBs 
were polydisperse and highly heterogeneous. In contrast, Mitra (2012) observed near-
homogeneous nanodiscs loaded with the parathyroid hormone receptor 1 (PTH1R) as did 
Whorton (2007) for the β2AR in POPC nanodiscs [118, 119] Similarly, Choi (2013) were 
capable of reconstructing a three dimensional model of human integrin αIIbβ3 loaded 
into nanodiscs showing that they were able to obtain high quality preparations by 
EM.[120] Zhang (2011) showed that the Rouleaux formation observed for HDL particles 
is a staining artifact that results from electrostatic interactions between the stain and 
discs.[121] Stains such as phosphotungstic acid intercalate between discs holding two 
discs together through electrostatic interactions with the choline headgroup in the 
phospholipids. Guha (2008) discovered that NABB aggregation results from 
apolipoprotein dissociating from the bilayer disc.[122] Solvent exposure causes discs to 
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fuse together eventually forming vesicles to minimize phospholipid exposure to water. 
Thus, we postulate that NABB dilution contributes to NABB aggregation and interactions 
with the copper grid contributed to the polydispersity observed. Given this, we decided to 
image and characterize the NABBs by AFM. 
We imaged empty and SNAP-CCR5 NABBs using an AFM microscope that allowed for 
imaging in fluids. In contrast to the EM images, empty NABBs by AFM were mostly 
homogeneous with little presence of larger aggregates or SUVs. SNAP-CCR5 NABBs 
were also mostly homogeneous but we did observe higher fraction of larger diameter 
NABBs. We did not observe any significant differences in the diameter and height of the 
empty and SNAP-CCR5 NABBs. Skar-Gislinge (2010) calculated for DLPC discs a 
bilayer thickness of 2.4 nm at 20 °C which is only 0.4 nm smaller than the thickness 
calculated from our AFM experiments. Skar-Gislinge (2010) deducted from their SANS 
and SAXS data that MSP determined disc bilayer thickness by minimizing hydrophobic 
mismatch between the membrane and protein.  
4.4.3 GPCR Incorporation into DLPC NABBs 
We incorporated Rhodopsin into DLPC NABBs and characterized the NABBs by SEC 
and FCS. Unlike CCR5-SNAP, we can obtain microgram quantities of Rhodopsin from 
bovine ROS which allow us to increase the ratio of receptor loaded NABBs to empty 
NABBs. Rhodopsin labeling with Fluorescein allow us to monitor Rhodopsin elution in 
SEC and observe the NABBs by FCS. SEC profile of Rho-Fl NABBs shows two peaks in 
the 280 nm absorbance and 1 peak in the 494 nm absorbance. Rho-FL NABBs elute at 
178 
10.5 ml while the empty NABBs elute at 13 ml. Choi (2013) observed a similar SEC 
profile for αIIbβ3 nanodiscs eluting in an Superdex 200 column indicating that the 
receptor loaded NABBs have a larger size than the empty NABBs. Bavishi (2016) also 
observed two different species for CYP709AI nanodiscs eluting from a Superdex 200 
column. However, Bavishi (2016) did not characaterize the individual peaks since they 
did not have enough chromatographic resolution to obtain good separation. We calculated 
for the Rho-Fl NABBs a Stokes radius (6.1 ± 0.6) nm. Bayburt (2007) calculated a Stokes 
diameter of 12 nm for bovine Rhodopsin incorporated into POPC nanodiscs. Likewise, 
For the PTH1R nanodiscs, Mitra (2013) calculated a similar diameter of 12.5 nm. Mitra 
(2013) makes an excellent observation that the Stokes diameter assumes that the diffusing 
particles are spherical while nanodiscs are discoidal. 
We also characterized Rho-Fl NABBs by FCS to determine the particles’ Stokes radius. 
We fitted the auto-correlation traces using a functional form that account for rotational 
and translational diffusion and triplet state transitions. We included the rotational 
diffusion term based on Gao (2011) where they attributed the fast component to be due to 
rotational diffusion. Gao (2011) did not consider the possibility that the fast component 
they observed was due to triplet state transitions. Fitting the Rho-Fl NABBs with the 
rotational component did not alter the fitted triplet state parameters. We calculated a 
triplet state relaxation time of 4 µs and triplet fraction of 25%, which is what we observe 
for Alexa-488. Gao (2011) calculated a rotational diffusion time of 5 µs, which is too 
short to be due to rotational diffusion, and is most likely due to triplet state transitions. 
We calculated for Rho-Fl NABBs a rotational diffusion time of 27 µs which is too high 
to be triplet state transitions but too low to be from free dye diffusion. We cannot exclude 
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the possibility that the rotational component is due to blinking or other non-diffusional 
process. We calculated a translational diffusion time of (380 ± 7) µs for Rho-Fl NABBs. 
Gao (2011) calculated a translational diffusion time of (350 ± 10) µs for BRho nanodiscs. 
Ly (2014) calculated a higher diffusion time for the Lcrv bound YopB nanodiscs of 630 
µs and derived a Stokes radius of 11.1 nm. We calculated a hydrodynamic radius of (5.1 
± 0.2) nm which is twice smaller than that determined by Ly (2014). We should note that 
the diffusion time measured is dependent on the size of the confocal volume. Thus, direct 
comparison between diffusion time is meaningful if FCS measurements were performed 
under identical conditions. On the other hand, we can compare Stokes radius derived 
from FCS measurements performed under different conditions since the diffusion 
coefficient is not depend on the size of the confocal volume. Differences in height and 
Stokes radii across different reports are due to differences in NABB assembly conditions, 
lipids employed, and apolipoprotein used to make NABBs. Nonetheless, we observe a 
general trend in height and Stokes radius for these particles across several reports.  
We also incorporated CCR5-SNAP-488 into DLPC NABBs and performed saturation 
binding with 2D7-Cy5. SEC profile of CCR5-SNAP NABBs shows a profile very like 
that obtained for empty NABBs. To determine where CCR5-SNAP eluted, we analyzed 
SEC fractions by western immunoblotting where we can detect down to femtomole 
quantities of receptor. Western immunoblotting shows that CCR5-SNAP is present in 
SEC fractions 21 to 23. We tested ligand binding by FCCS and calculated a 𝐾𝐷 (5 ± 1) 
nM for 2D7-Cy5 binding to CCR5-SNAP in NABBs. We did not perform control 
experiment where 2D7-Cy5 was added to empty NABBs to determine non-specific 
binding to the NABBs. Yet, a cross-correlation would only be observed if the empty 
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NABBs fluoresce under 488 nm excitation or are labeled with a 488 nm excitable 
fluorophore. We have not observed considerable fluorescence from NABBs under 488 
nm excitation. Future experiments will test ligand binding of 5P12- and 6P4-647 to 
CCR5-SNAP NABBs and test the effect of G-protein pre-coupling to CCR5 on 
chemokine affinity and ratio of high and low affinity receptor fractions. 
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CHAPTER 5: CONCLUSION 
CCR5 is a chemokine receptor that is involved in inflammation, chemotaxis, and T cell 
activation. CCR5 is also the major co-receptor for HIV-1 glycoprotein Env. Recently, 
four RANTES analogues were developed to block HIV-1 infection by mutating the first 9 
amino acids of RANTES. Despite their extensive pharmacological characterization in 
cell-based assays, we lack structural and mechanistic insights that explain the RANTES 
analogues functional selectivity. To address this issue, we performed single molecule 
fluorescence ligand binding assays using the RANTES analogues and CCR5 to derive 
equilibrium binding constants. We chose single molecule detection because we can 
observe reaction intermediates or receptor species that are averaged in ensemble ligand 
binding assays. To detect ligand binding, we employed fluorescence cross-correlation 
spectroscopy because fluorescent species concentrations can be derived directly, 
molecules are detected in solution avoiding immobilization effects, and it is suitable to 
detect ligand binding in the picomolar to nanomolar range. To perform single molecule 
assays, we generated a CCR5 construct fused to a SNAP tag for fluorescent labeling and 
two functional tags at the N- and C-termini of CCR5 for tandem affinity purification. We 
label CCR5 with Alexa-488 using the SNAP tag and purify the full-length monomeric 
receptor from receptor truncations and aggregates. We performed intracellular calcium 
mobilization and cAMP inhibition assays and we demonstrate that CCR5-SNAP can 
activate G-proteins. We show by TIRF microscopy and flow cytometry that CCR5-SNAP 
expresses at the cell surface of HEKC293T cells. 
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We performed saturation and competition-binding assays using Alexa-647 labeled 
RANTES analogues and purified CCR5-SNAP-488 in micelles by fluorescence cross-
correlation spectroscopy. Global fitting analysis of the binding isotherms revealed that 
25% of the receptor was functional. Within this fraction, chemokines bound with high 
affinity to 38% of the receptor and with low affinity to 62% of the active receptor. 
Competition binding analysis showed that 5P12 and 6P4 recognized the same receptor 
fractions observed in the saturation binding experiments. Competition analysis showed 
that Alexa-647 did not interfere with chemokine binding to CCR5-SNAP-488. 
Competition binding experiments with the sCD4/gp120 complex, RANTES, and MIP-1α 
revealed that the RANTES analogues remained bound to the receptor even in micromolar 
competitor concentrations.  
We hypothesize that the two CCR5-SNAP species observed by FCCS are due to 
receptors expressing different levels of covalent modifications. Indeed, we observe by 
SDS-PAGE analysis two bands which we correlate to the receptor species observed by 
FCCS. Future experiments such as mass spectrometry on purified CCR5-SNAP will shed 
insights into the covalent modifications that are present in the extracellular side of the 
receptor. If possible, enzymatic removal of CCR5-SNAP covalent modifications will 
shed light into how these modifications affect chemokine binding affinity. In case the 
covalent modifications are PMTs, CCR5 purification from different immune cells will be 
required to analyze the receptor by MS and determine if the receptor is differentially 
modified in vivo. Thus far, CCR7 is the only chemokine receptor known to be 
differentially glycosylated in vivo. CCR7 glycosylation is tissue dependent and the 
presence or lack of glycosylation on CCR7 mediates CCR7 signaling and coupling to 
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physiological responses. We can imagine that such mechanism of receptor regulation is 
present on other chemokine receptors and potentially other GPCRs.  
We hypothesize that high affinity binding of RANTES and MIP-1α requires pre-coupling 
of G-protein to CCR5-SNAP. We did not perform ligand-binding measurements in the 
presence of G-protein because CCR5-SNAP in micelles would not activate G-protein. 
Given this, we chose to reconstitute CCR5-SNAP into NABBs, which provide a more 
native lipid environment than detergent micelles. CCR5 has previously been incorporated 
into NABBs and it was shown that CCR5 is more thermally stable in NABBs than 
detergent micelles. However, we had to address several limitations with the NABBs 
before we could incorporate the receptor for G-protein functional studies. Previous 
NABB preparations were limited by the low purification yield of Zap1. Also, NABBs 
were assembled in a makeshift platform that did not allow for high-throughput and 
temperature control of NABB assembly. Lastly, NABBs assembly with the lipid of 
choice, POPC, yielded heterogeneous preparation, which are not suitable for single 
molecule experiments. 
We optimized the expression and purification of ZapN1, a codon optimized construct 
derived from Zap1, in E. coli. We also developed a novel high-throughout platform for 
mini-scale chromatography. We devised the platform to be compatible with any 96-well 
plate for sample collection and the EpMotion 5070 for automated liquid handling. We 
employed this platform to optimize assembly of NABBs with different saturated and 
unsaturated lipids. We discovered that NABBs assembled with DLPC are homogeneous 
by SEC and native-PAGE. NABBs assembled with DLPC are compatible with reagents 
used in CCR5 solubilization. AFM analysis shows that the DLPC NABBs are discoidal 
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and homogeneous. We successfully reconstituted rhodopsin-fluorescein and CCR5-
SNAP into DLPC NABBs and characterized the assemblies by SEC and FCS. We 
performed pilot ligand binding studies with 2D7 labeled with Cy5 and show that CCR5-
SNAP-488 in DLPC NABBs binds 2D7 with an affinity similar to ones reported in the 
literature.  
We propose to perform future saturation and competition ligand binding studies with 
CCR5-SNAP-488 reconstituted in DLPC NABBs in the presence and absence of G-
protein with 5P12- and 6P4-647. We will test if G-protein affects chemokine affinity and 
the ratio of high and low affinity receptor fractions. We will then perform saturation or 
competition ligand binding with the native chemokines to determine if G-protein pre-
coupling allows for high affinity binding. We should note that these experiments will 
require careful optimization since the receptor/G-protein complex is short lived in the 
presence of GTP/GDP. To lock G-protein in one state, we can employ GTP analogues 
such as GTPγS, which is a non-hydrolysable nucleotide analogue. Another alternative 
would be to employ G-protein mimetics such as nanobodies or mini G-proteins, modified 
G-proteins that bind the receptor but lack the catalytic domain, to study the effect of G-
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